OA17460A - Pyrrolo [2, 3 - D]pyrimidine derivatives as inhibitors of Janus-Related Kinases (JAK). - Google Patents
Pyrrolo [2, 3 - D]pyrimidine derivatives as inhibitors of Janus-Related Kinases (JAK). Download PDFInfo
- Publication number
- OA17460A OA17460A OA1201500328 OA17460A OA 17460 A OA17460 A OA 17460A OA 1201500328 OA1201500328 OA 1201500328 OA 17460 A OA17460 A OA 17460A
- Authority
- OA
- OAPI
- Prior art keywords
- linear
- branched chain
- chain alkyl
- cycloalkyl
- methyl
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract description 17
- 108091000081 Phosphotransferases Proteins 0.000 title abstract description 8
- 239000003112 inhibitor Substances 0.000 title abstract description 8
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 title abstract description 6
- 102000030951 Phosphotransferases Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 273
- 125000000217 alkyl group Chemical group 0.000 claims description 169
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 131
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 101
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 96
- -1 hydroxy, methoxy, amino Chemical group 0.000 claims description 79
- 125000003118 aryl group Chemical group 0.000 claims description 71
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 70
- 125000001072 heteroaryl group Chemical group 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 61
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 57
- 229910052805 deuterium Inorganic materials 0.000 claims description 57
- 125000005843 halogen group Chemical group 0.000 claims description 55
- 150000002431 hydrogen Chemical group 0.000 claims description 53
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 49
- 125000001424 substituent group Chemical group 0.000 claims description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 47
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 40
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 35
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 34
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000002619 bicyclic group Chemical group 0.000 claims description 26
- 125000002950 monocyclic group Chemical group 0.000 claims description 25
- YVVMIGRXQRPSIY-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound N1C(N)=NC=C2C=CN=C21 YVVMIGRXQRPSIY-UHFFFAOYSA-N 0.000 claims description 21
- 125000004429 atoms Chemical group 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 16
- 125000005842 heteroatoms Chemical group 0.000 claims description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 239000011593 sulfur Substances 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 229910003813 NRa Inorganic materials 0.000 claims description 10
- 229910003827 NRaRb Inorganic materials 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 229910004664 ORa Inorganic materials 0.000 claims description 5
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 5
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims description 4
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 125000005418 aryl aryl group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- SHIYOUABBILWML-TXEJJXNPSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC1 SHIYOUABBILWML-TXEJJXNPSA-N 0.000 claims description 2
- 229920001774 Perfluoroether Polymers 0.000 claims description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 2
- 229910004755 ORb Inorganic materials 0.000 claims 1
- DWJMBQYORXLGAE-UHFFFAOYSA-N pyridine-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=N1 DWJMBQYORXLGAE-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 177
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 176
- 239000000203 mixture Substances 0.000 description 147
- 239000000243 solution Substances 0.000 description 129
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 94
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 90
- 239000007787 solid Substances 0.000 description 84
- 238000006243 chemical reaction Methods 0.000 description 78
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 72
- 238000005160 1H NMR spectroscopy Methods 0.000 description 59
- 229940093499 ethyl acetate Drugs 0.000 description 59
- 235000019439 ethyl acetate Nutrition 0.000 description 59
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 51
- 239000000741 silica gel Substances 0.000 description 45
- 229910002027 silica gel Inorganic materials 0.000 description 45
- 201000010099 disease Diseases 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 44
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 41
- 229910052938 sodium sulfate Inorganic materials 0.000 description 40
- 235000011152 sodium sulphate Nutrition 0.000 description 40
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 39
- 239000012044 organic layer Substances 0.000 description 38
- 239000002904 solvent Substances 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 35
- 239000002585 base Substances 0.000 description 34
- 238000004587 chromatography analysis Methods 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 239000012267 brine Substances 0.000 description 23
- 102100019517 JAK1 Human genes 0.000 description 22
- 101700034277 JAK1 Proteins 0.000 description 22
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 239000003208 petroleum Substances 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 22
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 21
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 21
- 206010020751 Hypersensitivity Diseases 0.000 description 20
- 150000001412 amines Chemical class 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 238000010511 deprotection reaction Methods 0.000 description 18
- 201000004624 dermatitis Diseases 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- 238000007792 addition Methods 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atoms Chemical group C* 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 15
- 208000006673 Asthma Diseases 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 238000004808 supercritical fluid chromatography Methods 0.000 description 14
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 13
- 102100019516 JAK2 Human genes 0.000 description 12
- 101700016050 JAK2 Proteins 0.000 description 12
- 231100000406 dermatitis Toxicity 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 229910052799 carbon Inorganic materials 0.000 description 11
- 239000001184 potassium carbonate Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- 101700046984 CDK20 Proteins 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 230000035492 administration Effects 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 206010003645 Atopy Diseases 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 102000001253 Protein Kinases Human genes 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 235000011167 hydrochloric acid Nutrition 0.000 description 9
- 229960000443 hydrochloric acid Drugs 0.000 description 9
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 125000003396 thiol group Chemical group [H]S* 0.000 description 9
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- 206010003816 Autoimmune disease Diseases 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 208000003251 Pruritus Diseases 0.000 description 8
- 101700057652 TYK2 Proteins 0.000 description 8
- 206010052779 Transplant rejections Diseases 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 102100019518 JAK3 Human genes 0.000 description 7
- 101700007593 JAK3 Proteins 0.000 description 7
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 210000004027 cells Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 230000001684 chronic Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 210000000056 organs Anatomy 0.000 description 7
- 229960001663 sulfanilamide Drugs 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 208000005679 Eczema Diseases 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 102100016864 TYK2 Human genes 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 231100001003 eczema Toxicity 0.000 description 6
- QSFMGLFKZZCCHK-UHFFFAOYSA-N heptane-3-sulfonamide Chemical compound CCCCC(CC)S(N)(=O)=O QSFMGLFKZZCCHK-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 244000144972 livestock Species 0.000 description 6
- 201000004681 psoriasis Diseases 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 206010013774 Dry eye Diseases 0.000 description 5
- 241000283086 Equidae Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- NVBFHJWHLNUMCV-UHFFFAOYSA-N Sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 5
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- DATJETPTDKFEEF-UHFFFAOYSA-N pyrrolidine-3-carbonitrile Chemical compound N#CC1CCNC1 DATJETPTDKFEEF-UHFFFAOYSA-N 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 230000001131 transforming Effects 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 206010011401 Crohn's disease Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010025135 Lupus erythematosus Diseases 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 206010053643 Neurodegenerative disease Diseases 0.000 description 4
- 206010038683 Respiratory disease Diseases 0.000 description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 4
- 206010040767 Sjogren's syndrome Diseases 0.000 description 4
- 210000001744 T-Lymphocytes Anatomy 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 235000020127 ayran Nutrition 0.000 description 4
- 238000004296 chiral HPLC Methods 0.000 description 4
- SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory Effects 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- HORCNXKMXIIIKA-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1.COS(=O)(=O)C1=CC=C(C)C=C1 HORCNXKMXIIIKA-UHFFFAOYSA-N 0.000 description 4
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 150000002829 nitrogen Chemical group 0.000 description 4
- 230000000414 obstructive Effects 0.000 description 4
- GPHQHTOMRSGBNZ-UHFFFAOYSA-N pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC=C1 GPHQHTOMRSGBNZ-UHFFFAOYSA-N 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 150000003568 thioethers Chemical class 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 4
- VHWVXFKITKKZGZ-UHFFFAOYSA-N (1-methyl-3-methylidenecyclobutyl)methanol Chemical compound OCC1(C)CC(=C)C1 VHWVXFKITKKZGZ-UHFFFAOYSA-N 0.000 description 3
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 3
- DEAYGFQVUHWMCP-UHFFFAOYSA-N 2-(3-hydroxycyclobutyl)acetonitrile Chemical compound OC1CC(CC#N)C1 DEAYGFQVUHWMCP-UHFFFAOYSA-N 0.000 description 3
- NRUZGJCZHYLYLG-UHFFFAOYSA-N 4,4-difluoro-1$l^{2}-azinane Chemical group FC1(F)CC[N]CC1 NRUZGJCZHYLYLG-UHFFFAOYSA-N 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- 208000000884 Airway Obstruction Diseases 0.000 description 3
- 206010001897 Alzheimer's disease Diseases 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 206010023332 Keratitis Diseases 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- FXZWPZMCZNJILD-UHFFFAOYSA-N N-[(6-bromopyridin-3-yl)methyl]ethanamine;hydrochloride Chemical compound Cl.CCNCC1=CC=C(Br)N=C1 FXZWPZMCZNJILD-UHFFFAOYSA-N 0.000 description 3
- OSHXXOCGXCIKKN-UHFFFAOYSA-M N-phenylmethoxycarbamate Chemical compound [O-]C(=O)NOCC1=CC=CC=C1 OSHXXOCGXCIKKN-UHFFFAOYSA-M 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- 108060006633 Protein Kinases Proteins 0.000 description 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 3
- UPZKWBRGTGMPPT-UHFFFAOYSA-N S-[3-(cyanomethyl)-3-methylcyclobutyl] ethanethioate Chemical compound CC(=O)SC1CC(C)(CC#N)C1 UPZKWBRGTGMPPT-UHFFFAOYSA-N 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 102000036902 Thrombopoietin Human genes 0.000 description 3
- 108010041111 Thrombopoietin Proteins 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- DIZHTQAXUYZPBW-UHFFFAOYSA-N [3-(cyanomethyl)oxetan-3-yl]methanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1(CC#N)COC1 DIZHTQAXUYZPBW-UHFFFAOYSA-N 0.000 description 3
- FCGMOGXHPQIDAB-UHFFFAOYSA-N [3-(cyanomethyl)oxetan-3-yl]methyl thiocyanate Chemical compound N#CSCC1(CC#N)COC1 FCGMOGXHPQIDAB-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 3
- DRROTPCCFFMHNX-UHFFFAOYSA-N benzyl N-[3-(methylamino)cyclobutyl]carbamate Chemical compound C1C(NC)CC1NC(=O)OCC1=CC=CC=C1 DRROTPCCFFMHNX-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000002612 cardiopulmonary Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 3
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- AFNBMGLGYSGFEZ-UHFFFAOYSA-M potassium;ethanethioate Chemical compound [K+].CC([S-])=O AFNBMGLGYSGFEZ-UHFFFAOYSA-M 0.000 description 3
- 230000001823 pruritic Effects 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 3
- 229940001607 sodium bisulfite Drugs 0.000 description 3
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 125000003944 tolyl group Chemical group 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 201000006704 ulcerative colitis Diseases 0.000 description 3
- 238000002689 xenotransplantation Methods 0.000 description 3
- OKVDYEVFRPTUDY-UHFFFAOYSA-N (1-methyl-3-methylidenecyclobutyl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1(C)CC(=C)C1 OKVDYEVFRPTUDY-UHFFFAOYSA-N 0.000 description 2
- KSDQPTTTZMJYGQ-OLZOCXBDSA-N (1R,3S)-3-N-benzyl-1-N-methylcyclopentane-1,3-diamine Chemical compound C1[C@H](NC)CC[C@@H]1NCC1=CC=CC=C1 KSDQPTTTZMJYGQ-OLZOCXBDSA-N 0.000 description 2
- BCKQZBURCGQHFI-UHFFFAOYSA-N (3,3-difluorocyclobutyl)methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1CC(F)(F)C1 BCKQZBURCGQHFI-UHFFFAOYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- XQFGVGNRDPFKFJ-UHFFFAOYSA-N 1,2,3,5,6,7-hexahydropyrrolo[1,2-b]pyridazine Chemical compound N1CCC=C2CCCN21 XQFGVGNRDPFKFJ-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- IDHHSXMRNXRQSW-UHFFFAOYSA-N 1-methyl-3-methylidenecyclobutane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC(=C)C1 IDHHSXMRNXRQSW-UHFFFAOYSA-N 0.000 description 2
- MLTJOOBGZFDFRF-UHFFFAOYSA-N 2-(3-hydroxy-1-methylcyclobutyl)acetonitrile Chemical compound N#CCC1(C)CC(O)C1 MLTJOOBGZFDFRF-UHFFFAOYSA-N 0.000 description 2
- CFESRZFULNHJJU-UHFFFAOYSA-N 2-(3-phenylmethoxycyclobutylidene)acetonitrile Chemical compound C1C(=CC#N)CC1OCC1=CC=CC=C1 CFESRZFULNHJJU-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- JJUVMORPLVBMQL-UHFFFAOYSA-N 2-sulfanylidene-1H-pyridine-4-carbonitrile Chemical compound S=C1C=C(C#N)C=CN1 JJUVMORPLVBMQL-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- ZMMHJHWUKIEUJA-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane-1-carbonitrile Chemical compound C1NCC2(C#N)C1C2 ZMMHJHWUKIEUJA-UHFFFAOYSA-N 0.000 description 2
- YHOLAGDZXSDDPR-UHFFFAOYSA-N 4-cyano-N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]pyridine-2-sulfonamide Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C(C1)CC1NS(=O)(=O)C1=CC(C#N)=CC=N1 YHOLAGDZXSDDPR-UHFFFAOYSA-N 0.000 description 2
- SUJGVVCZKQCEOP-UHFFFAOYSA-N 4-cyanopyridine-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(C#N)=CC=N1 SUJGVVCZKQCEOP-UHFFFAOYSA-N 0.000 description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- WQAQPCDUOCURKW-UHFFFAOYSA-N Butanethiol Chemical compound CCCCS WQAQPCDUOCURKW-UHFFFAOYSA-N 0.000 description 2
- 102100004477 CLCF1 Human genes 0.000 description 2
- 101700062045 CLCF1 Proteins 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 2
- 208000009745 Eye Disease Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102100014204 IL22 Human genes 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 102000036507 JAK family Human genes 0.000 description 2
- 108091020259 JAK family Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 208000009856 Lung Disease Diseases 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- SHIYOUABBILWML-HAQNSBGRSA-N N([C@H]1C[C@@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC1 Chemical compound N([C@H]1C[C@@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC1 SHIYOUABBILWML-HAQNSBGRSA-N 0.000 description 2
- DSNWWEIXZLXIAO-TXEJJXNPSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1COC1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1COC1 DSNWWEIXZLXIAO-TXEJJXNPSA-N 0.000 description 2
- DBZPDOVADFHKLP-ZSZSROOQSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@H]1C[C@H](CC#N)C1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)[C@H]1C[C@H](CC#N)C1 DBZPDOVADFHKLP-ZSZSROOQSA-N 0.000 description 2
- 239000012425 OXONE® Substances 0.000 description 2
- 241000283903 Ovis aries Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- SUVIGLJNEAMWEG-UHFFFAOYSA-N Propanethiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229940100996 SODIUM BISULFATE Drugs 0.000 description 2
- 206010040070 Septic shock Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 229940083542 Sodium Drugs 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940091252 Sodium supplements Drugs 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 229960001967 Tacrolimus Drugs 0.000 description 2
- 206010043709 Thyroid disease Diseases 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N Trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- VADGYMAIAMJJLP-UHFFFAOYSA-N [3-(cyanomethyl)-3-methylcyclobutyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CC(C)(CC#N)C1 VADGYMAIAMJJLP-UHFFFAOYSA-N 0.000 description 2
- QJIXIPKLVVDFDO-UHFFFAOYSA-M [O-]S(=O)(=O)C(Br)I Chemical compound [O-]S(=O)(=O)C(Br)I QJIXIPKLVVDFDO-UHFFFAOYSA-M 0.000 description 2
- IUEWXNHSKRWHDY-PHIMTYICSA-N abrocitinib Chemical compound C1[C@@H](NS(=O)(=O)CCC)C[C@H]1N(C)C1=NC=NC2=C1C=CN2 IUEWXNHSKRWHDY-PHIMTYICSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 201000011186 acute T cell leukemia Diseases 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- LIQUZQIYBXPLDC-RBUKOAKNSA-N benzyl N-[(1R,3S)-3-(benzylamino)cyclopentyl]carbamate Chemical compound N([C@H]1CC[C@H](C1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 LIQUZQIYBXPLDC-RBUKOAKNSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- XJPMSKSCGIBWPC-UHFFFAOYSA-N cyclopropylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1CC1 XJPMSKSCGIBWPC-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000001146 hypoxic Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 201000002481 myositis Diseases 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 2
- YKOWCKUSQRRSSZ-UHFFFAOYSA-N oxetan-3-ylmethanesulfonyl chloride Chemical compound ClS(=O)(=O)CC1COC1 YKOWCKUSQRRSSZ-UHFFFAOYSA-N 0.000 description 2
- XNRDAEVPJXGQEO-UHFFFAOYSA-N oxetan-3-ylmethyl thiocyanate Chemical compound N#CSCC1COC1 XNRDAEVPJXGQEO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- HVAHYVDBVDILBL-UHFFFAOYSA-M potassium;oxidooxy hydrogen sulfate Chemical compound [K+].OS(=O)(=O)OO[O-] HVAHYVDBVDILBL-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000010405 reoxidation reaction Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229940026752 topical Sulfonamides Drugs 0.000 description 2
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- WEZZOFVMCBEZFW-UHFFFAOYSA-N 1-(trifluoromethyl)piperidin-4-ol Chemical compound OC1CCN(C(F)(F)F)CC1 WEZZOFVMCBEZFW-UHFFFAOYSA-N 0.000 description 1
- MHKJSOCUGZPRAA-UHFFFAOYSA-N 1-N-methyl-1-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclobutane-1,3-diamine;hydrochloride Chemical compound Cl.N=1C=NC=2NC=CC=2C=1N(C)C1CC(N)C1 MHKJSOCUGZPRAA-UHFFFAOYSA-N 0.000 description 1
- MBKPMXKMSILKBZ-UHFFFAOYSA-N 1-cyclopropyl-N-[3-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]cyclobutyl]azetidine-3-sulfonamide Chemical compound N=1C=NC=2N(S(=O)(=O)C=3C=CC(C)=CC=3)C=CC=2C=1N(C)C(C1)CC1NS(=O)(=O)C(C1)CN1C1CC1 MBKPMXKMSILKBZ-UHFFFAOYSA-N 0.000 description 1
- BWFQEOQVRYWZSG-UHFFFAOYSA-N 1-methyl-3-methylidenecyclobutane-1-carbonitrile Chemical compound N#CC1(C)CC(=C)C1 BWFQEOQVRYWZSG-UHFFFAOYSA-N 0.000 description 1
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- SDXZDWPJIYCVLF-UHFFFAOYSA-N 2-(1-methyl-3-methylidenecyclobutyl)acetonitrile Chemical compound N#CCC1(C)CC(=C)C1 SDXZDWPJIYCVLF-UHFFFAOYSA-N 0.000 description 1
- NXHBGJIJXKKIRL-UHFFFAOYSA-N 2-(1-methyl-3-oxocyclobutyl)acetonitrile Chemical compound N#CCC1(C)CC(=O)C1 NXHBGJIJXKKIRL-UHFFFAOYSA-N 0.000 description 1
- KDHCQHWJIJPVQW-UHFFFAOYSA-N 2-(3-phenylmethoxycyclobutyl)acetonitrile Chemical compound C1C(CC#N)CC1OCC1=CC=CC=C1 KDHCQHWJIJPVQW-UHFFFAOYSA-N 0.000 description 1
- URRCWJIXJMEOET-UHFFFAOYSA-N 2-(5-methoxythiophen-2-yl)ethanethioic S-acid Chemical compound COC1=CC=C(CC(S)=O)S1 URRCWJIXJMEOET-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- DNNDHBCKXZKMDG-UHFFFAOYSA-N 2-[[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]methylsulfanyl]pyridine-4-carbonitrile Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C(C1)CC1CSC1=CC(C#N)=CC=N1 DNNDHBCKXZKMDG-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- CSEJMYVAIPCCMY-UHFFFAOYSA-N 2-benzylsulfanylpyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(SCC=2C=CC=CC=2)=C1 CSEJMYVAIPCCMY-UHFFFAOYSA-N 0.000 description 1
- HJOQGBBHVRYTDX-UHFFFAOYSA-N 2-chloro-7H-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=C2C=CNC2=N1 HJOQGBBHVRYTDX-UHFFFAOYSA-N 0.000 description 1
- QRXBTPFMCTXCRD-UHFFFAOYSA-N 2-chloropyridine-4-carbonitrile Chemical compound ClC1=CC(C#N)=CC=N1 QRXBTPFMCTXCRD-UHFFFAOYSA-N 0.000 description 1
- JVOCWIRGDNWGKH-UHFFFAOYSA-N 2-cyclopropylethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1CC1 JVOCWIRGDNWGKH-UHFFFAOYSA-N 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- IQYWABFMCPBWBS-UHFFFAOYSA-N 2-methyl-1,3-thiazole-5-sulfonyl chloride Chemical compound CC1=NC=C(S(Cl)(=O)=O)S1 IQYWABFMCPBWBS-UHFFFAOYSA-N 0.000 description 1
- ONCWUIBQLZGBFF-UHFFFAOYSA-N 2-methyl-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazole;hydrochloride Chemical compound Cl.C1NCC2=NN(C)C=C21 ONCWUIBQLZGBFF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- NQLNHTOCFWUYQE-UHFFFAOYSA-N 2-methylpropane-1-sulfonyl chloride Chemical compound CC(C)CS(Cl)(=O)=O NQLNHTOCFWUYQE-UHFFFAOYSA-N 0.000 description 1
- JKWBMAJJDVYJNL-UHFFFAOYSA-N 2-oxo-1,3-oxazolidine-3-sulfonamide Chemical compound NS(=O)(=O)N1CCOC1=O JKWBMAJJDVYJNL-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QXYNIWCYMQIZBV-UHFFFAOYSA-N 3,3-difluorocyclobutane-1-sulfonyl chloride Chemical compound FC1(F)CC(S(Cl)(=O)=O)C1 QXYNIWCYMQIZBV-UHFFFAOYSA-N 0.000 description 1
- YFSNGMQPIKEGCW-UHFFFAOYSA-N 3-(1-hydroxyethyl)-N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]benzenesulfonamide Chemical compound CC(O)C1=CC=CC(S(=O)(=O)NC2CC(C2)N(C)C=2C=3C=CNC=3N=CN=2)=C1 YFSNGMQPIKEGCW-UHFFFAOYSA-N 0.000 description 1
- JOGCIOBFISPMGA-UHFFFAOYSA-N 3-(cyanomethyl)-3-methylcyclobutane-1-sulfonyl chloride Chemical compound N#CCC1(C)CC(S(Cl)(=O)=O)C1 JOGCIOBFISPMGA-UHFFFAOYSA-N 0.000 description 1
- ROWGHYMBNGHROG-UHFFFAOYSA-N 3-(cyanomethyl)cyclobutane-1-sulfonyl chloride Chemical compound ClS(=O)(=O)C1CC(CC#N)C1 ROWGHYMBNGHROG-UHFFFAOYSA-N 0.000 description 1
- ZCADJNLKKKYQPM-UHFFFAOYSA-N 3-(hydroxymethyl)-N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]benzenesulfonamide Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C(C1)CC1NS(=O)(=O)C1=CC=CC(CO)=C1 ZCADJNLKKKYQPM-UHFFFAOYSA-N 0.000 description 1
- UNIJBMUBHBAUET-UHFFFAOYSA-N 3-(methylamino)propanenitrile Chemical compound CNCCC#N UNIJBMUBHBAUET-UHFFFAOYSA-N 0.000 description 1
- KLCYDBAYYYVNFM-UHFFFAOYSA-M 3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC1CC(C([O-])=O)C1 KLCYDBAYYYVNFM-UHFFFAOYSA-M 0.000 description 1
- SFSHSIFYTWIGSF-UHFFFAOYSA-N 3-chloro-4-fluorobenzenethiol Chemical compound FC1=CC=C(S)C=C1Cl SFSHSIFYTWIGSF-UHFFFAOYSA-N 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- HLLGXEBDOPSSNT-UHFFFAOYSA-N 3-formyl-N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]benzenesulfonamide Chemical compound N=1C=NC=2NC=CC=2C=1N(C)C(C1)CC1NS(=O)(=O)C1=CC=CC(C=O)=C1 HLLGXEBDOPSSNT-UHFFFAOYSA-N 0.000 description 1
- CBYFMEDJHNTXQX-UHFFFAOYSA-N 3-hydroxycyclopentane-1-carbonitrile Chemical compound OC1CCC(C#N)C1 CBYFMEDJHNTXQX-UHFFFAOYSA-N 0.000 description 1
- ZRWMAMOBIQQJSA-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carbonitrile Chemical compound C=C1CC(C#N)C1 ZRWMAMOBIQQJSA-UHFFFAOYSA-N 0.000 description 1
- GPPSQLLIFNWNSB-UHFFFAOYSA-N 3-phenylmethoxycyclobutan-1-one Chemical compound C1C(=O)CC1OCC1=CC=CC=C1 GPPSQLLIFNWNSB-UHFFFAOYSA-N 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- FCKYIGWJVZIPLK-UHFFFAOYSA-N 4-(1H-pyrazol-5-yl)piperidine Chemical compound C1CNCCC1C1=CC=NN1 FCKYIGWJVZIPLK-UHFFFAOYSA-N 0.000 description 1
- AXPLSJSIKGZOMF-UHFFFAOYSA-N 4-(trifluoromethyl)piperidin-4-ol Chemical compound FC(F)(F)C1(O)CCNCC1 AXPLSJSIKGZOMF-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940092117 ATGAM Drugs 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- 206010004161 Basedow's disease Diseases 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- UENWRTRMUIOCKN-UHFFFAOYSA-N Benzyl mercaptan Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003432 Bone Disease Diseases 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010048396 Bone marrow transplant rejection Diseases 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- YSHOWEKUVWPFNR-UHFFFAOYSA-N Burgess reagent Substances CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 1
- LJWCTKDOBLLRBC-UHFFFAOYSA-M C(#N)CC1CC(C1)C1=C(C=CC(=C1)C)S(=O)(=O)[O-] Chemical compound C(#N)CC1CC(C1)C1=C(C=CC(=C1)C)S(=O)(=O)[O-] LJWCTKDOBLLRBC-UHFFFAOYSA-M 0.000 description 1
- NOTAIBNKJOSJBO-OYRHEFFESA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)OS(=O)(=O)C1=CC=C(C)C=C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)OS(=O)(=O)C1=CC=C(C)C=C1 NOTAIBNKJOSJBO-OYRHEFFESA-N 0.000 description 1
- ISQGUVXYSCPBBI-OKILXGFUSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC(C#N)=CC=N1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C1=CC(C#N)=CC=N1 ISQGUVXYSCPBBI-OKILXGFUSA-N 0.000 description 1
- WVPXLLNKSSQYKI-MCIONIFRSA-N C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@H](C#N)C1 Chemical compound C([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)N1CC[C@H](C#N)C1 WVPXLLNKSSQYKI-MCIONIFRSA-N 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- HBYTXXCPCDWTLW-UHFFFAOYSA-M C1N(C(=O)[O-])CC2CC21C=O Chemical compound C1N(C(=O)[O-])CC2CC21C=O HBYTXXCPCDWTLW-UHFFFAOYSA-M 0.000 description 1
- IDHHSXMRNXRQSW-UHFFFAOYSA-M CC1(CC(C1)=C)C(=O)[O-] Chemical compound CC1(CC(C1)=C)C(=O)[O-] IDHHSXMRNXRQSW-UHFFFAOYSA-M 0.000 description 1
- ZCLCARUQUJTUKH-UHFFFAOYSA-N CC1(CC(CC1)N)N Chemical compound CC1(CC(CC1)N)N ZCLCARUQUJTUKH-UHFFFAOYSA-N 0.000 description 1
- 102100003753 CCM2 Human genes 0.000 description 1
- 108060001227 CCM2 Proteins 0.000 description 1
- DSZFXAFWOBUIFN-ZKCHVHJHSA-N CN([C@@H]1C[C@H](C1)N)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN([C@@H]1C[C@H](C1)N)C=1C2=C(N=CN=1)NC=C2 DSZFXAFWOBUIFN-ZKCHVHJHSA-N 0.000 description 1
- MBWLFWCRQXQLRM-IYBDPMFKSA-M CN([C@H]1C[C@H](C1)NS(=O)(=O)C1CN(C1)C(=O)[O-])C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C=C1)C Chemical compound CN([C@H]1C[C@H](C1)NS(=O)(=O)C1CN(C1)C(=O)[O-])C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C=C1)C MBWLFWCRQXQLRM-IYBDPMFKSA-M 0.000 description 1
- 102100007493 CNTF Human genes 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 102100001997 CTF1 Human genes 0.000 description 1
- 101700011361 CTF1 Proteins 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N Chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N Chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- JEJWYGQWKNHONY-KYOXOEKESA-N Cl.CCOC(=O)[C@H]1C[C@H](N)C1 Chemical compound Cl.CCOC(=O)[C@H]1C[C@H](N)C1 JEJWYGQWKNHONY-KYOXOEKESA-N 0.000 description 1
- ROWGHYMBNGHROG-IZLXSQMJSA-N ClS(=O)(=O)[C@H]1C[C@H](CC#N)C1 Chemical compound ClS(=O)(=O)[C@H]1C[C@H](CC#N)C1 ROWGHYMBNGHROG-IZLXSQMJSA-N 0.000 description 1
- 206010009839 Coeliac disease Diseases 0.000 description 1
- 208000010007 Cogan Syndrome Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 210000004087 Cornea Anatomy 0.000 description 1
- 206010066968 Corneal leukoma Diseases 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229940109275 Cyclamate Drugs 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108010084740 Daclizumab Proteins 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N Di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229950010286 Diolamine Drugs 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 210000002351 Embryonic Muscle Cell Anatomy 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018651 Graft versus host disease Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 102100000579 HGF Human genes 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- 229950000177 Hibenzate Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 101700046422 IFNA Proteins 0.000 description 1
- 101700011451 IFNB1 Proteins 0.000 description 1
- 102100015720 IFNB1 Human genes 0.000 description 1
- 101700086956 IFNG Proteins 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 102000026182 IL-3 family Human genes 0.000 description 1
- 108091013091 IL-3 family Proteins 0.000 description 1
- 102100018957 IL19 Human genes 0.000 description 1
- 108060003940 IL6 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010027665 Immune disorder Diseases 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102100011646 LIF Human genes 0.000 description 1
- 101700037605 LIF Proteins 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 229940014456 MYCOPHENOLATE Drugs 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 208000008585 Mastocytosis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000008466 Metabolic Disease Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 201000009262 Mooren's ulcer Diseases 0.000 description 1
- 208000005264 Motor Neuron Disease Diseases 0.000 description 1
- 206010028003 Motor neurone disease Diseases 0.000 description 1
- 108090000393 Muromonab-CD3 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- BYYYODULJRBBBD-HDICACEKSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)CC1CC(F)(F)C1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CN(C=2N=CN=1)S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)CC1CC(F)(F)C1 BYYYODULJRBBBD-HDICACEKSA-N 0.000 description 1
- YDNLORWGBHLJEZ-BJHJDKERSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C(C1)CN1C1CC1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)C(C1)CN1C1CC1 YDNLORWGBHLJEZ-BJHJDKERSA-N 0.000 description 1
- QRBIOPYFNMJDBK-BETUJISGSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1(CC#N)COC1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1(CC#N)COC1 QRBIOPYFNMJDBK-BETUJISGSA-N 0.000 description 1
- SVHHNUAYDGGVHF-TXEJJXNPSA-N N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC(F)(F)C1 Chemical compound N([C@H]1C[C@H](C1)N(C)C=1C=2C=CNC=2N=CN=1)S(=O)(=O)CC1CC(F)(F)C1 SVHHNUAYDGGVHF-TXEJJXNPSA-N 0.000 description 1
- APLGHEBYNMYFAZ-NWDGAFQWSA-N N-[(1S,3R)-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclopentyl]propane-1-sulfonamide Chemical compound C1[C@@H](NS(=O)(=O)CCC)CC[C@H]1N(C)C1=NC=NC2=C1C=CN2 APLGHEBYNMYFAZ-NWDGAFQWSA-N 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N N-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- GHXJWGQVPJJPIE-UHFFFAOYSA-M N-[3-[(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-methylamino]cyclobutyl]carbamate Chemical compound N=1C(Cl)=NC=2NC=CC=2C=1N(C)C1CC(NC([O-])=O)C1 GHXJWGQVPJJPIE-UHFFFAOYSA-M 0.000 description 1
- VFXLCPGNCQSXKE-UHFFFAOYSA-N N-[3-[(4,4-difluoropiperidin-1-yl)sulfonylmethyl]cyclobutyl]-N-methyl-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N=1C=NC=2N(S(=O)(=O)C=3C=CC(C)=CC=3)C=CC=2C=1N(C)C(C1)CC1CS(=O)(=O)N1CCC(F)(F)CC1 VFXLCPGNCQSXKE-UHFFFAOYSA-N 0.000 description 1
- RQLXKQUZTLVUQY-UHFFFAOYSA-N N-[3-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]cyclobutyl]azetidine-3-sulfonamide Chemical compound N=1C=NC=2N(S(=O)(=O)C=3C=CC(C)=CC=3)C=CC=2C=1N(C)C(C1)CC1NS(=O)(=O)C1CNC1 RQLXKQUZTLVUQY-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 206010061877 Obstructive airways disease Diseases 0.000 description 1
- 229950004864 Olamine Drugs 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229960003975 Potassium Drugs 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N Potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M Potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 1
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 1
- 229940043131 Pyroglutamate Drugs 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- ZKFAOIPWHUQJJH-UHFFFAOYSA-N S-[3-(cyanomethyl)cyclobutyl] ethanethioate Chemical compound CC(=O)SC1CC(CC#N)C1 ZKFAOIPWHUQJJH-UHFFFAOYSA-N 0.000 description 1
- 102100019667 STAT3 Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Sodium cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 102100005288 TSLP Human genes 0.000 description 1
- 101700027709 TSLP Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-N Thioacetic acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- 206010047680 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- WNRQMQOPAVQWIR-UHFFFAOYSA-N [3-(cyanomethyl)cyclobutyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CC(CC#N)C1 WNRQMQOPAVQWIR-UHFFFAOYSA-N 0.000 description 1
- FKKPNLJBJLIKOI-UHFFFAOYSA-N [3-(cyanomethyl)oxetan-3-yl]methyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1(CC#N)COC1 FKKPNLJBJLIKOI-UHFFFAOYSA-N 0.000 description 1
- XTCODXIBYUDBPQ-UHFFFAOYSA-N [Li+].C[SiH](C)[N-][SiH](C)C Chemical compound [Li+].C[SiH](C)[N-][SiH](C)C XTCODXIBYUDBPQ-UHFFFAOYSA-N 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- LPOHISIOJHPMJN-UHFFFAOYSA-N [Na+].C[SiH](C)[N-][SiH](C)C Chemical compound [Na+].C[SiH](C)[N-][SiH](C)C LPOHISIOJHPMJN-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002009 allergen Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-M azetidine-1-carboxylate Chemical compound [O-]C(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-M 0.000 description 1
- PBIUUJCEMUAWJJ-UHFFFAOYSA-N azetidine-3-carbonitrile Chemical compound N#CC1CNC1 PBIUUJCEMUAWJJ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- PSAMWNBBHLUISE-UHFFFAOYSA-N benzyl N-(3-oxocyclobutyl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CC(=O)C1 PSAMWNBBHLUISE-UHFFFAOYSA-N 0.000 description 1
- GTRLQRHWPXEBLF-UHFFFAOYSA-N benzyl carbamimidothioate Chemical compound NC(=N)SCC1=CC=CC=C1 GTRLQRHWPXEBLF-UHFFFAOYSA-N 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 101710014509 celF Proteins 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 108060001790 con-10 Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XYXWCEWUIUOMAU-UHFFFAOYSA-N cyclobutyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CCC1 XYXWCEWUIUOMAU-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N deuteriooxymethane Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- BTFSVBAFIHSVBO-UHFFFAOYSA-N dichloromethane;1,4-dioxane Chemical compound ClCCl.C1COCCO1 BTFSVBAFIHSVBO-UHFFFAOYSA-N 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- XKHOHMXSBJQHCV-UHFFFAOYSA-N ethyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CC(NC(=O)OC(C)(C)C)C1 XKHOHMXSBJQHCV-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- NCTRLWWHIUUNBE-UHFFFAOYSA-N hexane-3-sulfonamide Chemical compound CCCC(CC)S(N)(=O)=O NCTRLWWHIUUNBE-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl radical Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108010052322 limitin Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-L lithium;dihydroxide Chemical compound [Li+].[OH-].[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-L 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000002887 neurotoxic Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-M orotate Chemical compound [O-]C(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-M 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- DZDXQYOMYPRXBA-UHFFFAOYSA-N oxetan-3-ylmethyl 4-methylbenzenesulfonate Chemical group C1=CC(C)=CC=C1S(=O)(=O)OCC1COC1 DZDXQYOMYPRXBA-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- FLKRMXAWABTWSH-UHFFFAOYSA-N piperidine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCCCC1 FLKRMXAWABTWSH-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 201000001263 psoriatic arthritis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-M pyrrolidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-M 0.000 description 1
- LMBZZTJQNYGICT-UHFFFAOYSA-N pyrrolidine-3-carbonitrile;hydrochloride Chemical compound Cl.N#CC1CCNC1 LMBZZTJQNYGICT-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium triacetoxyborohydride Substances [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- BTWDGFQQIGGAPU-UHFFFAOYSA-N tert-butyl 1-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CC21CO BTWDGFQQIGGAPU-UHFFFAOYSA-N 0.000 description 1
- OUEYQXTXPXEUEA-UHFFFAOYSA-N tert-butyl 3-[[3-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]cyclobutyl]methylsulfanyl]pyrrolidine-1-carboxylate Chemical compound N=1C=NC=2N(S(=O)(=O)C=3C=CC(C)=CC=3)C=CC=2C=1N(C)C(C1)CC1CSC1CCN(C(=O)OC(C)(C)C)C1 OUEYQXTXPXEUEA-UHFFFAOYSA-N 0.000 description 1
- AZNUWDVFBPYWSU-UHFFFAOYSA-N tert-butyl 3-chlorosulfonylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(S(Cl)(=O)=O)C1 AZNUWDVFBPYWSU-UHFFFAOYSA-N 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- YSHOWEKUVWPFNR-UHFFFAOYSA-O triethyl(methoxycarbonylsulfamoyl)azanium Chemical compound CC[N+](CC)(CC)S(=O)(=O)NC(=O)OC YSHOWEKUVWPFNR-UHFFFAOYSA-O 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Abstract
Described herein are pyrrolo{2,3-d} pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Description
Described herein are pyrrolo{2,3-d} pyrimidine dérivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
O.A.P.I. - B.P. 887, YAOUNDE (Cameroun) - Tel. (237) 222 20 57 00- Fax: (237) 222 20 57 27- Site web: http:/www.oapi.int - Email: oapi@oapi.int
DEMANDE DE BREVET D’INVENTION
PCT/IB2014/058889 DU 11/02/2014
Nom du Déposant(s): PFIZER INC.
Titre d’invention:
PYRROLO [2, 3 -DJPYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED
KINASES (JAK)
Noms d’inventeur(s):
1. BROWN,. MatthewFrank
2. FENWÏCK, Aëhley Edward
3. FLANAGAN, Mark Edward
4. GONZALES, Andrea
5. JOHNSON, Timothy Allan
6. KAILA, Neelu
7. MITTON-FRY, Mark J.
8. STROHBACH, Joseph Walter
9. TENBRINK, Ruth E.
10. TRZUPEK, John David
11. UNWALLA.' Rayomand Jal
12. VAZQUEZ, Michael L.
13. MIHIR, D. Parikh
Mandataire : SCP AKKUM, AKKUM & Associâtes
B.P 4966 Yaoundé - Cameroun.
l
PYRROLO[2,3-DJPYRIMIDlNE DERIVATIVES
FIELD OF THE INVENTION
The présent invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidine compounds and analogues. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.
BACKGROUND OF THE INVENTION
Protein kinases are families of enzymes that catalyze the phosphorylation of spécifie residues in proteins, broadly classified into tyrosine and serine/threonine kinases, inappropriate kinase activity, arising from mutation, over-expression, or inappropriate régulation, dys-regulation or de-regulation, as well as over- or under-production of growth factors or cytokines has been implicated in many diseases, including but not limited to cancer, cardiovascular diseases, allergies, asthma and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic disorders, and neurological and neurodegenerative disorders such as Alzheimer's disease. Inappropriate kinase activity triggers a variety of biological cellular responses relating to cell growth, cell différentiation, survival, apoptosis, mitogenesis, cell cycle control, and cell mobility implicated in the aforementioned and related diseases.
Thus, protein kinases hâve emerged as an important class of enzymes as targets for therapeutic intervention. In particular, the JAK family of cellular protein tyrosine kinases (JAK1, JAK2, JAK3, and Tyk2) play a central rôle in cytokine signaling (Kisseleva et al., Gene, 2002, 285,1; Yamaoka et al. Genome Biology 2004, 5, 253)). Upon binding to their receptors, cytokines activate JAK which then phosphorylate the cytokine receptor, thereby creating docking sites for signaling molécules, notably, members
of the signal transducer and activator of transcription (STAT) family that ultimateiy lead to gene expression. Numerous cytokines are known to activate the JAK family. These cytokines include, the IFN family (IFN-alpha, IFN-beta, IFN-omega, Limitin, IFN-gamma, IL-10, IL-19, IL-20, IL-22), the gp130 family (IL-6, IL-11, OSM, LIF, CNTF, NNT-1/BSF-3, G-CSF, CT-1, Leptin, IL-12, IL-23). gamma C family (IL-2, IL-7, TSLP, IL-9, tL-15, IL-21, IL-4, tL-13), IL-3 family (IL-3, IL-5, GM-CSF), single chain family (EPO, GH, PRL, TPO), receptor tyrosine kinases (EGF, PDGF, CSF-1, HGF), and G-protein coupled receptors (AT1).
There remains a need for new compounds that effectively and selectively inhibit spécifie JAK enzymes, and JAK1 in particuiar, vs, JAK2. JAK1 is a member of the Janus family of protein kinases composed of JAK1, JAK2, JAK3 and TYK2. JAK1 is expressed to various levels in ali tissues. Many cytokine receptors signal through pairs of JAK kinases in the following combinations: JAK1 /JAK2, JAK1 /JAK3, JAK1/TYK2, JAK2/TYK2 or JAK2/JAK2. JAK1 is the most broadly paired JAK kinase in this context and ts required for signaling by γ-common (IL-2Ry) cytokine receptors, IL-6 receptor family, Type I, II and III receptor families and IL-10 receptor family. Animal studies hâve shown that JAK1 is required for the development, function and homeostasis of the immune system. Modulation of immune activity through inhibition of JAK1 kinase activity can prove useful in the treatment of various immune disorders (Murray, P.J. J, Immunol., 178, 2623-2629 (2007); Kisseleva, T„ et al., Gene, 285,1-24 (2002); O'Shea, J. J., et al., Cell, 109, (suppl.) S121-S 131 (2002)) while avoiding JAK2 dépendent erythropoietin (EPO) and thrombopoietin (TPO) signaling (Neubauer H,, et al., Cell, 93(3), 397-409 (1998); Parganas E,, et al„ Cell, 93(3), 385-95 (1998)),
SUMMARY OF THE INVENTION
The présent invention provides a compound of formula I having the structure:
or a pharmaceutically acceptable sait thereof, wherein R1 is hydrogen or C1-C4 alkyl, wherein said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, CF3, and Ca-Ce cycloalkyl; R2 and R3 are each independently hydrogen, deuter5 ium, Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, Ci-Cs linear or branched chain perfluoroalkyl, Ci-Ce linear or branched chain alkoxy, Ci-Ce linear or branched chain perfluoroalkoxy, halogen, cyano, hydroxyl, amino, carboxy, aminocarbonyl, aryl, heteroaryl, (aryl)Ci-Ce linear or branched chain alkyl, (heteroaryl)Ci-Ce linear or branched chain alkyl, (heterocyclic)Ci-Ce linear or branched chain alkyl, (Ci-Ce linear or branched chain alkyl)aryl, (Ci-Ce linear or branched chain alkyljheteroaryl, (Ci-Ce linear or branched chain alkyl)heterocyclic, (Ci-Ce linear or branched chain alkoxyl)carbonyl, (Ci-Ce linear or branched chain alkyl)amino-carbonylamino, or (Ci-Ce linear or branched chain alkyl)aminocarbonyl; R4 is selected from hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, Ci-Ce linear or branched chain perfluoroalkyl, aryl, and alkylaryl; X is selected from -NH-- and —CRaRb-, where (a) Ra and Rb are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, (aryl)Ci-Ce linear or branched chain alkyl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, (heteroaryl)CiCe linear or branched chain alkyl. (heterocyclic)Ci-C6 linear or branched chain alkyl, or (b) Ra and Rb together form a chain comprising —(CRcRd)/-, where Rc and Rd are independently hydrogen, deuterium, C1Cë linear or branched chain alkyl, aryl, (Ci-Ce linear or branched chain alkyl)aryi, heteroaryl, (Ci-Ce linear
or branched chain alkylheteroaryl, haio, CN, CFa, hydroxyl, CONH2, or SO2CH3; Y is -A-R5, where A is a bond, --(CH2)k-- or -(CD2)k- and Rs is Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, or -NRa'Rb·, or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C3-C6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, hydroxy!, CF3, -ORa, --NReRf, S(0)PRe and C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH2, and SO2CH3, where (a) Ra- and Rb- are independently hydrogen, deuterium, Ci-Cb linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, (Ct-Ce linear or branched chain alkyl )aryl, heteroaryl, or (Ci-Ce linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc·, or (b) Ra- and Rb- together form a chain comprising —(CRcRd')r-. where Rc- and Rp are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, aryi, (Ci-Ce linear or branched chain alkyl)aryl, heteroaryl, (Ci-Ce linear or branched chain alkylheteroaryl, halo, CN, hydroxyl, CF3, CONH2, --ORe, NRaRf, or -S(O)PRe; where Re and Rt are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, or C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2;y is 2, 3, 4 or 5; /ris 1, 2; 3, or 4; p is 0, 1 or 2; and, n is 1 or 2.
In other aspects, the présent invention also provides:
pharmaceutical compositions which comprise a pharmaceutically acceptable carrier and a compound of formula I;
methods for treating conditions or disorders including myositis, vasculitis, pemphigus, Crohn’s disease, lupus, nephritis, psoriasis, multiple sclerosis, major dépréssion disorder, allergy, asthma, Sjogren's disease, dry eye syndrome, transplant rejection, cancer, inflammatory bowel disease, septic shock, cardiopulmonary dysfonction, acute respiratory disease, or cachexia by administering to a subject in need a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable sait thereof;
methods for treating conditions or disorders including atopie dermatitis, eczema, psoriasis, scleroderma, lupus, pruritus, other pruritic conditions, allergie réactions including allergie dermatitis in mammal, horse allergie diseases including bite hypersensitîvity, summer eczema, sweet itch in horses, heaves, inflammatory airway disease, récurrent airway obstruction, airway hyper-responsiveness, and chronic obstruction pulmonary disease by administering to a mammal in need a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable sait thereof; and, methods for the préparation of compounds of the présent invention. The présent invention will be further understood from the following description given by way of exampte only. The présent invention is directed to a class of pyrrolo[2,3-d]pyrimidine dérivatives. In particuiar, the présent invention is directed to pyrrolo[2,3-d]pyrimidine compounds useful as inhibitors of JAK, and particularly JAK1. While the présent invention is not so limited, an appréciation of various aspects of the invention will be gained through the following discussion and the examples.
The term alkyl, alone or in combination, means an acyclic, saturated hydrocarbon group of the formula CnH2n+i which may be linear or branched. Examples of such groups include methyl, ethyl, npropyl, isopropyl, π-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl and hexyl. Unless otherwise specified, an alkyl group comprises from 1 to 6 carbon atoms. The carbon atom content of alkyl and various other hydrocarbon-containîng moieties is indicated by a prefix designating a lower and upper number of carbon atoms in the moiety, that is, the prefix Ci-C, indicates a moiety of the integer i to the integer j carbon atoms, inclusive, Thus, for example, Ci-Ce alkyi refers to alkyi of one to six carbon atoms, inclusive.
The term “hydroxy, as used herein, means an OH radical. The term “heterocyclic refers to a saturated or partially saturated (i.e. non aromatic) heterocycle which may be attached via a ring nitrogen atom (when the heterocycle is attached to a carbon atom) or a ring carbon atom (in ail cases). Equally, when substituted, the substituent may be located on a ring nitrogen atom (if the substituent is joined through a carbon atom) or a ring carbon atom (in ail cases). Spécifie examples include oxiranyl, aziridinyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, piperazinyl, azepanyl, oxepanyl, oxazepanyl and diazepinyl.
The term “aryl” refers to an aromatic monocyclic or bicyclic hydrocarbon which may be attached via a ring carbon atom. Equally, when substituted, the substituent may be located on a ring carbon atom. Spécifie examples include phenyl, toluyl, xylyl. trimethylphenyl, and naphthyl. Examples of aryl substituents include alkyi, hydroxyl, halo, nrtrile, alkoxy, trifluoromethyl, carboxamido, SOîMe, benzyl, and substi15 tuted benzyl.
The term heteroaryl refers to an aromatic heterocycle which may be attached via a ring carbon atom (in ali cases) or a ring nitrogen atom with an appropriate valency (when the heterocycle is attached to a carbon atom). Equally. when substituted, the substituent may be located on a ring carbon atom (in ail cases) or a ring nitrogen atom with an appropriate valency (if the substituent is joined through a carbon 20 atom). Spécifie examples include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, îsothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrîmidinyl and pyrazinyl. The term cycloalkyl means a monocyclic, saturated hydrocarbon group of the formula CnHin17460
i. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cydohexyi, and cyclohaptyl. Unless otherwise specified, a cycloalkyl group comprises from 3 to 8 carbon atoms.
The terms “halo and “halogen refer to fluoride (F), chloride (Cl), bromide (Br) or iodide (I).
The term marnmal refers to human, livestock or companion animais.
The term companion animal or companion animais refers to animais kept as pets or household animal. Examples of companion animais include dogs, cats, and rodents Încluding hamsters, guinea pigs, gerbils and the like, rabbits, ferrets and birds.
The term livestock refers to animais reared or raised in an agricultural setting to make products such as food or fiber, or for its iabor. In some embodiments, livestock are suitable for consumption by mammals, for example humans. Examples of livestock animais include cattle, goats, horses, pigs, sheep, Încluding lambs, and rabbits, as well as birds, such as chickens, ducks and turkeys.
The term treating or “treatment means an alleviation of symptoms associated with a disease, disorder or condition, or hait of further progression or worsening of those symptoms. Dépending on the disease and condition of the patient, the term “treatment as used herein may include one or more of curative, palliative and prophyiactic treatment Treatment can also include administering a pharmaceutical formulation of the présent invention in combination with other thérapies.
The term therapeutically-effective indicates the capability of an agent to prevent, or improve the severity of, the disorder, while avoiding adverse side effects typically associated with alternative thérapies. The phrase therapeutically-effective is to be understood to be équivalent to the phrase effective for the treatment, prévention, or amelioration, and both are intended to qualify the amount of each agent for use in the combination therapy which will achieve the goal of improvement in the severity of cancer, cardiovascular disease, or pain and inflammation and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative thérapies.
Pharmaceutically acceptable means suitable for use in mammals, companion animais or livestock animais.
If substituents are described as being independently selected from a group, each substituent is selected independent of the other, Each substituent therefore may be identical to or different from the other substituent s).
DETAILED DESCRIPTION OF THE INVENTION
The présent invention is related to novel oompounds which are seiectrve JAK1 modulators useful for the treatment of diseases and conditions associated with dysrégulation of the JAK1. The présent invention further provides pharmaceutical compositions comprising such JAK1 modulators as well as methods of treating and/or preventing such diseases and conditions. Accordingly, the présent invention provides a compound of formula I having the structure:
or a pharmaceutically acceptable sait thereof, wherein R1 is hydrogen or C1-C4 alkyl, wherein said alkyl is further optionally substituted with one or more substituents selected from the group consîsting of halo, hydroxy, methoxy, amino, CF3, and C3-C6 cycloalkyl; R2 and R3 are each independently hydrogen, deuterium, C-i-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, Ci-Ce linear or branched chain perfluoroalkyl, Ci-Ce linear or branched chain alkoxy, Ci-Ce linear or branched chain perfltioroalkoxy, halogen, cyano, hydroxyl, amino, carboxy, aminocarbonyl, aryl, heteroaryl, (aryl)Ci-Ce linear or branched chain alkyl, (heteroaryl)Ci-C6 linear or branched chain alkyl, (heterocycircJCi-Ce linear or branched chain alkyl, (Ci-Ce linear or branched chain alkyl)aryl, (Ci-Ce linear or branched chain alkyljheteroaryl, (Ci-Ce linear or branched chain alkyl)heterocyclic, (Ci-Ce linear or branched chain alkoxy l)carbonyl, (Ci-Cg linear or branched chain alkyl)amino-carbony1amino, or (Ci-Ce linear or branched chain alkyl)aminocarbonyl; R4 is selected from hydrogen, deuterium, Ch-Ce linear or branched chain alkyl, Ci-Cs linear or branched chain perfluoroalkyl, aryl, and alkylaryl; X is selected from --NH-- and —CRaRb-, where (a) Ra and Rb are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, (aryl)CiCë linear or branched chain alkyl, heteroaryl, (Ci-Ce linear or branched chain aikyt)heteroaryl, (heteroarylJCi-Cs linear or branched chain alkyl, (heterocyclicJCi-Ce linear or branched chain alkyl, or (b) Ra and Rb together form a chain comprising — (CRcRdY. where Rc and Rd are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, aryl, (Ci-Cs linear or branched chain alkyl)aryl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, halo, CN, CF3, hydroxyl, CONH2, or SO2CH3; Y is -A-R5, where A is a bond, -(CHz)*-- or -(Œtejk-- and R5 is Ci-Ce linear or branched chain alkyl, C3Ce cycloalkyl, aryl, or ~NRaRb·, or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, Ca-Cs cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Cs linear or branched chain alkyl, CN, hydroxyl, CF3, -ORe, -NReRf, -S(O)pRe and Ca-Ce cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl.
CONHî, and SO2CH3, where (a) Ra· and Rb· are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl. C3-C6 cycloalkyl, aryl, (Ci-Ce linear or branched chain alkyljaryl, heteroaryl, or (C1Cs linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc , or (b) Ra· and R&· together form a chain comprising —(CRc-Rd·)/-, where Rc and Rd· are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, aryl, (C1-C6 linear or branched chain alkyljaryl, heteroaryl, (C1-C5 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl,
CFs, CONH2, “0Re, “NReRf, or --S(O)PRB: where Re and Rr are independently hydrogen, deuterium, C1Ce linear or branched chain alkyl, or C3-C5 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2; /is 2, 3, 4 or 5; k is 1, 2; 3, or 4; p is 0, 1 or 2; and, n ts 1 or 2.ln one embodiment, the inven tion provides a compound of formula IA having the structure:
or a pharmaceutically acceptable sait thereof, wherein Y is -A-Rs, where A is a bond, -(CH2)k- or (CD2)k-- and Rs is Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, or --NRa'Rb·, or is an un15 saturated, saturated or partially saturated monocyclîc or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C3-Ce cycloalkyl, aryl, or monocyclîc or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deu-
terium, halo, Ci-Cê linear or branched chain alkyl, CN, hydroxyI, CF3, -ORe, --NReRf, --S(O)PRa and Cs-Ce cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH2, and SO2CH3, where (a) Ra· and Rb· are independently hydrogen, deuterium, Ci-Ca linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, (Ci-Ce 5 linear or branched chain alkyljaryl, heteroaryl, or (Ci-Cs linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc·, or (b) Ra· and Rb· together form a chain comprising —(CRcRd·)/-, where Rc- and R<j· are independently hydrogen, deuterium, C1-C6 linear or branched chain alkyl, aryl, (Ci-Cs linear or branched chain alkyljaryl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CFs, CONH2, -ORe, -NReRt, or --S(O)PRe; where Re 10 and Rf are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, or Ca-Ce cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CFa, and CONH2;/is 2, 3, 4 or 5; fris 1.2; 3, or 4; and, p is 0, 1 or 2.
In one embodiment, the invention provides a compound of formula IA wherein A is a bond and R5 15 is a Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl or aryl. In another embodiment, the invention provides a compound of formula IA wherein A is a bond or —(CHîJk-, and R5 is C3-C6 cycloalkyl wherein said Ca-Ce cycloalkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, Ci-Ce linear or branched chain alkyl, and CN where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, 20 CN, hydroxyl, CONH2, and SO2CH3; where fris 1,2, or 3. In yet another embodiment, the invention provides a compound of formula IA wherein A îs a bond or --(CH2X-, and R5 is an unsaturated, saturated or partially saturated monocycltc or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sul-
fur, wherein said alkyl, C3-C6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, hydroxyI, CF3, -NRaRt>·, --0Re, -S(O)PRe and C3-C6 cycloalkyl; where fris 1, 2, or 3.
tn another embodiment, the invention provides the compound of formula IB having the structure:
Ra
or a pharmaceutically acceptable sait thereof, wherein (a) Ra· and Rb are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, Cî-Ce cycloalkyl, aryl, (Ci-Ce linear or branched chain alkyl)aryl, heteroaryl, or (Ci-Cs linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc, or (b) Ra- and Rb· together form a chain comprising --(CRc Rd )/-, where Rc and R<r are independently hydrogen, deuterium, Ci-Cs linear or branched chain alkyl, aryl, (Ci-Cb linear or branched chain alkyljaryl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF3, CONH2, -ORa, --NReRt, or-S(O)pRe: where Re and Rf are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, or C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2; or, (c) Ra· and Rt>· together form an unsaturated, saturated or partially
I3 saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, 5 hydroxyl, CF3, -NRa'Rb·, -0Re, --S(O)PRe and Ca-Ce cycloalkyl; /is 2, 3, 4 or 5; and, p is 0, 1 or 2.
In another embodiment, the invention provides the compound of formula IC having the structure:
IC or a pharmaceutically acceptable sait thereof, wherein (a) Ra- and Rb1 are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, (Ci-Ce linear or branched chain alkyl)aryl, 10 heteroaryl, or (Ci-Cs linear or branched chain alkylheteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc, or (b) Ra· and Rb· together form a chain comprising —(CRc Rd )/-, where Rc· and Rd· are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, aryl, (Ci-Cs linear or branched chain alkyl)aryl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CFa, CONH2, -OR0, --NReRt, or --S(O)PRa; where Re and Rt are independently hydro15 gen, deuterium, Ci-Ce linear or branched chain aikyi, or C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo,
CN, hydroxyl, CF3, and CONH2; or, (c) Ra- and Rb- together form an unsaturated, saturated or partialiy saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consîsting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic ring structure îs further optionally substituted with one or more sub5 stituents selected from the group consîsting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, hydroxyl, CFa, --NRa'Rb’, --0Ra, --S(O)PRa and Ca-Ce cycloalkyl; jis 2, 3, 4 or 5; and, p is 0, 1 or 2.
In another embodiment, the invention provides the compound of formula ID having the structure:
or a pharmaceutically acceptable sait thereof, wherein
Y is -AR5, where A is a bond or ~(CH2)k-, and R5 is Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consîsting of oxygen, nitrogen, and sulfur, wherein said alkyl, Cs-Ce cycloalkyl, aryl, or monocy15 clic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consîsting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, hydroxyl, CF3, --NRaRb·, -ORa, -S(O)pRb and C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consîsting of halo, CN, hydroxyl, CONH2, and SO2CH3,
I5 where (a) Ra· and Rb' are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyi, Ca-Ce cycloalkyl, aryl, (aryl)Ci*C6 linear or branched chain alkyi, heteroaryl, (Ci-Cs linear or branched chain alkyljheteroaryl, (heteroaryl)Ci-Ce linear or branched chain alkyi, (heterocyclic)Ci-Cs linear or branched chain alkyi, where said alkyi and cycloalkyl may be optionally substituted with one or more Rc·, or (b) Ra5 and Rb· together form a chain comprising —(CRc'Rd·)/-, where Rc and Rd are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyi, aryl, (Ci-Cs linear or branched chain alkyljaryl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CFa, CONH2, -ORa, -NReRr, or -S(0)PRB; where Re and Rr where are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyi, or C3-C6 cycloalkyl, where said alkyi and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2; /is 2, 3, 4 or 5; fris 1, 2, or 3; and, p is 0, 1 or 2. In one embodiment, the invention provides the compound of formula ID wherein R5 is a Ci-Ce linear or branched chain alkyi or C3-Ca cycloalkyl.
In another embodiment, the invention provides the compound of formula of formula ID wherein A îs a bond or -(CHîJk-, and R5 is an unsaturated, saturated or partially saturated monocyclic or bicyclic 15 ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyi, C3-C5 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Ce linear or branched chain alkyi, CN, hydroxyl, CF3, --NRaRb·, —ORe, —S(O)pRe and C3-C6 cycloalkyl; where Re and Rr are independently hydrogen, deu20 terium, Ci-Ce linear or branched chain alkyi, or Cs-Ce cycloalkyl, where said alkyi and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2; fris 1, 2, or 3; and, p is 0, 1 or 2, In another embodiment, the invention provides the compound of formula I wherein R5 is an unsaturated ring structure containing a total of five to eleven
atoms having one or two heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur. In other embodiments, the invention provides the compound of formula I wherein R5 is furyl, thiofuryl, pyrrolyl, pyrazolyl, oxazolyl, azetidinyl, piperidinyl or thiazolyl, optionally substituted by one or two methyl.
In another embodiment, the invention provides the compound selected from the group consisting of:
4-cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}pyridine-2-sulfonamide; 2,2,2-trifluoro-N-{cis-3-[methyf(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}ethanesulfonamide;
2-methyJ-N-{cis-3-[methyl(7H-pyrro!o[2,3-d]pyrimîdin-4-yl)amino]cyclobutyl}-propane-1sutfonamide;
N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide; 1-cyclopropyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide;
N-{cis-3-[(butylsulfonyl)methyl]cyclobutyl}-N-methyl-7H-pyrrofo[2,3-d]pyrimidin-4-amine;
1-cyclopropyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yi)amino]cyclobutyl}-azetidîne-3sulfonamide;
3-cyano-N-{cis-3-[methy I ( 7 H-pyrrolo[2,3 - d ] py rimidin-4-y Ijami no]cyciobuty l}-azetid ine-1 sulfonamide;
(1R,5S)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yi)amino]cyclobutyl}-6-oxa-3azabicyclo[3.1.1]heptane-3-sulfonamide;
(3R)-3-cyano-N-{cis-3-[methyl(7H-pyrrolo[2r3-d]pyrimidin-4-yl)amino]cycfobutyl}-pyrroiidine-1sulfonamrde;
(3S)-3-cyano-N-(cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidinZ-yi)amino]cyclobutyl}-pyrrolidine-1sulfonamîde;
N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-1-(oxetan-3'yl)methanesulfonamîde;
1-(3,3-difluorocyc!obutyl)-N-{cis-3-[methyl(7H-pyrToio[2,3-d]pyrimidin-4yl)amino]cyclobuty1}methane-sulfonamide;
trans-3-(cyanomethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrirnidin-4-yi)arnino]-cyclobutyl}cyclobutanesulfonamîde;
cîs-3-(cyanomethyl)-N-{cis-3-[methyl(7H'pyrrolo[2,3-d]pyrimidin-4-yl)amino]10 cyclobutyljcyclobutane-sulfonamide;
N-[cis-3-({[(3,3-difluorocyclobutyi)methyl]sulfonyl}methyl)cyclobutyl]-N-methyl-7H-pyrrolo[2,3dJpyrimidin-4-amine;
(1S,5S)-1-cyano-N-{cfS-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cydobutyl}-3azabicyclo[3.1.0]hexane-3-sulfonamide;
(1R,5R)-1-cyano-N-{cis-3-[methyl(7H-pynOlo[2,3-d]pyrïmidin-4-yl)amino]cyclobutyi}-3azabicyclo[3.1.0]hexane-3-sulfonamide:
(3R)-1-[({cis-3-[methyl(7H-pyrTolo[2,3-d]pyrïnntdin-4-yt)amÎno]cyclobutyi}methyl)sulfonyl]pyrrolidine-3-carbonitrile;
1-[({cis-3-[methyî(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]-420 (trifluoromethyl)piperidin-4-ol;
N-(cis-3-{[(4,4-dίfluoropiperidinΊ-yl)sulfonyl]methyl}cyclobutyl)-N-methyl·7H-pyπΌJo[2,3d]pyrimîdin-4-amine;
(3S)-1-[({ds-3-[methyl(7H-pyirolo[2,3-d]pyrimidin-4-yl)arnino]cyclobutyl}methyl)sulfonyl]pyaolidine-3-carbonitrile;
N-(ds-3'{[(3-chloro-4-fluorûphenyl)sulfonyl]methyl}cyclobutyl)-N-rnethyl-7H-pynOlo[2,3d]pyrimidin-4-amine;
N-(cis-3-{[(2-cyc!opropylethyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4amine;
N-methyl-N-[ds-3-({[1-(propan-2-yl)pyrroiidin-3-yl]sulfonyl}methyl)cydobutyl]-7H-pyrrolo[2,3d]pyrimidin-4-amine;
3,3-difluoro-N-{ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cydobutyl}-cydobutane10 sulfonamide;
1-[3-(cyanomethyi)oxetan-3-yl]-N-{ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cydobutyl}methanesulfonamide;
cis-S-lcyanomethyO-S-methyl-N-Îcis-S-IrnethyKZH-pyrrolop.S-dlpyrimidin^-ylJaminoJcyclobutyt}cydobutanesulfonamide;
trans-3-(cyanomethyl)-3-methyl-N-{ds-3-[methyl(7H-pyrTolo[2,3-d]pynmidin-4yl)amino]cydobutyl}cyclobutanesulfonamide;
N-(2-cyanoethy!)-N-methy!-N'-{ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amîno]cydobutyl}sulfuric diamide;
N-{( 1 S, 3R)-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cydopentyl}propane-1 -sulfonamide;
3-(2-hydroxypropan-2-yl)-N-{ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}benzene-sulfonamide;
N-(cydopropylmethy l)-N '-{ds-3-[methy I (7H-py rrolo[2,3-d]pyrimidin-4-y l)am ino]-cydobuty l}su Ifuric diamide;
N-{cÎs-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-4'(1 H-pyrazol-3-yl)piperidine-1 sulfonamide;
Z-methyl-N-icis-S-Imethyl^H-pyrroîofZ.S-dJpyrimidirM-ylJaminoJcyclobutylJYSdihydropyrrolo(3,4-c]pyrazole-5(4H)-su!fonamide;
2-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)-sulfonyl]pyridine-4carbonitrile;
(1SI3S)-3-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]cyclopentanecarbonitrile;
(1R,3R)-3-[({cis-3-[methyl(7H-pyrroto[2,3-d]pyrimidin-4-yi)amino]cyclobutyl}-methyl)sulfonyi] cyclopentanecarbonitrile;
1- cyclopropyl-N-{trans-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-methane sulfonamide;
3-cyano-N-{trans-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-y!)amino]cyclobutyl}-pyrrolidine-1sulfonamide;
N-methyl-N-{trans-3-Kpropyisulfonyi)methyl]cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; and,
2- methyl-N-{ciS’3-[methy[(7H-pyrrolo[2,3-d]pyrimÎdin-4-yl)amino]cyclobutyl}-1,3-thiazole-5sulfonamide; or, a pharmaceutically acceptable sait thereof.
In another embodiment, the invention provides the compound selected from the group consisting of;
1-(3,3-difluorocyclobutyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyljmethanesu Ifonamid e;
trans-3-(cyanomethyl)-N-{ciS-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyl}cyclobutanesulfonamide;
N-{ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide;
3,3-difluoro-N-{ds-3-[methyl(7H-pyrrdo[2,3-d]pyrimidin-4-yl)amino]cydobutyl}-cyclobutanesulfonamide; and,
N4(1 S, 3R)-3-[methyl(7H-pyrroIo[2,3'd]pyrimidin-4-yl)amino]cyclopentyl}propane-1-sulfonamide;
or, a pharmaceutically acceptable sait thereof.
In other embodiments, the invention provides the compound selected from the group consisting of:
(3R)-3-cyano-N-{cis-3-[methyî(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobuty1}pyrrolidine-1sulfonamide;
('lR,5S)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-y1)amino]cyclobutyl}-6-oxa-3azabicyclo[3.1.1]heptane-3-sulfonamide;
(1S,5S)-1-cyano-N-{ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cydobutyl}-3azabicyclo[3.1.0]hexane-3-sulfonamide;
N-(2-cyanoethyl)-N-methyl-N‘-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-415 yl)amino]cyclobutyl}sulfuric diamide; and,
2-methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-2,6dîhydropyrrolo[3,4-c]pyrazole-5(4H)-sulfonamide; or, a pharmaceutically acceptable sait thereof.
In another embodiment, the invention provides the compound selected from the group consisting of:
(3R)-1-[({ds-3-[methyt(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyljpyrrolidine-3-carbonitrile;
1-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cydobutyl}methyl)sulfonyl]-4(trifluoromethyl)piperidin-4-ol;
2l
N-(cis-3-{[(4,4-difluoropiperidin-1-yl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrTolo[2,3d]pyrimidin-4-amine;
(3S)-1-[({cis-3-[rnethy](7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyiIpyrrolidine-3-carbonitriie; and, or, a pharmaceutically acceptable sait thereof.
In yet another embodiment, the invention provides the compound selected from the group consisting of:
(1R,3R)-3-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyljcyclo-pentanecarbonitrile;
( 1 S, 3S)-3-[({cis-3-[methyl(7H-pyrrol o[2,3-d]pyrimidin-4-yl)amino]cyc!obuty l}-methyl JsulfonylJcyclopentanecarbonitrile;
2-[({ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)-sulfony!]pyridine-4carbonitrile;
N-[cis-3-({[(3,3-difluorocyclobutyl)methyl]sulfonyl}methyl)cyclobutyl]-N-methyl-7H-pyrrolo[2,315 dJpyrimidin-4-amine; and,
N-{cis-3-[(butylsulfonyl)methyî]cyclobutyl}-N-methyl-7H-pyrroÎo[2,3-d]pyrimidin-4-amine; or, a pharmaceutically acceptable sait thereof.
Particularly preferred embodiments include 2-methyl-N-{cis-3-[methyl(7H-pyrTOlo[2,3-d]pyrimidin4-yl)amino]cyclobutyl}-1,3-thiazole-5-sulfonamide, N-{ds-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-420 yl)amino]cyclobutyl}-propane-1-sulfonamide; N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}-1-oxetan-3-ylmethanesulfonamide; 1-(3,3-difluorocyclobutyl)-N-{cis-3-[methyl(7Hpyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-methanesulfonamide; 3,3-difluoro-N-{cis-3-[methyl(7Hpyrrolo[2,3-d]pyrimrdin-4-yl)amino]cyclobutyl}cydobutanesulfonamide ; trans-3-(cyanomethyl)-N-(cis-3-
[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-cyclobutanesulfonamide; (1S,5S)-1-cyano-N{cis-3-[meÜiyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-3-azabi-cyclo[3.1.0]hexane-3sulfonamide; and, (3S)-1-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}methyl)sulfonyl]pyrrolidine-3-carbonitrile; or, a pharmaceutically acceptable sait thereof.
The présent invention also provides a pharmaceutical or a veterinary composition comprising a compound of formula I, IA, IB, IC or ID, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier.
The présent invention also provides a method of treating a disorder or condition related to dysrégulation of JAK, and particulariy of JAK1, in a subject, comprising administering to the subject a therapeutically effective amount of the compound having the structure of formula I, IA, JB, IC or ID, or a pharmaceutically acceptable sait thereof. In certain embodiments, the disorder or condition treated by the method is selected from among rheumatoid arthritis, myositis, vasculitis, pemphigus, Crohn's disease,, ulcerative colîtis, Alzheimer’s disease, lupus, nephritis, psoriasis, atopie dermatitis, autoimmune thyroid disorders, multiple sclerosis, major dépréssion disorder, allergy, asthma, Sjogren’s disease, dry eye syndrome, organ transplant rejection, xeno transplantation, Type I diabètes and complications from diabètes, cancer, leukemia, T cell acute lymphoblastic leukemia, adult T cell leukemia activated B-cell like, diffuse large B cell lymphoma, înflammatory bowel disease, septîc shock, cardiopulmonary dysfunction, chronic pulmonary obstructive disorder, acute respiratory disease, and cachexia comprising the step of adminis20 tering to a subject an effective amount of a composition comprising a compound of formula I, IA, IB, IC or ID. In certain embodiments, the therapeutically effective amount used in accord with the method is from 0.01 mg/kg of body weight/day to 100 mg/kg of body weight/day. In certain other embodiments, the therapeutically effective amount used in accord with the method is the therapeutically effective amount is
from 0.1 mg/kg of body weight/day to 10 mg/kg of body weight/day. In the practice of the method, the compound of formula I is preferably selected from N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}-propane-1-sulfonaniide, N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}-1-oxetan-3-ylmethanesulfonamrde; 1-(3,3-difluorocyclobutyl)-N-{cis-3-[methyl(7H5 pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-methanesulfonamide; 3,3-difluoro-N-{cis-3-[methyl(7Hpyrrolo[2,3-d]pyrimidin-4-yl)amino]cyctobutyl}cyclobutanesulfonamide ; trans-3-(cyanomethyl)-N-{cis-3[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclQbutyl}-cyctobutanesulfonamide; (1S,5S)-1-cyano-N(cis-3-[rnethyl(7H-pyrrolo[2,3-d]pyrinnidin-4-yl)amino]cyctobutyl)-3-azabi-cyclo[3.1.0]hexane-3sulfonamide; and, (3S)-1-[({cis-3-[methyl(7H-pynolo[2,3-d]pyrimidin-410 yl)amino]cycÎobutyl)methyi)sulfonyl]pyrrolidine-3-carbonitrile:, or a pharmaceutically acceptable sait thereof.
The présent invention further provides a method for treating or preventing a disorder or condition selected from atopie dermatitis, eczema, scleroderma, pruritus, other pruritic conditions, allergie reactions including allergie dermatitis in mammal, horse allergie diseases including bite hypersensitivity, summer eczema, sweet itch in horses, heaves, inflammatory airway disease, récurrent airway obstruction, and airway hyper-responsiveness by administering to a mammal in need a therapeutically effective amount of a compound of formula I, IA, IB, IC or ID, or a pharmaceutically acceptable sait thereof.
In certain embodiments, the therapeutically effective amount used in accord with the method is from 0.01 mg/kg of body weight/day to 100 mg/kg of body weight/day. In certain other embodiments, 20 the therapeutically effective amount used în accord with the method is wherein the therapeutically effective amount is from 0.1 mg/kg of body weight/day to 10 mg/kg of body weight/day. In accord with the method, the mammal treated with the compound of the invention is selected from companion animais, dogs, and livestock. In certain embodiments, the compound of formula I, IA, IB, IC or ID, or a pharma-
ceutically acceptable sait thereof, may be administered in accord with the method orally, parenterally, or topically.
In the practice ofthe method, the compound of formula I is preferably selected from N-{cîs-3-[methyl(7Hpyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-propane-1-sulfonamide; N-{cis-3-[methyl(7H-pyrrolo[2,35 d]pyrimidin-4-yl)amino]cyclobutyl}-1-oxetan-3-ylmethanesulfonamide; 1-(3,3-difluorocyclobutyl)-N-{cis-3[methyl(7H-pynOlo[2,3’d]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide; 3,3-difluoro-N-{cîs-3[methyl(7H-pyrTolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyi}cyclobutanesulfonamide ; trans-3-(cyanomethyl)N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-cyclobutanesulfonamide; (1 S,5S)-1 cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-3-azabi-cyclo[3.1.0]hexane-310 suifonamide; and, (3S)-1-[({cîs-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}methyl)suifonyl]pyrrolidine-3-carbonîtrile; or, a pharmaceutically acceptable sait thereof.
Compounds that hâve the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed ''isomers. Isomers that differ in the 15 arrangement of their atoms in space are termed stereoisomers”. It will be appreciated by those skilled in the art that the compound of formula 1, IA, IB, IC or ID can exist as cis- and trans- achiral diastereomers.
Included within the scope of the described compounds are ail isomers (e.g. cis-, trans-, or diastereomers) of the compounds described herein alone as well as any mixtures. Ail of these forms, including enantiomers, diastereomers, cis, trans, syn, anti, solvatés (including hydrates), tautomers, and 20 mixtures thereof, are included in the described compounds. Stereoisomeric mixtures, e.g. mixtures of diastereomers, can be separated into their correspondîng tsomers in a known manner by means of suitable séparation methods. Diastereomeric mixtures for example may be separated into their individual diastereomers by means of fractionated crystallization, chromatography, solvent distribution, and similar
procedures. This séparation may take place either at the level of one of the starting compounds or in a compound of formula I, IA, IB, IC or ID rtself. Enantiomers may be separated through the formation of diastereomeric salts, for example by sait formation with an enantiomer-pure chiral acid, or by means of chromatography, for example by HPLC, using chromatographie substrates with chiral ligands.
in therapeutic use for treating disorders in a mammal, a compound of the présent invention or its pharmaceutical compositions can be administered orally, parenterally, topically, rectally, transmucosally, or intestinally. Parentéral administrations include indirect injections to generate a systemic effect or direct injections to the afflicted area. Topical administrations include the treatment of skin or organs readily accessible by local application, for exampîe, eyes or ears. It also includes transdermal delivery to generate a systemic effect. The rectal administration includes the form of suppositories. The preferred routes of administration are oral and parentéral.
Pharmaceutically acceptable salts of the compounds of formula I, IA, IB, IC or ID include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besyiate, bicarbonate/carbonate, bi15 sufphate/sulfate, borate, camsylate, citrate, cyclamate, edisytate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsuifate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stéarate, succinate, tannate, tartrate, tosylate, 20 trifluoroacetate and xinofoate salts.
Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnésium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts. For a revîew on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Sélection, and Useby Stahl and Wermuth (Wiley-VCH, 2002).
Pharmaceutically acceptable salts of compounds of formula I, IA, IB, IC or ID may be prepared, respectively, by one or more of three methods: (i) by reacting the compound of formula I, IA, IB, IC or ID with the desired acid or base; (ii) by removing an acid- or base-labile protecting group from a suitable precursor of the compound of formula I, IA, IB, IC or ID or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or (iii) by converting one sait of the compound of formula I, IA, IB, IC or ID to another by reaction with an appropriate acid or base or by means of 10 a suitable ion exchange column. Ail three reactions are typically carried out in solution. The resulting sait may precipitate out and be collected by filtration or may be recovered by évaporation of the solvent. The degree of ionization in the resulting sait may vary from completely ionized to almost non-ionized.
Pharmaceutical compositions of the présent invention may be manufactured by methods well known in the art, e.g., by means of conventional mixing, dissoiving, granulation, dragee-making,
I5 levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.
Pharmaceutical compositions for use in accordance with the présent invention may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compound into préparations, which can be used pharmaceutically. Proper formulation is dépendent upon the route of administration chosen. Pharmaceu20 tically acceptable excipients and carriers are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, în Remington's Pharmaceutical Sciences Mack Pub. Co., New Jersey (1991). The formulations ofthe invention can be
designed to be short-acting, fast-releasing, long-acting, and sustained-releasing. Thus, the pharmaceutical formulations can also be formulated for controlled release or for slow release.
Pharmaceutical compositions suitable for use in the présent invention include compositions wherein the active ingrédients are contained in an amount sufficient to achieve the intended purpose, i.e., 5 control or the treatment of disorders or diseases. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms/signs of disease or prolong the survival of the subject being treated.
The quantity of active component, which is the compound of this invention, in the pharmaceutical composition and unit dosage form thereof, may be varied or adjusted widely depending upon the manner 10 of administration, the potency of the particuiar compound and the desired concentration. Détermination of a therapeutically effective amount is well within the capability of those skilled in the art. Generally, the quantity of active component will range between 0,01 % to 99% by weight of the composition.
Generally, a therapeutically effective amount of dosage of active component will be in the range of about 0.01 to about 100 mg/kg of body weight/day, preferably about 0.1 to about 10 mg/kg of body 15 weight/day, more preferably about 0.3 to 3 mg/kg of body weight/day, even more preferably about 0,3 to 1.5 mg/kg of body weight/day It is to be understood that the dosages may vary depending upon the requirements of each subject and the severity of the disorders or diseases being treated.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day, The sub-dose 20 itself may be further divided, e.g,, into a number of discrète loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired plasma concentration. On the other hand, the
initial dosage may be smaller than the optimum and the daily dosage may be progressive^ increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.
Compounds ofthe présent invention are directed to pyrrolo[2,3-d]pyrimidine compounds useful as
Janus Kinase inhibitors (JAK-î). They are useful as therapeutic agents in connection with the treating or preventing a disorder or condition selected from rheumatoid arthritis, myositîs, vasculitis, pemphigus, Crohn's disease, ulcerative colitis, Alzheimer's disease, lupus, nephritis, psoriasis, atopie dermatitis, autoimmune thyroid disorders, multiple sclerosis, major dépréssion disorder, allergy, asthma, Sjogren's disease, dry eye syndrome, organ transplant rejection, xeno transplantation, Type I diabètes and complica10 lions from diabètes, cancer, leukemia, T cell acute lymphoblastic leukemia, adult T cell leukemia activated B-cell like, diffuse large B cell lymphoma, inflammatory bowei disease, septic shock, cardiopulmonary dysfunction, chronic pulmonary obstructive disorder, acute respiratory disease, cachexia, and other indications where immunosuppression/immunomodulation would be désirable, comprising the step of administering to a subject an effective amount of a compound of the invention.
There are substantial needs for safe and efficadous agents to control disorders related to JAK, such as atopie dermatitis, both in human and animais. The market for treating atopie dermatitis in animais is currently dominated by corticosteroids, which cause distressing and undesirable side effects in animais, specifically in companion animais such as dogs. Antihistamines are also used, but are poorly effective. A canine formulation of cyclosporine (ATOPICA™) is currently being marketed for atopie der20 matitis, but is expensive and has a slow onset of effîcacy. In addition, there are Gl toleration issues with ATOPICA™. Compounds of the présent invention are JAK inhibitors with sélective effîcacy against JAK1. These compounds are expected to provide an alternative to steroid usage and provide resolution of
chronic pruritus and inflammation that would either persist in atopie dermatitis or slowly regress following removal of allergen or causative agent, such as fleas in flea-allergic dermatitis.
Compounds of the présent invention may be administered in a pharmaceutically acceptable form either alone or in combination with one or more additional agents which modulate a mammalian immune
System or with anti-inflammatory agents. These agents may include but are not limited to cyclosporin A (e.g., Sandimmune™ or Neoral™, rapamycin, FK-506 (tacrolimus), leflunomlde, deoxyspergualin, mycophenolate (e.g., Cellcept™, azathioprine (e.g., Imuran™), daclizumab (e.g., Zenapax™), OKT3 (e.g., Orthocolone™), AtGam, aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, and antiinflammatory steroids (e.g., prednisolone or dexamethasone). These agents may be administered as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art.
Accordingly, the invention provides methods of treating or preventing a disease, condition or disorder associated with JAK in a subject, such as a human or non-human mammal, comprising administer15 ing an effective amount of one or more compounds described herein to the subject. Suitable subjects that can be treated include domestic or wild animais, companion animais, such as dogs, cats, horses and the like; tivestock including, cows and other ruminants, pigs, poultry, rabbits and the like; primates, for example monkeys, such as rhésus monkeys and cynomolgus (also known as crab-eating or long-tailed) monkeys, marmosets, tamarins, chimpanzees, macaques and the like; and rodents, such as rats, mice, gerbils, guinea pigs and the like. In one embodiment, the compound is administered in a pharmaceutically acceptable form, optionally in a pharmaceutically acceptable carrier.
Conditions in which sélective targeting of the JAK pathway or modulation of the JAK kinases, particularly JAK1, are contemplated to be therapeutically useful include, arthritis, asthma, autoimmune dis-
eases, cancers or tumors, diabètes, certain eye diseases, disorders or conditions, inflammation, intestinal inflammations, allergies or conditions, neurodegenerative diseases, psoriasis, and transplant rejection. Conditions which can benefit from sélective inhibition of JAK1 are discussed in greater detail below.
Accordingly, the compound of formula I, IA, IB, IC or ID, or its pharmaceutically acceptable salts, and pharmaceutical compositions thereof can be used to treat a variety of conditions or diseases such as the following;
Arthritis, including rheumatoid arthritis, juvénile arthritis, and psoriatic arthritis;
Autoimmune diseases or disorders, including those designated as single organ or single cell-type autoimmune disorders, for example Hashimoto's thyroiditis, autoimmune hemolytic anémia, autoimmune atrophie gastritis of pernîcious anémia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy, those designated as invotving systemic autoimmune disorder, for example systemic lupus erythematosis, rheumatoid arthritis, Sjogren's syndrome, Reiter’s syndrome, polymyositis15 dermatomyositis, systemic sclerosis, polyarteritîs nodosa, multiple sclerosis and bullous pemphigoid, and additional autoimmune diseases, which can be O-cell (humoral) based or T-cell based, including Cogan’s syndrome, ankylosing spondylitis, Wegener's granulomatosis, autoimmune alopecia, Type I or juvénile onset diabètes, or thyroiditis;
Cancers or tumors, including alimentary/gastrointestinal tract cancer, colon cancer, liver cancer, skin cancer including mast cell tumor and squamous cell carcinoma, breast and mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, including acute myelogenous leukemia and chronic myelogenous leukemia, kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer, brain cancer, melanoma including oral and metastatic melanoma, Kaposi's sarcoma, myelomas including mul-
tiple myeloma, myeloproliferative disorders, proliférative diabetic retinopathy, or angiogenic-assocrated disorders including solid tumors;
Diabètes, including Type I diabètes or complications from diabètes;
Eye diseases, disorders or conditions including autoimmune diseases of the eye, keratoconjunctivitis, vernal conjunctivitis, uveitis including uveitis associated with Behcet's disease and lens-induced uveitis, keratitis, herpetic keratitis, contcal keratitis, corneai épithélial dystrophy, keratoleukoma, ocular premphigus, Mooren’s ulcer, scleritis, Grave's ophthalmopathy, Vogt-KoyanagiHarada syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule, îridocyclitis, sarcoidosis, endocrine ophthaimopathy, sympathetic ophthalmitis, allergie conjunctivitis, or ocular neovascularization;
Intestinal inflammations, allergies or conditions including Crohn’s disease and/or ulcerative colitis, inflammatory bowel disease, celiac diseases, proctitis, éosinophilie gastroenteritis, or mastocytosis;
Neurodegenerative diseases including motor neuron disease, Alzheimeris disease, Parkinson’s disease, amyotrophie latéral sclerosis, Huntington's disease. cérébral tschemia, or neurodegenerative disease caused by traumatic injury, strike, glutamate neurotoxicity or hypoxia; ischemic/reperfusion injury in stroke, myocardial ischemica, rénal ischemia, heart attacks, cardiac hypertrophy, atherosclerosis and arteriosclerosis, organ hypoxia, or platelet aggregation;
Skin diseases, conditions or disorders including atopie dermatitis, eczema, psoriasis, scleroderma, pruritus or other pruritic conditions;
Allergie reactions including allergie dermatitis in mammal (including horse allergie diseases such as bite hypersensitivity), summer eczema, sweet itch in horses, heaves, inflammatory airway disease, récurrent airway obstruction, airway hyper-responsiveness, or chronic obstruction pulmonary disease;
Asthma and other obstructive airways diseases, including chronic or inveterate asthma, late asthma, bronchitis, bronchial asthma, allergie asthma, intrinsrc asthma, extrinsic asthma, or dust asthma;
Transplant rejection, including pancréas islet transplant rejection, bone marrow transplant rejection, graft-versus-host disease, organ and cell transplant rejection such as bone marrow, cartilage, cornea, heart, intervertébral dise, islet, kidney, limb, liver, Jung, muscle, myoblast, nerve, pancréas, skin, small intestine, or trachea, or xeno transplantation; and
Another embodiment provides a method of selectively inhibiting a JAK1 enzyme, which includes contacting the JAK enzyme with either a non-therapeutic amount or a therapeutically effective amount of one or more of the presently taught compounds. Such methods can occur in vivo or in vitro, in vitro contact can involve a screening assay to détermine the efficacy of the one or more compounds against a selected enzyme at various amounts or concentrations, in vivo contact with a therapeutically effective amount of the one or more compounds can involve treatment of a described disease, disorder or condition or prophylaxie of organ transplant rejection in the animal in which the contact occurs, The effect of the one or more compounds on the JAK enzyme and/or host animal can also be determined or measured. Methods for determining JAK activity include those described in the Exemples as well as those disclosed in WO99/65908, WO 99/65909, WO01/42246, W002/00661, W002/096909, W02004/046112 and W02007/012953.
Chemical Synthesis
The following schemes and written descriptions provide general details regarding the préparation of the compounds of the invention.
SULFONAMIDES
Compounds of formula I, wherein p is 2, X is NH, Y is AR5,and A is a bond, may be prepared according to Scheme 1.
Step 1
VII
Step 5
I (p = 2, X = NH, Y = AR5; A = bond)
It will be apparent to those skilled in the art that sensitive functional groups (PG) may need to be protected and deprotected during the synthesis of a compound of the invention. Protection and deprotection may be achieved by conventional methods, as described, for example, in “Protective Groups in Organic Synthesis by T. W. Greene and P. G. M. Wuts, John Wiley & Sons Inc. (1999), and référencés therein. Thus, in Scheme 1, Step 1, a compound of formula II, wherein Q1 is halogen, is treated with a protecting agent to provide a compound of formula III, wherein PG' is an arylsulfonyl protecting group such as benzenesulfonyl, or preferably pa/a-toluenesulfonyl (“tosyl). The protecting group may be installed by reaction of the compound of formula II with an arylsulfonyl chloride, preferably tosyl chloride, 10 in the presence of a base such as aqueous sodium hydroxide solution and an organic solvent such as acetone. The reaction is typically run at 0°C to about 50°C, preferably at about 23°C (room température).
Altematively, bases such as sodium hydride and potassium tert-butoxide may be used, employing a suit-
able solvent such as N,N-dimethylfomnamide or tetrahydrofuran. Several compounds of formula II are known in the literature and hâve been prepared by the methods above. For example, the synthesis of compound of formula ll, wherein Q1 is Cl and R2 and R3 are hydrogen has been reported previously, for example in WO 2007 012953.
in Scheme 1, Step 2, the protected compound of formula III is combined with 1-2 équivalents of an amine of formula IV in the presence of a 1-3 équivalents of a base and a protic solvent to afford a compound of formula V. Suitable bases include triethylamine, diisopropylethylamine, and potassium carbonate while suitable solvents include methanol, éthanol, diisopropyl alcohol and water or mixtures thereof. The réaction is typically run at about 23°C to about 15Û°C, preferably about 75°C. It will be noted that the amine of formula IV contains a second amino group that îs protected with a protecting group PG2 that can be removed under conditions that do not lead to loss of PG1. Suitable protecting groups PG2 include t-butoxycarbonyl (“Boc’j and f'Cbz), preferably benzyloxycarbonyl.
In Scheme 1, Step 3, the protecting group PG2 is removed from the compound of formula V under conditions that do not lead to loss of PG1 to give a primary amine (or a sait thereof) of formula VI. When
PG2 is benzyloxycarbonyl, the benzyloxycarbonyl protecting group may be removed by hydrogenolysis wherein the compound of formula V is exposed to hydrogen or a hydrogen transfer reagent such as cy~ clohexene in the presence of a hydrogénation catalyst such as palladium hydroxide using a solvent such as methanol, acetic acid or, preferably, éthanol. Altematively, when PG2 is benzyloxycarbonyl, the benzyloxycarbonyl protecting group may be removed by treatment of the compound of formula V with a solution of hydrogen bromide (about 6 équivalents) in acetic acid optionally in the presence of a suitable solvent such as ethyl acetate at a température from about minus 20DC to about 40°C, preferably less than 25°C. This latter deprotectîon method is preferred wherein n is 1, R2, R3 and R4 are hydrogen, R’ is methyl, PG1 is tosyl and PG2 is benzyloxycarbonyl and provides the amine of formula VI as the
dihydrobromide sait. When PG2 is t-butoxycarbonyl, the t-butoxycarbonyl protecting group may be removed by treatment with an excess of an acid such as hydrochlorrc acid or trifluoroacetic acid in a solvent such as dichloromethane or 1,4-dioxane.
In Scheme 1, Step 4, the primary amine of formula VI (or sait thereof) is converted to a sulfona5 mide dérivative of formula VII by treatment with an activated sulfonic acid dérivative of formula VIII, wherein Q2 is halogen, O-alkyl or O-aryl in the presence of a base. Most commonly, VIII is a sulfonyl chloride dérivative wherein Q2 is CI. Many sulfonyl chlorides may be obtained from commercial sources. Also, several methods exist for the préparation of sulfonyl chlorides, which are well known to those skilled in the art and hâve been described in texts such as Advanced Organic Chemistry by J. March, John
Wiley & Sons (1985). Typically, the amine of formula VI is treated with a sulfonyl chloride dérivative of formula VIII wherein Q2 is Cl in the presence of at least one équivalent of a base such as triethylamine or diisopropylamine in a suitable solvent such as dichloromethane, tetrahydrofuran or acetonitrile. When a sait form of the amine is used, an additional équivalent of base is used for each équivalent of acid forming the sait. For example, using a dihydrobromide sait, two extra équivalents of base are used. The reaction may be run from about minus 20°C to about 50°C, preferably starting the reaction at about 0°C and then allowing it to warm to about 23DC (room température).
Finally, in Scheme 1, Step 5, the sulfonamide dérivative of formula Vil is deprotected to afford a compound of formula 1, wherein p is 2. X is NH, Y is AR5and A is a bond. Two methods are typically employed, the choice of which is determined by the compatibility of the conditions with other functional groups on the molécule. The first method involves exposure of the compound of formula VII to an excess (about 4 équivalents) of a base such as lithium hydroxide or sodium hydroxide. The reaction is run in a solvent mixture containing water and an alcohol such as methanol or éthanol. It may also be run în a mixture of water and tetrahydrofuran, and, optionally an alcohol such as methanol or éthanol. The reaction
may be run at a température of about 23 “C to about 100°C, typically about 60’C. The second method, which is preferred in instances where there is hydroxide-sensitive functionality such as nitrile présent in the molécule, involves reaction of the compound of formula VII with an excess of tetrabutylammonium fluoride (4-25 équivalents) in a solvent such as 1,2-dimethoxyethane or, preferably tetrahydrofuran, The deprotection is conducted at a température of about 0°C to about 60°C, preferably about 23°C.
Compounds of formula II, wherein Q’ is halogen, are commercialiy available or are known in the chemical literature. For exampie, 4-chloro-7W-pyirolo[2,3-a]pyrimidine, wherein Q1 is Cl and R2 and R3 are both hydrogen, is a readily available commercial compound.
Compounds of formula IV are known in the chemical literature or may be prepared by standard chemical reactions well known to one skilled in the art.
An alternative method of preparing compounds of the invention wherein p is 2, X is NH, Y is AR5, A is a bond is shown in Scheme 2.
Scheme 2
= bond)
In Scheme 2, Step 1, a compound of formula IX is combined with a benzyloxycarbamate dériva tive of formula X in the presence of a base (1-5 équivalents) to provide a benzyloxycarbamate dérivative
of formula XI. The reaction is carried out in a solvent such as water or an alcohol such as éthanol, optionally with addition of a miscible co-solvent such as tetrahydrofuran. Suitable bases include potassium carbonate, césium carbonate, triethylamine and diisopropylethylamine. The reaction is run at about 23°C to about 100°C. When n is 1, R2, R3 and R4 are hydrogen, and R1 is methyl, the preferred conditions are to run the reaction in water, using potassium carbonate (3 équivalents) as base, starting the reaction at about 23°C and then heating to about 95°C.
In Scheme 2, Step 2, the benzyloxycarbamate dérivative of formula XI is deprotected by exposure to hydrogen or a hydrogen transfer reagent such as cyclohexene in the presence of a hydrogénation catalyst such as palladium hydroxide. At the same time, under the conditions of the deprotection, the chlorine atom at the 2-position of 7H-pyrrolo[2,3-d]pyrimidine ring is replaced with hydrogen to provide an amine hydrochloride sait of formula XII. The reaction is run in a solvent such as methanol or éthanol at a température of about 50°C to about 80°C. When R2, R3 and R4 are hydrogen, and R’ is methyl, the preferred conditions are to run the réaction in éthanol at about 78°C using palladium hydroxide as catalyst, and cyclohexene (about 20 équivalents) as a hydrogen transfer reagent.
Finaily, in Scheme 2, Step 3, the amine hydrochloride of formula XII is converted to a sulfonamide of formula I, wherein p is 2, X is NH, Y is AR5, A is a bond by reaction with an activated sulfonic acid dérivative of formula VIII, wherein Q2 is halogen, O-alkyl or O-aryl in the presence of at least two équivalents of a base. Most commonly, VIII is a sulfonyl chloride dérivative wherein Q2 is Cl. Suitable bases include triethylamine, diisopropylethylamine and potassium carbonate. Suitable solvents include N,N20 drmethylformamide, and a mixture of tetrahydrofuran and water. The reaction may be run at a température of about minus 20“C to about 50°C preferably at about 23°C. Altematively, the amine hydrochloride of formula XII is first treated with about 2 équivalents of trimethylchlorosilane in the presence of about 2-3 équivalents of a base such as lithium bis(dimethylsilyl)amide or sodium bis(dimethylsilyl)amide in an suit-
able aprotrc solvent such as tetrahydrofuran. Then, after about 1 hour, about 1.2 équivalents of the sulfonyl chloride of formula VIII, Q2 is Cl is added to provide, after workup, the sulfonamide of formula I, wherein p is 2, X is NH, Y is AR5, A is a bond The reaction may be run at a température of about minus 20°C to about 50°C, preferably at about 23°C.
Compounds of formula IX, are commercially available or are known in the chemical literature. For example, 2,4-dichloro-7Z/-pyrrolo[2,3-a]pyrimidine1 wherein R2 and R3 are both hydrogen, is commercially available. Its synthesis is described in PCT International Publication No. W02007/012953.
SULFAMIDES
Compounds of formula I, wherein p is 2, X is NH, and Y is NRaRb, may be prepared according to
Scheme 3.
l(p = 2,X = NH, Y = NRaRb)
In Scheme 3, Step 1, an amine of formula VI (or sait thereof), wherein PG1 is an arylsulfonyl protecting group such benzenesulfonyl, or preferably tosyi, is converted to oxazolidinone dérivative of formu la XIII. First, a solution of N-chlorosulfonylisocyanate (1 équivalent) is slowly added to a solution of 2bromoethanol (1 équivalent) at a température of about -40°C to about 10°C, preferably about 0°C. Subsequently, after 0.5 to 2 hours, a solution of the amine of formula VI (1 équivalent) and a base such as triethylamine or diisopropylethylamine (about 3 équivalents, plus one équivalent for each mole of acid
forming a sait) is added slowly and frie reaction is allowed to warm to about 23°C over a period of about to 24 hours. Suitable solvents for the reaction include chloroform or preferably dichloromethane.
In Scheme 3, Step 2, the oxazolidinone dérivative of formula Xlll is reacted with 1-3 équivalents of an amine of the formula HNRaRb, in the presence of a base (2-5 équivalents), to afford a sulfamide de5 rivative of formula XIV. Suitable bases include triethylamine and diisopropylethylamine. The reaction is preferably carried out by heating to about 90°C to about 150°C in a pressure vessel using a suitable solvent such a N.N-dimethylformamide or acetonitrile.
In Scheme 3, Step 3, the compound of formula XIV is deprotected, removing the arylsulfonyl protecting group PG1 to provide a sulfamide dérivative of formula 1, wherein p is 2, X is NH, and Y is NRaRt>.
The reaction may be carried out by one of the two general methods described for Scheme 1, Step 5.
Again, the choice of deprotection method is determined by the compatibility of the conditions with other functional groups on the molécule. Altematively, the sulfamides of the formula XIV may be obtained directly from an amine of formula VI (or sait thereof). Thus, in Scheme 3, Step 4, the amine of formula VI (or sait thereof) is treated with a sulfamoyl chloride of the formula CI-SOïNRaRb and a base such as tri15 ethylamine or diisopropylethylamine as described for Scheme 1, Step 4. Sulfamoyl chlorides of the formula CI-SOîNRaRb may be prepared, in turn, from amines of the formula HNRaRb according to the procedures reviewed by W. R. Bowman and R. J. Marmon in Comprehensive Organic Functional Group Transformations, Volume 2”, Pergamon (1995).
The compounds of formula I, wherein p is 2, X is NH, and Y is NRaRb may also be obtained di20 rectly from an amine of formula XII (or sait thereof). Thus, in Scheme 3, Step 5, the amine of formula Xll(or sait thereof) is treated with a sulfamoyl chloride of the formula CI-SOzNRaRb and a base such as triethylamine or diisopropylethylamine as described for Scheme 1, Step 4. Amines of formula XII are obtained as described for Scheme 2. Amines of formula XII (or salts thereof) may be obtained by the re-
moval of the arylsulfonyl protecting group PG1 from a compound of the formula VI (refer to Scheme 1).
The deprotection may be carried out by one of the two general deprotection methods described for Scheme 1, Step 5. The chotce of deprotection method is determined by the compatibility of the conditions with other functional groups on the molécule.
REVERSE SULFONAMIDES
Compounds of formula I, wherein p is 2, X is CH2, and Y is NRaRb, may be prepared according to Scheme 4.
Scheme 4
Jn Scheme 4, Step 1, a compound of formula IJI (refer to Scheme 1), is combined with an amino alcohol of formula XV in the presence of a base and a polar solvent to afford a compound of formula XVI. Suitable bases include triethylamine and diisopropylethylamine while suitable solvents include methanol,
diisopropyl alcohol and acetone. The reaction is typically run at about 23°C to about 70°C. Preferably, a catalytic amount (about 1 mole %) of potassium iodide is added to the reaction.
In Scheme 4, Step 2, the compound of formula XVI is converted to a compound of formula XVII, wherein LG is a leaving group such as bromo, iodo, methanesulfonate or, preferably, para5 toluenesulfonate. Methods for installing such leaving groups are well-known to those skilled in the art and hâve been described in texts such as “Advanced Organic Chemistry” by J. March, John Wiley & Sons (1985). In the case where LG is pa/a-toluenesulfonate, the compound of formula XVI is treated with para· toluenesulfonyl chloride in the presence of a base such as triethylamine, diisopropylethylamine or N,Ndimethylaminopyridine in an aprotic solvent such as dichloromethane or tetrahydrofuran. The reaction is run at a température of about -10°C to about 40°C, preferably beginning at around 0°C and allowing the reaction to warm to about 23°C.
In Scheme4, Step 3, the compound of formula XVII is combined with a sait of thioacetic acid, preferably potassium thioacetate to yield a thioester dérivative of formula XVIII. The reaction is carried out in a polar solvent such as Ν,Ν-dimethylformamide or N-methytpyrrolidine, at a température of about 23°C 15 to about 80°C, preferably at about 55°C.
In Scheme 4, Step 4, the thioester dérivative of formula XVIII is converted to a sulfonic acid dérivative of formula XIX by reaction with an aqueous solution of hydrogen peroxide, typically 30% by weight. The reaction is carried out in an acidic solvent such as formic or acetic acid at a température from about 0°C to about 40°C, preferably at about 23°C.
In Scheme 4, Step 5, the sulfonic acid dérivative of formula XIX is converted to a sulfonyl chloride dérivative of formula XX. Several methods for carrying out this functional group transformation are known in the literature. The preferred method is to treat the compound of formula XIX with an excess (3-15 équivalents) of thionyl chloride in the presence of a catalytic amount of Ν,Ν-dimethylforrnamide in an
aprotic solvent such as dichloromethane or chloroform. The reaction may be run from about minus 20°C to about 100°C, preferably beginning the réaction at about 0°C, and then warming to about 75°C.
Altematively, in Scheme 4, Step 6, the thîoester dérivative of formula XVIII may be directly converted to the sulfonyl chloride dérivative of formula XX by treatment with a chlorinating agent. Several methods for canrying out this functional group transformation are known in the literature. Chlorinating agents include chlorine gas and N-chlorosuccinimide, and the reaction is commonly run in the presence of an acid such as hydrochloric acid or acetic acid. Mixed aqueous solvents Systems are often used, such as water and dichloromethane and water and acetonitrile.
In Scheme 4, Step 7, the sulfonyl chloride dérivative of formula XX is combined with 1-3 équivalents of an amine ofthe formula HNRaRb to form a sulfonamide dérivative of formula XXI. The reaction is run in the presence of at least one équivalent of a base such as trrethylamine or diiosopropylethylamine at a température from about minus 20°C to about 50°C, preferably starting the reaction at about 0°C and allowing the reaction to warm to about 23°C. The reaction is run in an aprotic solvent such as tetrahydrofuran or dichloromethane.
Finally in Scheme 4, Step 8, the arylsulfonyl protecting group PG1 is removed to provide a compound ofthe formula I, wherein p is2, X isCI-b, and Y is NRaRb. The reaction may be carried out by one ofthe two general deprotection methods described for Scheme 1, Step 5. The choice of deprotection method îs determined by the compatibility ofthe conditions with other functional groups on the molécule. Amino alcohols of formula XV are known in the chemical literature or may be prepared by methods well known to one skilled in the art.
SULFONES, Sulfoxides and Thioethers
Compounds of formula I, wherein p is 0, 1, or 2, X is CHs, Y is AR5 and A is a bond, may be prepared according to Scheme 5.
Scheme 5
In Scheme 5, Step 1, a compound of formula XVII (refer to Scheme 4) is treated with 1-2 équivalents of a thiol of the formula R5SH in the presence of 1-2 équivalents of a base to give a sulfide of the formula XXIII. Suitable bases include sodium hydride, sodium bis(trimethylsilyl)amide, 1,55 diazabicyclo[4.3.0]non-5-ene (DBN) and preferably, 1,8-diazabicyc!o[5.4.0]undec-7-ene (DBU). The reaction is carried out in a solvent such as N.N-dimethylforrriamide or N-methylpyrrolidinone at a température from about 0°C to about 50°C, preferably at about 23°C.
In Scheme 5, Step 2, the compound of formula XXIII is deprotected, removing the aryfsuifonyi protecting group PG1 to provide a compound of formula XXIV. The reaction may be carried out by one of
the two general deprotection methods described for Scheme 1, Step 5. The choice of deprotection method is determined by the compatibility of the conditions with other functional groups on the molécule.
In Scheme 5, Step 3, a sulfide of formula XXIV is oxidized to yield a sulfone of formula I, wherein p is 2, X is CH2, Y Is AR5and A is a bond. Several methods are known in the literature and ail involve the use of an oxidant such as meta-chloroperbenzoic acid, hydrogen peroxide, or potassium peroxymonosulfate (Oxone®). A preferred method is to treat the compound of formula XXIV with 2 équivalents of potassium peroxymonosulfate (Oxone®) in a solvent mixture of tetrahydrofuran, éthanol and water at a température of about 23°C. The sulfide of formula XXIV may also be oxidized under milder conditions, for exampie using 1 équivalent of meta-chlorobenzoic acid in a solvent such as dichloromethane at 10 about Û°C to produce a sulfoxide of formula I, wherein p is 1, X is CH2, Y rs AR5 and A is a bond
It is noted that the order of Steps 2 and 3 in Scheme 5, may optionally be reversed such that the oxidation step is carried out prior to the deprotection step.
Compounds of the formula I, wherein p is 0, X is CH2, Y is AR5and A is a bond are prepared in
Scheme 5, Step 4 by removing the arylsulfonyl protecting group PG1 from a compound of formula XXIII.
The reaction may be carried out by one of the two general deprotection methods described for Scheme 1,
Step 5. Again, the choice of deprotection method is determined by the compatibility of the conditions with other functional groups on the molécule.
In Scheme 5, Step 5, compounds of the formula XXIII are altematively prepared from a thîoacetate dérivative of formula XVIII. First, the thioacetate of formula XVIII is dissolved in a solvent such 20 as éthanol, methanol, or water (or a mixture thereof). A suitable base such as potassium carbonate or césium carbonate (about 2 équivalents) is added and nitrogen is bubbled through the solution to remove oxygen. An aikylating agent of the formula R5-LG is then added, wherein LG is a leaving group such as bromo, iodo, methanesulfonate or, para-toluene-sulfonate. The reaction is conducted at a température
from about minus 20°C to about 30°C. Preferably, the reaction is started at about 0°C and then allowed to warm to about 23°C.
Many thiols of the formula R5SH and alkylating agents of the formula R5-LG may be obtained from commercial sources. Also, several methods exist for the préparation of such compounds, which are well known to those skilled in the art and hâve been described in texts such as Advanced Organic Chemistry” by J. March, John Wiley & Sons (1985).
It is noted that certain compounds of the invention can be obtained by functional group transformations at a late stage of the synthesis, for example, by chemical modification of the groups R4 or R5 after carrying out Steps 4 or 5 in Scheme 1, Step 3 în Scheme 2, Steps 2, 3 or 4 in Scheme 3, Steps 7 or 8 10 Scheme 4 and Steps 2, 3, 4 or 5 in Scheme 5. Such functional group transformations may include one step or multiple steps, for example, réduction of an ester to an alcohol, reoxidation to an aldéhyde, addition of an organomagesium reagent to form a secondary alcohol, reoxidation to a ketone and, finally, addition of an organomagesium reagent to yield a tertiary alcohol.
In executing the synthesis of the compounds of the invention, one skilled in the art will recognize the need to sample and assay reaction mixtures prior to work up in order to monitor the progress of reactions and décidé whether the reaction should be continued or whether it is ready to be worked up to obtain the desired product. Common methods for assaying reaction mixtures include thin-layer chromatography (TLC), liquid chromatography/mass spectroscopy (LCMS), and nuclear magnetic résonance (NMR).
One skilled in the art will also recognize that the compounds of the invention may be prepared as mixtures of diastereomers or géométrie isomers (e.g., cis and trans substitution on a cycloalkane ring). These isomers can be separated by standard chromatographie techniques, such as normal phase chromatography on silica gel, reverse phase préparative high pressure liquid chromatography or supercritical
fluid chromatography. One skilled in the art will also recognize that some compounds of the invention are chiral and thus may be prepared as racemic or scalemic mixtures of enantiomers. Several methods are available and are well known to those skilled in the art for the séparation of enantiomers. A preferred method for the routine séparation enantiomers is supercritical fluid chromatography empioying a chiral stationary phase.
EXPERIMENTAL SECTION
Except where otherwise noted, reactions were run under an atmosphère of nitrogen. Chromatography on silica gel was carried out using 250-400 mesh silica gel using pressurized nitrogen (-10-15 psi) to drive solvent through the column (flash chromatography). Where indicated, solutions and reaction mixtures were concentrated by rotary évaporation under vacuum.
Example 1: 2,2,2- Trifluoro-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}ethanesuifonamide
Step 11 Benzyl[cis-3-(methylamino)cyclobutyl]carbamate and benzyl[trans-315 (methylamino)cyclobutyijcarbamate
A 33% solution of methylamine (1000 mL, 9.13 mol) in absolute éthanol was added to a mixture of benzyl (3-oxocyclobutyl)carbamate (WO2012/75381 A1 and WO2012/09678 A1) (200 g. 0.913 mol) and acetic acid (88 mL) stirring in éthanol (1000 mL) at 0°C. The réaction mixture stirred for at 0°C for 1.5 hours and then stirred at room température for 2 hours. Lithium borohydrîde (41g, 2.05 mol) was added in portions to the reaction mixture at -70°C. After addition was complété, the reaction mixture was stirred at -70°C for 1 hour and then allowed to warm to room température over 12 hours. The reaction mixture was quenched with water (400 mL), and concentrated under vacuum to remove éthanol. The aqueous layer was acidîfïed with concentrated hydrochloric acid to pH 2, washed with ethyl acetate (2 x 1000 mL),
basified with 10 % sodium hydroxide to pH 9-10 and then extracted with dichloromethane (3 x 1000 mL). The combined organic layers were washed with brine (1000 mL), dried over sodium sulfate, and concentrated to obtain the crude product as a pale brown liquid. This was dissolved in dichloromethane (400 mL) and cooled to 0°C. To the resulting solution was added a solution of 4M HCI in dioxane (300 mL). The mixture was stirred at 0°C for 30 minutes, and then at room température for 12 hours. The reaction mixture was filtered and the remaining solid was recrystallized from a mixture of methanol and methyl tertbutyl ether to afford the cis-isomer as a white solid (111.09 g, 52%). 1H NMR: (400 MHz, D2O): δ 7.337.38 (m, 5H); 5.02 (s, 2H), 3.83-3.87 (m, 1H), 3.89-3.41 (m, 1H), 2.66-2.70 (m, 2H), 2.56 (s, 3H), 2.032.05 (m, 2H). LC/MS (exact mass) calculated for C13H18N2O2; 234.137, found (M + H+); 235,1.
The trans isomer was isolated from the mother liquor using supercritical fluid chromatography.
Step 2: Benzyl (cis-3-[(2-chloro-7H-pyrrolo[2,3-d]pyrimidin~4~yl)(rnethyl)amino]-cyclobutyl}carbamate To a solution of potassium carbonate (20.47 g, 148 mmol) in water (180 mL) was added benzyl [cis-3-(methylamino)cyc1obutyl]carbamate (13.57 g, 50.2 mmol), followed by 2,4-dichloro-7H-pyrrolo(2,3djpyrimidine (9.0 g, 47.9 mmol) at room température. After addition was complété, the reaction mixture was stirred at 95°C ovemight. The mixture was filtered to collect the solid. The filter cake was washed with water and dried under vacuum to afford the title compound (16.5 g, 89.7%) as a yellow solid. 1H NMR (400 MHz, DMSO-ûfe): δ 11.81 (sm 1 H), 7.65 (d, 1 H), 7.38 (m, 5 H). 7.16 (m, 1 H), 6.67 (d, 1 H), 5.02 (s, 2 H), 4.81 (m, 1 H), 3.85 (m, 1 H), 3.25 (s, 3 H), 2.53 (m, 2 H), 2.25 (m, 2 H). LC/MS (exact mass) calculated for C19H20CIN5O2; 385.131, found (M + H*); 386.1.
Step 3: cis-N-Methyl-N-7H-pyrroio[2,3-d]pyrimidîn-4-ylcyclobutane-1,3-diamîne hydrochioride
A mixture of {cis-3-[(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)-amino]cyclobutyl}carbamate (13.0 g, 34,0 mmol), Pd(OH)2 (40.3 g, 40.8 mmol) and cyclohexene (72.5 mL, 0.71 mol) in éthanol (300 mL) was stirred at reflux for 3 hours. The reaction mixture was filtered through a pad of Celite® and the
pad was washed with methanol. The filtrate was concentrated under vacuum to afford the title compound (4.8 g, 66%) as a white solid. 1H NMR (400 MHz, DMSO-de): δ 11.68 (br, 1H), 8.11 (s, 1H), 7.67 (br, 2H), 7.17 (d, 1H), 6.65 (d, 1H), 5.08 (m, 1 H), 3.45 (m, 1H), 3.26 (s, 3H), 2.31 (m. 4H). LC/MS (exact mass) calculated for CnHisNsl 217.133, found (M + H*); 218.1.
Step 4: 2,2,2-Trifluoro-N-{cis-3-[methyl(7H-pyrrolo[2,3-dJpyrimidin-4-yl)3mino]cyclobuty!}ethanesulfonam/de
To a solution of cis-N-methyl-N-7H-pyrrolo[2.3-d]pyrimidin-4-ylcyclobutane-1,3-diamine hydrochioride (100 mg, 0.39 mmol) în tetrahydrofuran (0.8 mL) was added lithium bis(trimethylsilyl)amide (1M solution in tetrahydrofuran) (0.9 mL, 0.9 mmol) and chlorotrimethylsilane (94 mg, 0.88 mmol) at room température. The reaction mixture was stirred for 45 minutes and then 2,2,2-trifluoroethanesulfonyl chtoride (86 mg, 0.47 mmol) was added slowly. The mixture was stirred at room température for 18 hours and then partitioned between dichloromethane and water. The aqueous layer was and extracted twice with dichloromethane and the combined organic layers were concentrated to afford the crude product as a tan solid. The crude material was purified by chromatography on silica gel eluting with a mixture of dîchloro15 methane and methanol (93:7) to afford the title compound as a white solid (93 mg, 65%). 1H NMR (400 MHz, DMSO-de): δ 11.61 (br. s„ 1 H), 8.20 (d. 1 H), 8.08 (s. 1 H), 7.13 (d, 1 H), 6.60 (d, 1 H), 4.80-4.94 (m, 1 H). 4.34 (q. 2 H), 3.58-3.71 (m, 1 H), 3.23 (s, 3 H), 2.55-2.67 (m, 2 H), 2.17-2.30 (m, 2 H). LC/MS (exact mass) calculated for CiaHieFaNsOïS; 363.098, found (M + H+); 363.9.
The following compounds, Examples 2-7, were prepared from cis-N-methyl-N-7H-pyrrolo[2,3-d]pyrimidin4-ylcyctobutane-1,3-diamine hydrochioride (Example 1, Step 3) in a similar manner to that described in Example 1, Step 4, substituting the indicated sulfonyl chloride for 2,2,2-trifluoroethanesulfonyl chloride.
Example 2: N-{às-3-[Methyi(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cydobutyl}-propane- 1-sulfonamide
This compound was prepared using 1-propanesulfonyl chloride. The crude compound was purified by chromatography on silica gel eluting with a mixture of dichloromethane and methanol (93:7) to afford the title compound as a tan solid (78% yield). 1H NMR (400 MHz, DMSO-de): δ 11.60 (br s, 1 H),
8.08 (s, 1 H), 7.46 (d, 1 H), 7.12 (d, 1 H), 6.61 (d, 1 H), 4.81-4.94 (m, 1 H), 3.47-3.62 (m, 1 H), 3.23 (s, 3
H), 2.87-2.96 (m. 2 H), 2.52-2.63 (m, 2 H), 2.14-2.27 (m, 2 H) 1.60-1.73 (m, 2 H) 0.96 (t, 3 H). LC/MS (exact mass) calcutated for C14H21N5O2S; 323.142, found (M + H+); 324.1.
Example 3: 2-Methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyc!obutyl}propane-110 sulfonamide
This compound was prepared using 2-methyl-1propanesulfonyl chloride, The crude compound was purified by chromatography on silica gel eluting with a mixture of dichloromethane and methanol (93:7) to afford the title compound as a white solid (52%). 1H NMR (400 MHz, DMSO-de): δ 11.64 (br s, 1 H). 8.12 (s, 1 H), 7.51 (d, 1 H). 7.03-7.26 (m, 1 H), 6.65 (d, 1 H), 4.82-5.02 (m, 1 H). 3.52-3.70 (m. 1 H),
3.26 (s, 3 H), 2.87 (d, 2 H), 2.55-2.67 (m, 2 H), 2.18-2.30 (m, 2 H), 2.11 (dt, 1 H), 1.04 (d, 6 H). LC/MS (exact mass) calculated for C15H23N5O2S; 337.157, found (M + H+); 338.0.
Example 4A and Example 4B: c/s- andÎrans-3-(Cyanomethyl)-N-{cis-3-[methyl(7H-pyrmlc>[2,3d]pyrimidin-4-yl)amino]cydobutyÎ}cydobutanesulfonamîde
These compounds were prepared using a mixture (-1:1) of cis- and trans-3(cyanomethyl)cyclobutanesulfonyl chloride. The crude mixture of cis and trans isomers was purified by chromatography on silica gel eluting with a gradient of dichloromethane and methanol (100:0 to 10:1) to
afford a mixture (420 mg) of the title compounds as a white solid (67%). The ois and trans isomers were separated by supercritical fluid chromatography.
cis-isomer 4A: 160 mg (21%). ’H NMR (400 MHz, methanol-d4): δ 8.12 (s, 1H), 7.13-7.12 (d. 1H), 6.696.69 (d, 1 H), 4.92-4.89 (m, 1 H), 3.84-3.78 (m, 1 H), 3.76-3.67 (m, 1 H), 3.36 (s, 3 H), 2.79-2.73 (m, 2 H), 2.65-2.64 (m, 3H), 2.58-2.52 (m, 2 H), 2.32-2.19 (m, 4 H). LC/MS (exact mass) calculated for C17H22N6O2S; 374.152, found (M + H+); 375.3.
trans-isomer 4B: 155 mg (20%). 1H NMR (400 MHz, methanol-d4): 6 8.13 (s, 1H). 7.13 (d. 1H). 6.70 (d, 1 H), 4.94-4.89 (m, 1H), 3.89-3.85 (m, 1H), 3.72-3.69 (m, 1H), 3.36 (s, 3H), 2.85-2.62 (m, 7H), 2.31-2.23 (m, 4H). LC/MS (exact mass) calculated for C17H22N6O2S; 374.152, found (M + H*); 374.9.
The mixture of cis- and trans-3-(cyanomethyl)cyclobutanesu1fonyl chlorides was prepared as follows:
Step 1 : [3-(Benzyloxy)cyclobutylidene]acetonitrile
To a cold suspension of sodium hydride (125 mg, 3.12 mmol) in tetrahydrofuran (12 mL) at 0°C was added diethyl cyanomethylphosphonate (1.21 g, 3.40 mmol). The mixture was stirred at room température for 1 hour before adding a solution of 3-(benzyloxy)cyclobutanone (500 mg, 2.84 mmol) in tetrahydrofuran (8 mL). The mixture was stirred at room température overnight, and was then quenched with water. The mixture was extracted with ethyl acetate (3 x 25m L) and the combined organic layers were dried over sodium sulfate and concentrated. The residue was chromatographed on silica gel eluting with a gradient of petroleum ether and ethyl acetate (100:0 to 85:15) to afford the title compound (450 mg, 80%) as a yellow oil.
Step 2: [3-(Benzyloxy)cyclobutyl]acetoniïrile
A mixture of [3-(benzyloxy)cyclobutylidene]acetonitrile (10.2 g, 51 mmol,) and 10% Pd/C (2.0 g) in dry tetrahydrofuran was pressurized to 50 psi with hydrogen and stirred at room température for 3 days.
The mixture was then filtered and concentrated under vacuum. The residue was chromatographed on silica gel eluting with a gradient of petroleum ether and ethyl acetate (100:0 to 80:20) to give the title compound (7 g, 70%) as a colorless oil. 1H NMR (400 MHz, CDCb): δ 7.36-7.28 (m, 5 H), 4.44-4.43 (m, 2 H), 4.30-4.09 (m, 1 H). 3.98-3.95 (m, 1 H), 2.64-2.45 (m, 4 H), 1.81-1.759 (m, 2 H).
Step 3: (3-Hydroxycyclobutyl)acetoniïrile
To a solution of [3-(benzyloxy)cyclobutyl]acetonitrile (1 g, 5.00 mmol) in acetonitrile (15 mL) was added dropwise iodotrimethylsilane (1.5 g, 7.50 mmol) at 0°C. The mixture was stirred at room température overnight. The mixture was quenched with triethylamine, concentrated and then purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (1:0 to 1:1) to afford the title compound (340 mg, 62%) as yellow oil. 1H NMR (400 MHz, CDCIa): 64.55-4.15 (m, 1H), 2.49-2.46 (m, 2H), 2.25-2.21 (m, 2H), 2.14-2.08 (m, 1H), 1.79-1.72 (m, 2H).
Step 4: 3-(Cyanomethyl)cyclobutyl-4-methylbenzenesulfonate
To a solution of (3-hydroxycyclobutyl)acetonitrile (333 mg, 3.0 mmol) in dry dichloromethane (25 mL) was added 4-dimethylaminopyridine (732 mg, 6.0 mmol). The mixture stirred ai room température for
5 minutes and then p-toluenesulfonyl chloride (859 mg, 4.5 mmol) was added. The resulting mixture was stirred at room température overnight. The mixture was washed with water (2 x 15mL). The organic layer was dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (10:0 to 7:3) to afford the title compound (520 mg, 65% yield) as colorless oil.
Step 5: S-[3-(Cyanomethyl)cycfobutyl] ethanethioate
The mixture of 3-(cyanomethyl)cyclobutyl 4-methylbenzenesulfonate (1.5 g, 5.7 mmol) and potassium thioacetate (1.29 g, 3.00 mmol) in N,N-dimethylformamide (8 mL) was heated at 80°C overnight. The mixture was diluted with ethyl acetate (15 mL), washed with water (30 mL) and brine (2 x 30 mL),
dried over sodium sulfate and concentrated. The residue was purified by préparative thin layer chromatography eluting with a mixture of petroleum ether and ethyl acetate (3:1) to afford the title compound (750 mg, 78%) as colorless oil. 1H NMR (400 MHz. CDCb): δ 4.12-3.92 (m, 1 H), 2.86-2.77 (m, 2 H), 2.712.47 (m, 2 H), 2.42-2.37 (m, 2 H), 2.30-2.29 (m,3 H), 1.97-1.90 (m, 1 H).
Step 6: 3-(Cyanomethyl)cyclobutanesulfonyl chloride
A mixture of N-chlorosuccinimide (1.6 g, 12.0 mmol) in concentrated HCl (3 mL) and acetonitrile (12 mL) was stirred at room température for 10 minutes. S-[3-(cyanomethyî)cyclobutyl] ethanethioate (507 mg, 3.0 mmol) in acetonitrile (3 mL) was added at 0°C and stirred for 10 minutes. The mixture was diluted with aqueous sodium bicarbonate (50 mL), and extracted with methyl tert-butyl ether (3 x 50 mL). The combined dried organic layers were dried over anhydrous sodium sulfate and concentrated. The crude product was purified by chromatography on silica gel eluting with a mixture of petroleum ether and ethyl acetate (100:0 to 50:50) to afford the title compound (400 mg, 69%) as a yellow oil. Ή NMR (400 MHz, CDCb): δ 4.45-4.40 (m, 1H), 3.06-2.71 (m, 3H), 2.61-2.49 (m, 4H).
Example 5: 1-[3-(Cyanomethyl)oxetan-3-yl]-N-(cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimîdîn-4yl)amino]cyclobutyl}methanesulfonamîde
This compound was prepared from [3-(cyanomethyl)oxetan-3-yl]methanesulfonyl chloride. The crude compound was purified using préparative thin layer chromatography eluting with ethyl acetate to afford the title compound as a white solid (32%). Ή NMR (400 MHz, methanol-d4): δ 8.13 (s, 1 H), 7.14-
7.13 (m, 1 H), 6.71-6.70 (m, 1 H), 5.06-5.05 (m, 1 H), 4.85-4.81 (m, 2 H), 4.52-4.50 (m, 2 H), 3.77-3.75 (m, 1 H), 3.63 (m, 2 H), 3.39 (s, 3 H). 3.29-3.26 (m, 2 H), 2.85-2.78 (m, 2 H), 2.38-2.30 (m, 2 H). LC/MS (exact mass) calculated for C17H22N6O3S; 390.147, found (M + H+); 391.0. [3-(Cyanomethyl)oxetan-3-yl]methanesulfonyl chloride
Step 1: [3-(Cyanomethyl)oxetan-3-yl]methyl 4-methylbenzenesulfonate
This compound was prepared following the procedure of Example 4 Step 4, substituting [3(Hydroxymethyl)-3-oxetanyl]acetonitnle for (3-hydroxycyclobutyl)acetonitrile. The crude compound was purified by chromatography on silica gel eluting with a mixture of petroieum ether and ethyl acetate (1:0 to
1:1) to afford the title compound as a white solid (10%). 1H NMR (400 MHz, CDCIa): S 7.82-7.80 (m, 2 H),
7.41-7.39 (m. 2 H), 4.54-4.35 (m, 4 H), 4.31 (s, 2 H), 2.79 (s, 2 H), 2.45 (s, 3H).
Step 2: [3-(Cyanomethyl)oxetan-3-yl]methyl thiocyanate
A solution of [3-(cyanomethyi)oxetan-3-yl]methyl 4-methylbenzenesulfonate (150 mg, 0.53 mmol) and potassium thiocyanate (104 mg, 1.07 mmol) was stirred in éthanol (10 mL). The reaction was heated
I0 to 85°C and stirred for 16 hours. The solvent was evaporated to afford the crude title compound as a white solid.
Step 3; [3-(Cyanomethyl)oxetan-3-yl]methanesulfonyl chloride
Chlorine gas was bubbled through a solution of [3-(cyanomethyl)oxetan-3-yl]methyl thiocyanate (0.53 mmol, crude) in water (10 mL) at 0°C for 30 minutes. The reaction mixture was extracted with me15 thyl tert-butyl ether (2 x 20 mL). The combined organic layers were dried over sodium sulfate and concentrated to afford the title compound (20 mg, 18%).
Example 6: N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}- 1-oxetan-3ylmethanesulfonamide
This compound was prepared using oxetan-3-ylmethanesulfonyl chloride. The crude compound was purified by chromatography on silica gel eluting with a mixture of dichloromethane and methanol (85:15) to afford the title compound as a white solid (23%). 1H NMR (400 MHz, methanol-di): δ 8.13 (m, 1 H), 7.13 (d, J = 4Hz, 1 H), 6.70-6.69 (m, J = 4Hz, 1 H). 4.93-4.91 (m,1 H), 4.84-4.83 (m, 2 H). 4.63-4.59
(m, 2 H), 3.74-3.68 (m, 1 H), 3.58-3.56 (m, 1 H), 3.47-3.45 (m, 2 H), 3.37 (s, 3 H), 2.79-2.77 (m, 2 H), 2.32-2.29 (m, 2 H). LC/MS (exact mass) calculated for C15H21N5O3S; 351.136, found (M + H*); 352.1.
Oxetan-3-ylmethanesulfonyl chloride
Step 1: Oxetan-3-ylmethyl thiocyanate
This compound was prepared according to the procedure of Example 5, Step 2, substituting oxetan-3-ylmethyl 4-methylbenzenesulfonate (WO2012/117000A1) for [3-(cyanomethyl)oxetan-3yljmethyl 4-methylbenzenesulfonate to afford the crude title compound as a white solid. (100%).
Step 2: Oxetan-3-ylmethanesulfonyI chloride
This compound was prepared in crude form (25% yield) following the procedure of Example 5 Step 3, substituting oxetan-3-ylmethyl thiocyanate for [3-(cyanomethyl)oxetan-3-yl]methyl thiocyanate.
Example 7A and 7B: cis- and trans-3-(Cyanomethyl)-3-methyl-N-{cis-3-[methyl(7/-l-pyrrolo[2,315 d]pyrimidin-4-yl)amino]cyclobutyl}cyclobutanesulfonamide
These compounds were prepared using a mixture (-1:1) of cis- and trans-3-(cyanomethyl)-3methylcyclobutanesulfonyl chloride. The crude mixture of cis- and trans isomers was purified by chromatography on silica gel eluting with a gradient of petroleum ether:ethyl acetate (10:1 to 1:15) to afford a mixture (70 mg) of the title compounds as a light brown solid (28%). The cis and trans isomers were then 20 separated by supercritical fluid chromatography (SFC).
cis-isomer (7A): 26 mg (10%); SFC rétention time = 7.11 minutes; Ή NMR (400 MHz, methanol-d4): δ
8.13 (s, 1 H), 7.13-7,13 (d, 1 H), 6.69 (d, 1 H), 4.93-4.86 (m. 1 H), 3.91-3.87 (m, 1 H), 3.71-3.65 (m, 1 H),
3.37-3.33 (m, 3 H), 2.77-2.75 (m, 2 H), 2.68 (s, 2 H), 2.41-2.36 (m, 2 H), 2.26-2.21 (m, 2 H), 1.34 (m. 3 H). LC/MS (exact mass) calculated for C18H24N6O2S; 388.168, found (M + H+); 389.1.
trans-isomer (7B) 24 mg (10%); SFC rétention time = 11.35 minutes; 1H NMR (400 MHz, methanol-do): δ
8.13 (s, 1 H), 7.14 (d, 1 H). 6.69 (d, 1 H), 4.93-4.86 (m, 1 H), 3.96-3.86 (m, 1 H), 3.72-3.65 (m, 1 H), 3.36-
3.31 (m, 3 H), 2.77-2.75 (m, 2 H), 2.71 (s. 2 H), 2.34-2.26 (m, 6 H), 1.33 (m, 3 H). LC/MS (exact mass) calculated for C18H24N6O2S; 388.168, found (M + H+); 389.0.
The mixture of cis- and trans-3-(cyanomethyl)-3-methylcyclobutanesulfonyl chlorides was prepared as follows:
Step 1: 1-Methyl-3-methyienecyciobutanecarbonitrile
To a solution of 3-methylenecyclobutanecarbonîtrile (35.0 g, 373.0 mmol) în tetrahydrofuran (200 mL) was added dropwise lithium bis(trimethylsilyl)amide (450 mL, 1M) at -78°C. The solution was stirred for 1 hour at -78C and iodomethane (30 mL, 448 mmol) was added to the reaction. After 1 hour, the mixture was warmed to room température and stirred overnight. The reaction mixture was quenched with aqueous ammonium chloride (380 mL) and extracted with methyl tert-butyl ether (3 x 400 mL). The com15 bined organic layers were dried over sodium sulfate and concentrated. The crude product was purified by distillation under reduced pressure to afford the title compound (20 g, 50%) as ciear oil. ’H NMR (400 MHz, CDCb): δ 4.90-4.89 (m, 2 H), 3.24-3.20 (m, 2 H), 2.67-2.62 (m, 2 H), 1.50 (s, 3H).
Step 2; 1-Methyl-3-methylenecyclobutanecarboxylic acid
To a solution of 1-methyl-3-methylenecyclobutanecarbonitrile (10.0 g, 93.3 mmol) in water (50 mL) and éthanol (50 mL) was added potassium hydroxide (25.6 g, 466.6 mmol). The reaction mixture was heated to reflux and stirred overnight. The éthanol was removed under reduced pressure, and the solution was cooled to below 10‘C, acidified with concentrated hydrochloric acid to pH 1. The aqueous phase was extracted with ethyl acetate (3 x 150 mL). The combined organic layers were dried over sodi-
um sulfate and concentrated to afford the title compound (9 g, 77%). 1H NMR (400 MHz, CDCb): δ 11.90 (s, 1 H), 4.88-4.85 (m, 2 H), 3.23-3.17 (m, 2 H), 2.53-2.41 (m, 2 H), 1.45 (s, 3 H).
Step 3: Ethy! 1-methyl-3-methylenecyclobutanecarboxylate
To a solution of 1-methyl-3-methylenecyclobutanecarboxylic acid (6 g, 47.6 mmol) in dichloromethane (30 mL) at 0°C was added dropwise thionyl chloride (11.0 mL, 143 mmol). The solution was stirred at 0°C for 1 hour. Three drops of Ν,Ν-dimethylformamide were added to the solution. The solution was stirred at 0'C for 30 minutes. The solvent was evaporated and dichloromethane (20 mL) and éthanol (125 mL) were added to the residue. The resulting solution was stirred for 16 hours at room température. The solvent was evaporated and water (20 mL) was added to the residue. The aqueous layer was extracted with dichloromethane (4 x 20 mL). The combined organic layers were dried over sodium sulfate and concentrated. The crude product was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (20:1 to 10:1) to afford the title compound (5 g, 68%). 1H NMR (400 MHz, CDCb): δ 4.85-4.83 (m, 2 H), 4.17-4.12 (m, 2 H), 3.18-3.12 (m, 2 H), 2.48-2.42 (m, 2H), 1.41 (s, 3 H), 1.27-1.23 (m, 3 H).
Step 4: (1-Methyl-3-methylenecyclobutyl)methanol
A mixture of ethyl 1-methyl-3-methyîenecyclobutanecarboxylate (4.55 g, 29.5 mmol) lithium aluminum hydride (2.8 g, 72 mmol) in tetrahydrofuran (50 mL) was stirred ovemight at room température. To the reaction mixture was added Na2SO4'10H2O (3.7 g, 11.5 mmol) and the resulting mixture was stirred for 1 hour at room température. The solrds were removed by filtration and the filtrate was concentrated under vacuum. The residue was extracted with dichloromethane (3 x 50 mL). The combined organic extracts were dried over sodium sulfate and concentrated to afford the title compound (2.6 g, 79%) as a colorless oil. Ή NMR (400 MHz, CDCb): δ 4.79-4.78 (m. 2 H), 3.48 (s, 2 H), 2.53-2.48 (m, 2 H), 2.36-2.27 (m, 2 H), 1.16 (s, 3 H).
Step 5: (1-Methyl-3-methylenecyclobutyl)methyl 4-methylbenzenesulfonate
This compound was prepared following Example 4, Step 4, substituting (1-methyl-3methylenecyclobutyl) methanol for (3-hydroxycyclobutyl)acetonitrile. The crude compound was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (20:1 to 4:1) to afford the title compound (70%). 1H NMR (400 MHz, CDCh): δ 7.79 (d, 2 H), 7.34 (d, 2 H), 4.79-4.78 (m, 2 H), 3.90 (s, 2 H), 2.51-2.47 (m, 2 H), 2.44 (s, 3 H), 2.35-2.31 (m, 2 H). 1.15 (s, 3 H).
Step 6: (1-Methyl-3-methylenecyclobutyl)acetonitrile
A mixture of (1-methyl-3-methylenecyclobutyl)methyl 4-methylbenzenesulfonate (2.5 g, 9.4 mmol), potassium cyanide (1.3 g, 19 mmol) and Ν,Ν-dimethylformamide (8mL) was stirred ovemight at
70°C. Water (10 mL) and methyl tert-butyl ether (20 mL) were added to the mixture and the organic layer was separated. The aqueous phase was extracted with methyl tert-butyl ether (3 x 30 mL). The combined organic layers were washed with an aqueous saturated sodium bicarbonate solution (15 mL), dried over sodium sulfate, and concentrated. The crude product was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (10:1 to 5:1) to afford the title compound (1.1 g, 97%) as light brown oil. 1H NMR (400 MHz, CDCh): 54.88-4,87 (m, 2 H), 2.62-2.54 (m, 2 H), 2.50 (s, 2 H), 1.33 (s, 3 H).
Step 7: (1-Methyl-3-oxocyciobutyl)acetonitrile
Ozone gas was bubbled through a solution of (1-methyl-3-methyîenecyc!o-butyi)acetonitrile (1.08 g, 8.91 mmol) in dichloromethane (30 mL) -78'C for 10 minutes. After purging the solution with nitrogen gas, dimethylsulfide (10 mL) was added dropwise to the solution at -78°C. The solution was stirred for 30 minutes at -78C and the solvent was removed under reduced pressure. The crude product was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (20:1 to 8:1)
to afford the title compound (920 mg, 84%) as a colorless oil. ’H NMR (400 MHz, CDCb): δ 3.11-3.06 (m, 2 H), 2.96-2.91 (m, 2 H), 2.69 (s, 2 H), 1.53 (s, 3 H).
Step 8: (3-Hydroxy-1-methylcyclobutyl)acetonitrile
To a solution of (1-methyl-3-oxocyclobutyl)acetonitrile (400 mg, 3.25 mmol) in tetrahydrofuran (15 mL) was added sodium borohydride (246 mg, 6.5 mmol). The mixture was stirred for 3 hours at room température. Acetone (2 mL) was added and then the solvent was evaporated. Water (10 mL) was added to the residue and the aqueous phase was extracted with dichloromethane (4x15 mL). The combined organic layers were dried over sodium sulfate and concentrated. The crude product was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (10:1 to 1:1 ) to afford the title compound (300 mg, 74%) as a colorless oil. ’H NMR (400 MHz, CDCb): 64.38-4.34 (m, 2 H), 2.46-2.27 (m, 4 H), 1.94-1.86 (m, 2 H), 1.33-1.12 (m, 3 H).
Step 9: 3-(Cyanomethyl)-3-methylcyclobutyl 4-methylbenzenesulfonate
This compound was prepared following Example 7, Step 5, substituting (3-hydroxy-1methylcyclobutyl)acetonitrile for (1-methyl-3-methylenecyclo-butyl)methanol. The crude compound was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (20:1 to 4:1) to afford the title compound (36%). ’H NMR (400 MHz. CDCb): δ 7.77 (d, 2 H), 7.35 (d, 2 H), 4.894.81 (m, 1 H), 2.45 (s, 3 H), 2.43-2.34 (m, 3 H), 2.26-2.21 (m, 1 H), 2.15-2.11 (m, 2 H), 1.33 (s, 3 H). Step 10: S-[3-(Cyanomethyl)-3-methylcyclobutyl]ethanethioate
This compound was prepared in 89% yield (crude) following the procedure of Example 4, Step 5, substituting 3-(cyanomethyl)-3-methylcyclobutyl 4-methylbenzenesulfonate for 3-(cyanomethy1)cyclobutyl 4-methylbenzene-sulfonate. ’H NMR (400 MHz, CDCb): δ 3.12 (s, 1 H), 2.46-2.30 (m, 4 H), 2.19 (s, 2 H), 1.29 (s, 1 H) 1.26-1.24 (m, 1 H), 1.18-1.14 (m, 1 H), 1.13 (s, 3H).
Step 11: 3-(Cyanomethyl)-3-methylcyclobutanesulfonyl chloride
6l
This compound was prepared following Example 4 Step 6, substituting S-[3-(cyanomethyl)-3methylcyclobutyl] ethanethioate for S-[3-(cyanomethyl)-cyclobutyl] ethanethioate. The crude compound was purified using chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (90:10 to 30:70) to afford the title compound as a yellow liquid (66%). 1H NMR (400 MHz, CDCh): δ
4.45-4,38 (m, 1 H), 2.67-2.55 (m, 4 H), 2.46-2.40 (m, 2 H), 1.42-1.40 (m, 3 H).
Example 8: 4-Cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyl}pyridine-2sulfonamide
Step 1:2-(Benzylthio)isonicotinonitrile
A 60% suspension of sodium hydride in minerai oil (8.36 g, 210.0 mmol) was suspended in tetrahydrofuran (100 mL). A solution of benzyl mercaptan (21.5 g, 173 mmol) in tetrahydrofuran (50 mL) was then added dropwise. A thick slurry formed during the addition. 4-Cyano-2-chloropyridine (12.5 g, 90.2 mmol) was added and the resulting mixture was stirred for 3 hours at room température. After carefully quenching with water, the mixture was partitioned between water and diethyl ether. The ether layer was washed with saturated aqueous sodium bicarbonate solution, dried over magnésium sulfate and concentrated under reduced pressure. Heptane was added to the residue with solids forming rapidly. The solids were collected by filtration, washed with heptane, and dried to give (33.02 g, 84%) of the title compound as an off-white solid. 1H NMR (400 MHz, CDCta): δ 8.61 (d, 1 H), 7.25-7.46 (m, 6 H), 7.16-7.22 (m, 1 H), 4.47 (s, 2 H). LC/MS (exact mass) calculated for C13H10N2S; 226.056, found (M + H+); 227.1.
Step 2: 4-cyanopyridine-2-sulfonyl chloride
To a mechanically-stirred mixture of 2-(benzyithio)isonicotinonitrile (8.92 g, 39.4 mmol) in dichloromethane (139 mL) and water (31 mL) was added dropwise sulfuryl chloride (22.5 mL, 278 mmol), keeping the température of the mixture below 3°C. After addition was complété, the mixture was stirred
for 30 minutes with continued cooling in an ice bath. A slurry of water (50 mL) and ice (20 g) was added. The aqueous phase was extracted twice with dichloromethane. The combined extracts were dried over magnésium sulfate and concentrated under reduced pressure to afford the crude title compound. Step 3: 4-Cyano-N-{cis-3-[methyl(7H-pyrro!o{2,3-d]pyrimidin-4-yl)amino]cydobutyl}pyr-idine-25 suiïonamide
A solution of 4-cyanopyridine-2-sulfonyl chloride (9.7 g, 47.9 mmol) in N,N-dimethylformamide (10 mL) was added to a solution of cis-N-methyl-N-7H-pyrrolo[2,3-d]pyrimidin-4-ylcyclobutane-1,3-diamine hydrochloride (8.0 g, 36.8 mmol) and 4-dimethylaminopyridine (150 mg, 0.03 mmol) in N,Ndimethylformamide (90 mL) at room température. Diisopropylethylamine (13 mL, 77 mmol) was added and the resulting mixture was stirred at room température for 2 hours. The mixture was diluted with ethyl acetate (200 mL) and aqueous saturated sodium bicarbonate solution was added. Water was added to dissolve the precipitated solids. The aqueous phase was extracted three times with ethyl acetate. The combined organic extracts were washed four times with brine, dried over anhydrous magnésium sulfate and concentrated under reduced pressure. A 1:1 mixture of ethyl acetate and hexanes was added to the residue. The solids were coliected by filtration and then dissolved in dichloromethane and a minimum amount of methanol. The resulting solution was passed through a silica gel plug eluting with a 5% solution of methanol in dichloromethane. The solvents were evaporated to afford a solid to which was added a solution of 10% methanol in dichloromethane. The mixture was briefly stirred and then let stand overnight. The solids were filtered, washed with dichloromethane and dried to afford the title compound (5.58 g, 39%) as an off-white solid. 1H NMR (400 MHz, DMSO-de): δ 11.62 (br. s., 1 H), 9.02 (d, 1 H), 8.52 (d, 1 H), 8.38 (s, 1 H), 8.17 (dd, 1 H), 8.07 (s, 1 H), 7.10-7.15 (m, 1 H), 6.59 (dd, 3.41 Hz. 1 H), 4.80-4.91 (m, 1 H), 3.58-3.71 (m, 1 H), 3.19 (s, 3 H), 2.25-2.36 (m, 2 H), 2.10 (m, 2 H). LC/MS (exact mass) calculated for C17H17N7O2S: 383.116, found (M + H+); 384.1.
Example 9: 3-(1-Hydroxy- 1-methy!ethyl)-N-{cis-3-[methy!(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyc!obutyl}benzenesulfonamide
Step 1 : Methyl 3-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyl}amino)5 sutfonytjbenzoate
To a suspension of cis-N-methy!-N-7H-pynOlo[2,3-d]pyrimidin-4-ylcyclobutane-1,3-diamine hydrochloride (1.8 g, 8.29 mmol) in N.N-dimethylformarnide (100 mL) was added portionwise triethylamine (6.7 mL, 49 mmol) at 0°C. Methyl 3-{chlorosulfonyÎ)benzoate (2.3 g, 9.9 mmol) was added at 0°C. The resulting mixture was stirred at room température for 3 hours. The solvent was removed under vacuum.
The residue was chromatographed on silica gel eluting with a gradient of methanol in dichloromethane (3% to 10%) to afford the title compound (1.6 g, 47%) as a yellow solid.
Step 2; 3-(Hydroxymethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyc!obutyl}benzenesutfonamide
To a solution of methyl 3-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-415 yl)amino]cyclobutyl}amino)sulfonyl]benzoate (800 mg, 1.92 mmol) in tetrahydrofuran (120 mL) was added lithium aluminum hydride (0.25 g, 6.7 mmol) at 0°C. The reaction was warmed to 25°C and stirred for 3 hours. The reaction was quenched with water (2 mL) and stirred for 15 minutes. The reaction mixture was filtered. The filter cake was stirred in tetrahydrofuran (50 mL) and filtered again. The combined filtrate was concentrated to dryness to afford the title compound (430 mg, 58%) as a yellow solid.
Step 3: 3-Formyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobuty!}benzenesulfonamide To a solution of 3-(hydroxymethyl)-N-(cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}benzenesulfonamide (400 mg, 1.03 mmol) in chloroform (50 mL) and methanol (5 mL) was added manganèse dioxide (0.89 g, 10.0 mmol). The reaction mixture was stirred at 25°C overnight.
The réaction mixture was filtered and the filter cake was washed with chiorofomn (3 x 25 mL). The cornbined filtrâtes were concentrated. The residue was chromatographed on silica gel eluting with a gradient of methanol tn dichloromethane (2% to 8%) to afford the title compound (240 mg, 60%) as an oil.
Step 4: 3-(1-Hydroxyethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d}pyr!midin-4yl)amino]cyclobutyl}benzenesulfonamide
To a solution of 3-formyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}benzenesulfonamide (260 mg, 0.68 mmol) in tetrahydrofuran (20 mL) was added méthylmagnésium bromide (1.8 mL, 5.4 mmol) at 0°C under nitrogen. The reaction was stirred at 25°C ovemight and was then quenched with aqueous ammonium chloride (10 mL). The reaction mixture was extracted with ethyl acetate (3 x25 mL), The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by préparative high performance liquid chromatography to afford the title compound (60 mg. 22%) as a white solid. 1H NMR (400 MHz, DMSO-de): δ 11.6 (s, 1 H), 8.08 (s, 1 H), 8.03 (d, 1 H), 7.86 (s, 1 H), 7,70 (m, 1 H), 7.55 (m, 2 H), 7.15 (m, 1 H), 6.61 (m, 1 H), 5.44 (m, 1 H), 4.85 (m. 1 H), 3.56 (m. 1 H), 3.18 (s. 3 H), 2.18 (m, 2 H). 2.04 (m. 2 H), 1.32 (d, 3 H). LC/MS (exact mass) calculated for C19H23N5O3S; 401.152, found (M + H+); 402.2.
Step 5: 3-Acety!-N-{cis-3-[methyÎ(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyl}benzenesulfonamide To a solution of 3-(1-hydroxyethyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl)benzenesulfonamide (60 mg, 0.15 mmol) in chloroform (30 mL) and methanol (5 mL) was added manganèse dioxide (190 mg, 2.2 mmol). The reaction mixture was stirred at 45°C ovemight. Then the reaction mixture was filtered and the filter cake was washed with chloroform (3 x 25 mL), The combined filtrâtes were concentrated. The residue was purified by préparative high performance liquid chromatography to afford the title compound (15 mg, 25%) as a white solid. 1H NMR (400 MHz, DMSOde): 8 11.58 (s, 1 H), 8.31 (s, 1 H), 8.21 (m, 2 H), 8.16 (m, 2 H), 7.76 (m, 1 H), 7.09 (d, 1 H), 6.56 (s. 1 H),
4.82 (m, 1 H), 3.54 (m, 1 H), 3.14 (s, 3 H), 2.81 (m, 3 H), 2.26 (m, 2 H), 1.98 (m, 2 H). LC/MS (exact mass) calculated for C19H21N5O3S; 399.136, found (M + H+); 400.1.
Step 6: 3-(1-Hydroxy- 1-methylethyl)-N-{cis-3-[methyi(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyi}benzenesulfonamide
To a solution of 3-acetyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyciobutyl}benzenesulfonamide (240 mg, 0.58 mmol) in tetrahydrofuran (20 mL) was added méthylmagnésium bromide (2.4 mL, 7.2 mmol) at 0°C under nitrogen. The reaction was stirred at 25°C for 2 hours and was quenched with aqueous ammonium chloride solution (10 mL). The reaction mixture was extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by préparative high performance liquid chromatography to afford the title compound (101 mg, 42%) as a white solid. 1H NMR (400 MHz, DMSO-de): δ 11.6 (s, 1 H), 8.05 (s, 1 H), 7.97 (m, 2 H), 7.67 (m, 2 H). 7.52 (m, 1 H), 7.12 (m, 1 H), 6.57 (m, 1 H), 5.29 (s, 1 H), 4.85 (m, 1 H), 3.53 (m. 1 H), 3.15 (s, 3 H), 2.24 (m, 2 H), 1.98 (m, 2 H), 1.44 (s, 6 H). LC/MS (exact mass) calculated for CaoHïsNsOaS; 415.168, found (M + H+); 416.0.
Example 10: 1-Cyclopropyl-N-{trans-3-[methyl(7H-pyrrolo[2,3-d]pyrimidîn-4yl)amîno]cyclobutyl}methanesulfonamide
This compound was synthesized starting from benzyl (trans-3-(methylamino)cyclobutyljcarbamate (Example 1, Step 1), following procedures similar to those described for Example 1, Steps 2 and 3 to obtain ΐΓθη5-Ν-ιιπ6ΐΐΊνΙ-Ν-7Η-ργΓΓθΙο[2,3<1]ρνΓΪΓηίάίη-4-νΙογο^υΐ3ηβ-1,3-άί3Γηίηβ hydrochloride. To the resulting hydrochloride (60 mg, 0.28 mmol) in THF (10 mL) was added potassium carbonate (76 mg, 0,55 mmol), H2O (5 mL) and cycfopropylmethanesulfonyl chloride (52 mg, 0.33 mmol). The mixture stined for two hours, was diluted with dichloromethane, washed with brine, dried over sodium
sulfate, filtered, and concentrated. The crude product was purified by préparative high performance liquid chromatography to afford the title compound as a white solid (7 mg; 8%). 1H NMR (400 MHz, methanold+): δ 8.14 (s, 1 H), 7.16 (d, 1 H,), 6.72 (d, 1 H), 5.44-5.40 (m, 1 H), 4.07-4.06 (m, 1 H), 3.41 (s. 3 H), 3.01-2.99 (m, 2 H), 2.81-2.74 (m, 2 H), 2.54-2.49 (m, 2 H), 1.15-1.13 (m, 1 H), 0.720-0.69 (m, 2 H), 0.425 0.41 (m, 2 H). LC/MS (exact mass) calculated for C15H21N5O2S; 335.142, found (M + H+); 336.1.
Example 11: N-{(1S,3R)-3-[Methyl(7H-pyrrolo[2,3-d]pyrimîdin-4-yl)amino]cyclopentyl}propane-1sulfonamide
This compound was prepared following Example 10 substituting (1 S,3/î)-N-benzyl-N'10 methylcyclopentane-1,3-diamine for benzyl [trans-3-(methylamino)-cyclobutyl]carbamate, (1R,3S)-Nmethyl-N-7H-pynolo[2,3-d]pyrimidin-4-ylcyclopentane-1,3-diamine hydrochioride for trans-N-methyl-N-7Hpyrrolo[2,3-d]pyrimîdin-4-ylcyclobutane-1,3-diamine hydrochioride, and propane-1-sulfonyl chloride for cyclopropylmethanesuifonyi chloride to afford the title compound as an off-white solid (11%). The crude compound was purified using préparative high performance liquid chromatography. 1H NMR (400 MHz, methanol-d4): δ 8.08 (s, 1 H), 7.08 (s, 1 H,), 6.65 (s, 1 H), 5.27-5.23 (m, 1 H), 3.81-3.76 (m, 1 H), 3.31 (s,
H), 2.33-2.29 (m, 1 H), 2.13-2.04 (m, 1 H), 1.98-1.92 (m. 2 H), 1.82-1.75 (m. 4 H). 1.06 (t. 3 H), 0.420.41(m, 2 H). LC/MS (exact mass) calculated for C15H23N5O2S; 337.157, found (M + H+); 337.8. (1S,3R)-N-benzyl-N'-methylcyclopentane-1,3-diamine was prepared as follows:
Step 1: Senzy! [(1R,3S)-3-aminocydopenty!]carbamate
Trifluoroacetic acid (15 mL, 190 mmol) was added to a solution of benzyl tert-butyl (1 /?,3S)-cyclopentane1,3-diylbiscarbamate (prepared as described in WO2011/086053A1) (5.02 g, 15.0 mmol) in dichloromethane (75 mL) at room température. The reaction was stirred for 2 hours and was then concentrated to afford the title compound as a light brown oil (6.70 g, crude)
Step 2: Benzyl [(1R,3S)-3-(benzylamino)cyclopentyl]carbamate
Sodium triacetoxyhydroborate (4.38 g, 20.0 mmol) was added to a solution of benzyl [(1 /7,35)-3arninocyclopentyl]carbamate (5.23 g, 15.0 mmoî) and benzaldehyde (1.7 mL, 16.0 mmol) in dichloromethane (75 mL) at room température. The mixture was stirred for 21 hours and then aqueous 1 M sodi5 um hydroxide solution (75 mL) was added to make the solution basic. The aqueous layer was extracted with dichloromethane (2 x 25 mL). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate and concentrated. The crude material was chromatographed on silica gel eluting with a mixture of dichloromethane and methanol (100:0 to 88:12) to afford the title compound as a yellow oil (3.47 g, 71%). 1H NMR (400 MHz, CDCb): δ 7.35-7.31 (m, 5 H), 7.30-7.26 (m, 5 H), 5.07 (s, 2 H), 4.1710 4.07 (m. 1 H) 3.76-3.68 (m. 2 H), 3.27-3.20 (m. 1 H), 2.02-1.51 (m, 6 H).
Step 3: (1S,3R)-N-Benzyl-N’-methylcyclopentane-1,3-diamine
Lithium aluminum hydride (1.02 g, 26.9 mmol) was added in portions to a solution of benzyl [(1R,3S)-3-(benzylamino)cyclopentyl]carbamate (3.47 g, 10.7 mmol) in tetrahydrofuran (70 mL) at room température. The reaction was heated to reflux for 3.5 hours. The mixture was then cooled in an ice bath and sequentially quenched with water (1.0 mL), aqueous 15% sodium hydroxide solution (1.0 mL) and water (3.0 mL). The suspension was diluted with ethyl acetate and filtered through Celite. The filtrate was concentrated and the residue was taken up in aqueous 0.5 M hydrochloric acid solution. The mixture was washed with diethyl ether (2 x 20 mL) and the aqueous solution was made basic (pH-11 ) with sodium hydroxide. The resulting mixture was extracted with dichloromethane (3 x 25 mL). The combined organic layers were dried over sodium sulfate and concentrated. The crude material was chromatographed on silica gel eluting with a mixture of dichloromethane and methanol (90:10) to afford the title compound as a yellow oil (204 mg. 9%). 1H NMR (400 MHz, CDCb): δ 7.33-7.20 (m, 5 H), 3.74 (s, 2 H), 3.19-3.13 (m. 1
H), 3.08-3.02 (m, 1 H) 2.39 (s, 3 H), 2.09-2.03 (m, 1 H),1.87-1.81 (m, 2 H), 1.67-1.54 (m, 2 H), 1.46-1.39 (m, 1 H). LC/MS (exact mass) calculated for CtaHîoNî; 204.163, found (M + H+); 205.1.
Example 12: 1-(3,3-Difluorocyclobutyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-45 yl)amino]cyclobutyl)methanesuifonamide
Step 1 : Benzyl[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-dJpyrimidin-4yl}amino)cyclobutyl]carbamate
4-Chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-dIpyrimidine (15 g, 48.7 mmol) and benzyl [cis-3-(methylamino)cyclobutyl]carbamate (17.2 g, 63.5 mmol) were mixed with isopropyl alcohol (180 mL) and diisopropylethylamine (28 mL, 161 mmol). The resulting slurry was heated at 75°C for 6 hours.
The reaction was cooled to room température, filtered, washed with isopropyl alcohol (150 mL) and dried in an oven at 50°C to give the title compound (23.5 g, 95%) as a white solid. 1H NMR (400 MHz, DMSOde): δ 8.38 (s, 1 H), 8.03 (d, 2 H), 7.45 (d, 1 H). 7.38-7.28 (m. 4 H), 7.26 (s. 1 H), 7.25 (d, 1 H), 6.61 (d, 1
H), 5.08 (s, 2 H), 4.96 (d, 1 H), 4.77 (m, 1 H), 3.88 (m, 1 H), 3.23 (s, 3 H), 2.71 (m, 2 H), 2.36 (s, 3 H),
2.18 (m, 2 H).
Step 2: cis-N-Methyl-N-{7-[(4-methylphenyl)su!fonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}cyc!obutane-1,3diamine dihydrobromide
Benzyl [cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pynrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyf]carbamate (15.2 g, 30.1 mmol) was suspended in ethyl acetate (45 mL) and acetic acid (45 mL). To the slurry was slowly added a 4M solution of HBr in acetic acid (45 mL, 180 mmol), maintaining the température below 25°C. The resulting slurry was stirred at room température for 2 hours. The solids were collected by filtration, washed with ethyl acetate (450 mL), and dried at40°C to afford the title compound (16 g; 100%) as a white solid. ’H NMR (400 MHz, DMSO-de): δ 8.31 (s, 1 H). 8.20 (s, 2 H),
7.97 (d, 2 H), 7.72 (d, 1 H), 7.44 (d, 2 H), 7.08 (d, 1 H), 4.93 (m, 1 H), 3.54 (m, 1 H), 3.30 (s, 3 H), 2.50 (m, 4 H). 2,35 (s. 3 H). LC/MS (exact mass) calculated for C18H21N5O2S; 371.142, found (M + H*); 372.1. Step 3: ({[(3,3-Difluorocyclobutyi)methyl]thio}rnethyl)benzene
A mixture of (3,3-difluorocyclobutyl)methyl 4-methylbenzenesulfonate (see W02010/032200A1) (4 g, 14,5 mmol), benzyl imidothiocarbamate (3.53g, 17.4 mmol), sodium hydroxide solution (1.45 g, 36.2 mmol, dissolved in 16 mL water) and Ν,Ν-dimethylformamide (16 mL) was stirred at 60°C for 16 hours. Water (40 mL) and ethyl acetate (150 mL) were added. The organic layer was washed with water (40 mL), separated, dried over sodium sulfate and concentrated. The residue was chromatographed on silica gel eluting with a gradient of petroleum ether and ethyl acetate (100:0 to 95:5) to afford the title com10 pound as colorless oil (3.2 g, 81%). NMR (400 MHz, CDCb): 5 7.34-7.24 (m, 5 H), 5.71 (s, 2 H), 2.712.61 (m, 2 H), 2.57-2.55 (m, 2 H), 2.30-2.14 (m, 3 H).
Step 4: (3,3-Difluorocyclobutyl)methanesulfonyl chtoride
This compound was prepared following the procedure of Example 8 Step 2, substituting S-[3(cyanomethyl)-3-methylcyclobutyl] ethanethioate for 2-(benzylthio)isonicotinonitri!e to afford the title com15 pound as a colorless oil (93%). 1H NMR (400 MHz, CDCb,}: δ 3.88-3.86 (m, 2 H), 3.03-2.94 (m, 3 H), 2.61-2.49 (m,2H).
Step 5: 1-(3,3-Difluorocyclobutyl)-N-[cis-3-(methyl{7-[(4-rnethylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin4-yl}amino)cyclobutyl]methanesulfonamide
A solution of (3,3-difluorocyclobutyf)methanesulfonyl chloride (2.5 g, 12,19 mmol) in 10 mL di20 chloromethane was added dropwise to a solution of cis-N-methyl-N-{7-[(4-methylphenyl)sulfony)]-7Hpyrrolo[2,3-d]pyrimidin-4-yl}cyclobutane-1,3-diamine dihydrobromide (3.25 g, 6.10 mmol) and triethylamine (3.08 g, 30.49 mmol) in dichloromethane (150 mL) at 0°C over 15 minutes. The reaction was stirred at room température for 4 hours. Water (50 mL) was added and the organic layer was separated. The
aqueous layer was extracted with dîchloromethane (2 x 150 mL), and the combined organic layers were separated dried over sodium sulfate. The crude compound was purified by chromatography on silica gel eluting with a gradient of dîchloromethane and methanol (100:0 to 90:10) to afford the title compound as a white solid (2.0 g, 61%). LC/MS (exact mass) calculated for C23H27F2N5O4S2; 539.147, found (M + H+);
540.1.
Step 6: 1-(3,3-Difîuorocyclobutyl)-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimîdin-4yi)amino]cyclobutyl}methanesulfonamide
A solution of 1-(3,3-difluorocyclobutyl)-N-[cis-3-(methyl{7-[(4-methylphenyl)-sulfonyl]-7Hpyrrolo[2,3-d]pyrimidin-4-yl}amino)cyclobutyl]methanesulfonamide (2 g, 3.71 mmol) and lithium hydroxide 10 monohydrate (780 mg, 18.6 mmol) in éthanol (40 mL) and water (20 mL) was stirred at 60°C for 4 hours.
The éthanol was evaporated and the remaining aqueous layer was neutralized to pH 7 with hydrochloric acid and subsequently extracted with dîchloromethane (2 x 200 mL). The combined organic layers was dried over sodium sulfate, filtered, concentrated, and purified by préparative high performance liquid chromatography to afford the title compound (800 mg, 56%) as a white solid. 1H NMR (400 MHz, metha15 nol-d4): 68.15 (s, 1H), 8.13 (s, 1 H), 7.16-7.15 (m, 1 H), 6.73-6.62 (m, 1 H), 4.95-4.88 (m, 1 H), 3.73-3.71 (m, 1 H), 3.38 (s, 3 H), 3.28-3.26 (m, 2 H), 2.87-2.78 (m, 4 H), 2.63-2.61 (m, 1 H), 2.56-2.48 (m, 2 H), 2.35-2.28 (m, 2 H). LC/MS (exact mass) calculated for C16H21F2N5O2S; 385.138, found (M + H+); 386.1.
The following compounds, Examples 13-14, were prepared from cis-N-methyl-N-{7-[(420 methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}cyclobutane-1,3-diamine dihydrobromide (Example
12, Step 2) in a similar manner to that described in Example 12, Step 5, substituting the indicated sulfonyl chloride for (3,3-difluorocyc!obutyl)methanesulfonyl chloride and using the deprotection method îllustrated in Example 12, Step 6.
Example 13: 3,3-Difluoro-N-{cÎs-3-[methyl(7H-pyrmlo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}cyclobutanesulfonamide
This compound was prepared using 3,3-difluorocyclobutanesulfonyl chloride using the procedure in PCT Publication No. WO2011/068881.The crude compound was purified by chromatography on silica gel eluting with a gradient of petroleum ether and ethyl acetate (80:20 to 10:90) to afford the title compound as an off-white solid (22% over 2 steps). 1H NMR (400 MHz, methanol-d4): δ 8.13 (s, 1 H), 7,13 (d,
H), 6.70 (d, 1 H), 4.86-4.81 (m, 1H), 3.78-3.72 (m. 2 H), 3.35 (s, 3 H), 3.01-2.93 (m, 4 H), 2.78-2.76 (m,
H), 2.32-2.25 (m. 2 H). LC/MS (exact mass) calculated for CisHwFîNsOzS; 371.123, found (M + H*);
372.1.
Example 14: 1-Cyclopropyl-N-{cis-3-[meihyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}methanesulfonamide
This compound was prepared as a white solid using cyclopropylmethanesulfonyl chloride (73% over 2 steps). 1H NMR (400 MHz, DMSO-de): δ 11.64 (br. s„ 1 H), 8.11 (s, 1 H), 7.53 (d, 1 H), 7.12-7.19 (m. 1 H), 6.64 (m, 1 H), 4.84-4.97 (m, 1 H). 3.54-3.70 (m, 1 H), 3.26 (s, 3 H), 2.93 (d, 2 H), 2.55-2.66 (m, 2 H), 2.29-2.22 (m, 2 H), 0.96-1.09 (m, 1 H), 0.53-0.64 (m, 2 H). 0.29-0.39 (m, 2 H). LC/MS (exact mass) calculated for C15H19F2N5O2S; 335.142, found (M + H+); 336.0.
Example 15: 1-Cyclopropyl-N-{cis-3-[methyl(7H-pyrrolo[2.3-d]pyrimidin-4-yl)amino]cyclobutyl}azetidine-3sulfonamide
Step 1 : tert-Buty! 3-({[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]amino}sulfonyl)azetidine-1-carboxylate
cis-N-Methyl-N-{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}cyclobutane-1,3diamin© dihydrobromide (7.0 g, 18.8 mmoi) was free-based by stirring in excess aqueous 1N sodium hydroxide solution for 3 minutes and then extracting into dichloromethane. The organic layer was dried over sodium sulfate and concentrated. The remaining free base was taken up in dichloromethane (200 mL), cooled to 0°C and treated with and triethylamine (13 mL, 94 mmol) and tert-butyl 3(chlorosulfonyl)azetidine-1-carboxylate, The reaction was allowed to stir at room température for 10 minutes. The crude mixture was washed with water and brine, then dried over sodium sulfate and concentrated to afford the crude product as a white solid. The solid was crystallized using a mixture of dichloromethane and diethyl ether to afford the title compound as a white solid (9.61 g, 90%). 1H NMR (400
MHz, methanol-di): S 8.19 (s, 1 H), 7.92-8.01 (m, 2 H), 7.54 (d, 1 H), 7.35 (d. 2 H). 6.86 (d, 1 H), 4.764.65 (m, 1 H), 4.18 (br. s., 2 H), 3.99-4.10 (m, 3 H), 3.66-3.78 (m, 1 H), 3.25 (s, 3 H), 2.64-2.78 (m, 2 H), 2.37 (s, 3 H), 2.10-2.25 (m, 2 H), 1.41 (s, 9 H). LC/MS (exact mass) calculated for CzbHmNgOgSî; 590.198, found (M + H+); 591.45.
Step 2: N-[cis-3-(Methyl{7-[(4-methylpheny!)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-415 yl}amino)cyclobutyl]azetidine-3-sulfonamide
Acetyl chloride (0.20 mL, 2.8 mmol) was added to a solution of tert-butyl 3-({[cis-3-(methyl{7-[(4methylphenyl)sulfony!]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyclobutyl]amino}sulfonyl)azetidine-1carboxylate (1.64 g, 2.78 mmol) in anhydrous dichloromethane (18 mL) and methanol (7 mL) at 0°C. The reaction mixture was stirred at room température for 16 hours. The white precipitate was filtered off and taken up in saturated aqueous sodium bicarbonate solution (20 mL). The resulting solution was extracted with dichloromethane (3 x 20 mL) and the combined organic layers were dried over sodium sulfate and concentrated to afford the title compound (810 mg, 60%) as a white solid. LC/MS (exact mass) calculated forCïiHîeNeOiSz; 490.146, found (M + H*); 491.0.
Step 3: 1-Cyclopropyl-N-[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]azetidine-3-sulfonamide
N-[cis-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl)amino)cyclobutyl]azetidine-3-sulfonamide (810 mg, 1.65 mmol), methanol (10 mL), molecular sieves, and [(1-ethoxycyclopropyl)oxy](trimethyl)silane (0.53 mL, 2.64 mmol) were combined in a sealable reaction vessel. The vessel was purged with nitrogen and acetic acid (1.28 mL, 8.26 mmol) was added. The vessel was sealed and then heated at 80°C for 2 hours. After the mixture was cooled to room température, sodium cyanoborohydride (273 mg, 4.13 mmol) was added. The vessel was resealed and heated slowly to 40°C for 1.5 hours. The crude mixture was filtered over a bed of Celîte, rinsing with methanol.
The filtrate was concentrated and the residue was taken up an aqueous saturated sodium bicarbonate solution. The resulting solution was extracted with dichloromethane (5 x 20 mL), and the combined organic layers were dried over sodium sulfate and concentrated to afford the title compound (576 mg, 74%) as a white solid. 1H NMR (400 MHz, methanol-d4): δ 8.23 (s, 1 H), 7.95-8.05 (m, 2 H), 7.58 (d, 1 H), 7.39 (d, 2 H), 6.90 (d, 1 H), 4.69-4.83 (m, 1 H), 3.94-4.09 (m, 1 H), 3.65-3.75 (m, 3 H), 3.54-3.64 (m, 2 H), 3.29 (s, 3 H), 2.67-2.79 (m, 2 H), 2.41 (s, 3 H). 2.15-2.29 (m, 2 H), 2.02-2.15 (m. 1 H), 0.43-0.51 (m, 2 H),
0.29-0.39 (m, 2 H). LC/MS (exact mass) calculated for C24H30N6O4S2; 530.177, found (M + H*); 531.0. Step 4: 1-Cyclopropyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}azetidine-3sutfonamide
A solution of césium carbonate (976 mg, 3.0 mmol) in water (5 mL) was added to a solution of 120 cyclopropyl-N-[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]azetidine-3-suîfonamide (530 mg, 1,0 mmol) in éthanol (10 mL). The reaction mixture was heated to reflux for 16 hours. After the solvent was removed, remaining material was taken up in water and extracted with a mixture of dichloromethane and methanol (96:4; 3x10 mL). The combined or-
ganic layers were dried over sodium sulfate and concentrated, The crude solid was crystallized from methanol to afford the title compound (225 mg, 59%) as a white solid, 1H NMR (400 MHz, methanol-d4): δ
8.10 (s, 1 H), 7.09 (d, 1 H), 6.66 (d, 1 H), 4.88-4.80 (m, 1 H), 4.03-3.96 (m, 1 H), 3.73-3.65 (m. 3 H), 3.613.57 (m, 2 H), 3.32 (s. 3 H), 2.77-2.68 (m, 2 H), 2.28-2.19 (m. 2 H), 2.08-2.03 (m, 1 H), 0.46-0.41 (m, 2
H), 0.34-0.31 (m, 2 H). LC/MS (exact mass) calculated for C17H24N6O2S; 376.168, found (M + H*); 377.0.
Example 16: N-(Cyclopropylmethyl)-N'-{cis-3-[methyÎ(7H-pyrrolo[2,3-d]pyn'midin-4yl)amino]cyclobutyl}sulfamide
Step 1 : N-[cis-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin^l-yl}amino)cyclobutyl]-210 oxo-1,3-oxazolidine-3-sulfonamide
To a solution of chforosulfonyl isocyanate (1.76 mL, 20.6 mmol) in dichloromethane (150 mL) was added dropwise a solution of 2-bromoethanol (1.43 mL, 20.6 mmol) in dichloromethane (80 mL) at 0‘C. After 30 minutes at 0'C, a solution of cis-N-methyl-N-{7-[(4-methylphenyî)sulfonyl]-7H-pyrrolo[2,3d]pyrimidin-4-yl}cyclobutane-1,3-diamine dihydrobromide (11.0 g, 20.6 mmol) and triethylamine (10.42 g,
103.2 mmol) in dry dichloromethane (80 mL) was added dropwise, and the reaction mixture was allowed to warm to room température ovemight. The reaction solution was dissolved in dichloromethane (1 L), washed with aqueous 1M hydrochloric acid solution (2 x 800 mL) and brine (500 mL). The solution was dried over sodium sulfate and concentrated to afford the title compound as white solid (8.5 g, 79%). 1H NMR (400 MHz, CD3OD): δ 8.22 (s, 1 H), 8.00 (d, 2 H), 7.58 (d, 1 H), 7.38 (d, 2 H), 6.91 (d, 1 H), 4.88 (m,
1 H). 4.45-4.41 (m, 2 H), 4.06-4.02 (m, 2 H), 3.75 (m, 1 H), 3.29 (s, 3 H), 2.72-2.69 (m, 2 H), 2.40 (s, 3 H);
2.30-3.27 (m, 2 H). LC/MS (exact mass) calculated for C21H24N6O6S2; 520.120, found (M + H*); 521.4. Step 2: N-(Cyclopropy/methyl)-N'-[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4y/}amino)cyclobutyl]sulfamide
A solution of N-[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]-2-oxo-1,3-oxazoÎidine-3-sulfonamide (150 mg, 0.29 mmol), cyclopropanemethylamine (51 mg, 0.72 mmol) and triethylamine (116 mg, 1.15 mmol) in acetonitrile (3 mL) was stirred for 15 minutes at 100°C using microwave heating. The reaction mixture was concentrated to afford the crude title compound (146 mg, 100% crude yield) as a yellow oil. LC/MS (exact mass) calculated for C22H28N6O4S2; 504.161, found (M + H+); 505.2.
Step 3: N-(Cyclopropylmethy!)-N'fcis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4yl)amino]cyclobutyl}sulfamide
A solution of N-(cyclopropylmethyi)-N'-[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,310 d]pyrimidin-4-yl)amrno)cyclobutyl]sulfamide (146 mg, 0.29 mmol), lithium hydroxide monohydrate (48 mg,
1.15 mmol) in éthanol (5 mL) and water (2.5 mL) was stirred at 100°C for 1 h. The reaction mixture was concentrated under vacuum and the crude product was purified by préparative high performance liquid chromatography to afford the title compound (14 mg, 14%) as a white solid. Ή NMR (400 MHz, methanol-d-»): δ 8.12 (s, 1 H), 7.13 (d, 1 H), 6.90 (d, 1 H), 4.90-4.86 (m, 1 H), 3.63-3.59 (m, 1 H), 3.37 (s, 3 H), 15 2.85-2.83 (m, 2 H), 2.78-271 (m, 2 H), 2.33-2.26 (m, 2 H), 1.05-1.03 (m. 1 H), 0.57-0.52 (m, 2 H); 0.300.25 (m, 2 H). LC/MS (exact mass) calculated for C15H22N6O2S; 350.152, found (M + H*); 351.2.
The following compounds, Examples 17-18, were prepared from N-[cÎs-3-(methyl{7-[(4methy!phenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyclobutyl]-2-oxo-1,3-oxazolidine-320 sulfonamide (Example 16, Step 1 ) in a similar manner to that described in Example 16, Step 2, substituting the indicated amine for cyclopropanemethylamine, and using the deprotection method illustrated in
Example 16, Step 3.
Example 17Aand 17B: (R)-and (S)-3-Cyano-N-{c!s-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4y/)amino]cyclobutyl}pyrrolidine- 1-sulfonamide
These compounds were prepared using racemic pyrrolidine-3-carbonitrile hydrochloride. The crude racemic mixture was purified by high performance liquid chromatography to afford a white solid (60 mg, 52% over 2 steps). The enantiomers were separated by supercritical fluid chromatography.
Enantîomer A (17A): 24 mg (21%): 1H NMR (400 MHz, CD3OD):Ô8.13 (s. 1 H), 7.13 (d, J = 3.2 Hz, 1 H),
6.69 (d, 1 H, J = 3.6 Hz, 1 H), 4.87-4.84 (m, 1 H), 3.73-3.67 (m, 1 H), 3.65-3.57 (m, 1 H), 3.53-3.50 (m, 2 H), 3.48-3.44 (m, 2 H), 3.405 (s, 3 H). 2.77-2.75 (m, 2 H), 2.42-2.20 (m, 4 H). LC/MS (exact mass) calculated for C16H21N7O2S; 375.148, found (M + H+); 376.1. Chiral HPLC rétention time = 5.97 minutes.
Enantîomer B (17B)r 25mg(21%)JH NMR (400 MHz, CDsOD): δ 8.13 (s, 1 H), 7.13 (d, J = 3.2 Hz, 1 H),
6.69 (d, 1 H, J = 3.6 Hz, 1 H), 4.87-4.84 (m, 1 H), 3.73-3.67 (m, 1 H), 3.65-3.57 (m, 1 H), 3.53-3.50 (m, 2 H). 3.48-3.44 (m, 2 H), 3.405 (s, 3 H), 2.77-2.75 (m, 2 H). 2.42-2.20 (m, 4 H). LC/MS (exact mass) calculated for C16H21N7O2S; 375.148, found (M + H+); 376.1. Chiral HPLC rétention time = 5.16 minutes.
I5 Example 18: 2-Methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}2,6· dihydropyrrolo[3.4-c]pyrazole-5(4H)-sulfonamide
This compound was prepared using 2-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole hydrochloride. The crude compound was purified by high performance liquid chromatography to afford the title compound as an off-white solid (24% over 2 steps). 1H NMR (400 MHz, methanol-d4): δ 8.08 (s, 1 H),
7.38 (S, 1 H), 7.10 (d, 1 H). 6.66 (d, 1 H). 4.87-4.86 (m, 1 H), 4.42-4.41 (m, 4 H), 3.87 (s, 3 H), 3.71-3.67 (m, 1 H), 3.31 (s, 3 H), 2.68-2.61 (m, 2 H), 2.27-2.22 (m, 3H). LC/MS (exact mass) calculated for Ci7H22NeO2S; 402.159, found (M + H*); 403.2 and (M + Na); 425.1.
Example 19: N-{cis-3-[Methyl(7H-pyrro!o[2,3-d]pyrimidin-4-yl)amino]cyc!obutyl}-6-oxa-3azabicyclo[3.1.1]heptane-3-sulfonamide
Step 1 : N-[cis-3-(Methyl{7-[(4-methylpheny!)sulfonyl]-7H-pyrro!o[2,3-d]pyrimidinM-y!}amino)cyc!obutyl]-6oxa-3-azabicyc!o[3.1.1]heptane-3-sulfonamide
A mixture of N-[cis-3-(Methyl{7-[(4-methylphenyl)sutfonyl]-7H-pyrroioE2,3-d]pyrimidin-4yl}amino)cyclobutyl]-2-oxo-1,3-oxazolidine-3-sulfonamide (208 mg, 0.40 mmol), 6-oxa-3azabicycio[3.1.1lheptane (50 mg, 0.50 mmol), triethylamine (220 pL, 1.58 mmol) in acetonitrile (15 mL), was heated in a 20 mL microwave vial in a microwave reactorfor 1 hour at 120°C. Excess solvent was evaporated and the resulting oil was taken up in dichloromethane. The solution was washed with aque10 ous ammonium chloride and brine. The crude material was dried over sodium sulfate and concentrated to give an oil. This was chromatographed on silica gel eluting with a gradient methanol in dichloromethane (0:100 to 5:100) to afford the title compound as a foam (82 mg, 30%). 1H NMR (CDCh): 5 8.38 (s, 1 H), 8.04 (d. 2 H), 7.48 (d. 1 H), 7.28 (d, 2 H), 6.63 (d, 1 H), 4.78-4.69 (m, 1 H), 4.62 (d, 1 H), 4.47 (d, 1 H), 3.69-3.61 (m, 1 H). 3.58 (d, 3 H), 3.26-3.17 (m, 1 H), 3.24 (s, 3 H), 2.83-.275 (m, 2 H), 2.37 (s, 3 H), 2.18I5 2.11 (m, 2 H), 2.04 (d, 1 H), 1.18 (t, 1 H). LC/MS (exact mass) calculated for CasHaeNeOsSa; 532.156, found (M + H+); 533.
Step 2: N-{cis-3-[Methyl(7H-pyrro!o[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-6-oxa-3azabicydo[3.1.1]heptane-3-sulfonamide
N-[cis-3-(Methyl[7-[(4-methylphenyl)sulfonyl]-7H-pyrrola[2,3-d]pyrimidin-4-yl}amino)cyctobutyi]-620 oxa-3-azabicycîo[3.1.1 ]heptane-3-sulfonamide (229 mg, 0.43 mmol) was added to a solution of in 1M tetrabutylammonium fluoride in tetrahydrofuran (6.5 mL, 6.4 mmol). The reaction was stirred at room température for 10 hours. The mixture was concentrated and the remaining material was chromatographed on silica gel eluting with a mixture of methanol in ethyl acetate (1:9). A yellow oil was isolated that was
triturated with a mixture of ethyl acetate and heptane to give a yellow solid. The solid was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate and concentrated to afford an off-white solid. This was triturated with diethyl ether and then isopropyl alcohol to afford the title compound as a white solid (14 mg, 9%). Ή NMR (CDsOD) δ 8.08 (s, 1 H), 7.09 (d, 1 H), 6.66 (s, 1 H), 4.90-4.81 (m, 1H), 4.62 (d, 2 H), 3.86-8.84 (m , 1 H), 3.66 (t, 1 H), 3.56-3.49 (m, 3 H), 3.33 (s, 3 H), 3.19-3.13 (m, 1 H), 2.75-
2.70 (m, 2 H), 2.32-2.24 (m, 2 H), 2.05-2.03 (d, 1 H). LC/MS (exact mass) calculated for CwHzîNeOsS; 378.147, found (M + H*); 379.5.
The following compounds, Examples 20-24, were prepared from N-[cis-3-(methyl{7-[(4methylphenyl)suifonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyclobutyl]-2-oxo-1,3-oxazolidine-3sulfonamide (Example 16, Step 1) in a similar manner to that described in Exampte 16, Step 2, substituting the indicated amine for cyclopropanemethylamine, and using the deprotection method illustrated in Example 19, Step 2.
Exampfe 20: 3-Cyano-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-cyclobutyfazetidine-1sulfonamide
This compound was prepared using azetidine-3-carbonitrile. The crude compound was purified by high performance liquid chromatography to afford the title compound as a white solid (23% over 2 steps).
Ή NMR (400 MHz, CDaOD): δ 8.10 (s, 1 H), 7.11 (d, 1 H), 6.68 (d, 1 H), 4.80 (m, 1 H), 4.02 (m. 2 H). 3.90 (m, 2 H), 3.58 (m, 2 H), 3.32 (s, 3 H), 2.72 (m, 2 H), 2.25 (m, 2 H). LC/MS (exact mass) calculated for C15H19N7O2S; 361.132, found (M + H+); 362.1.
Example 21 : N-{cis-3-[Methy!(7H-pyirolo[2,3-d]pyrimidin-4-y!)amino]cyclobutyl}-4-( 1H-pyrazo!-3yfpiperidine- 1-sulfonamide
This compound was prepared using 4-(1H-pyrazol-3-yl)piperidine. The crude compound was purified by chromatography on silica gel eluding with a mixture of dichloromethane and methanol (9:1 ). The isolated material was triturated with diethyl ether and then ethyl acetate to afford the title compound as a white solid (10% over 2 steps). 1H NMR (300 MHz, CD3OD): δ 8.09 (s, 1 H), 7.48 (s, 1 H), 7.12-7.05 (m, 1 H), 6.71-6.60 (m, 1 H), 6.22-6.08 (m, 1 H), 4.92-4.73 (m, 1H), 3.80-3.55 (m, 3H), 3.41 (s, 3H), 2.90-2.65 (m, 5 H), 2.38-2.19 (m, 2 H), 2.09-1.90 (m, 2 H) and 1.83-1.65 (m, 2 H). LC/MS (exact mass) calculated for CisHîeNaOîS; 430.190, found (M + H+); 431.1.
Example 22: N-(2-Cyanoethyl)-N-methy!-N'-{cis-3-[methyl(7H-pyrrolo[2,3-d]pynmidin-4yl)amino]cyclobutyl}su/famide
This compound was prepared using 3-methylaminopropionitrile. The crude compound was purified by high performance liquid chromatography to afford the title compound (7% over 2 steps). LC/MS (exact mass) calculated for C15H21N7O2S; 363.148, found (M + H+): 364.0.
Example 23 and 27: (1S,5S)-1-Cyano-N-{cis-3-[methyi(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}3-azabicyc!o[3.1.0]hexane-3-sulfonamide and ( 1R,5R)- 1-Cyano-N-fcis-3-[methyl(7H-pyirolo[2,3d]pyrimidin-4-yl)amino]cyclobutyl}-3-azabicyclo[3.1.0]hexane-3-sulfonamide
These compounds were prepared using racemic 3-azabicyclo[3.1.0]hexane-1-carbonitrile. The crude racemic compound was purified as a white solid (92 mg, 21 % over 2 steps) by chromatography on silica gel eluting with a gradient of dichloromethane and methanol (30:1 to 5:1). The title enantiomers were separated by supercritical fluid chromatography.
Enantiomer 23: 41 mg (9%); SFC rétention time = 4.28 minutes; 1H NMR (400 MHz, methanol-ch): 5 8.13 (s, 1 H), 7.13 (d, 1 H), 6.70 (d, 1 H), 4.61 (s, 1 H), 3.57 - 3.72 (m, 2 H), 3.43 - 3.51 (m, 3 H), 3.36 (s, 3 H),
2.70 - 2.77 (m, 2 H), 2.24 - 2.38 (m, 3 H), 1.41 - 1.48 (m, 1 H), 1.32 (t, 1 H). LC/MS (exact mass) catculated forCnHiiNzOaS; 387.148, found (M + H+); 388.1.
Enantiomer 27: 40 mg (9%); SFC rétention time = 4.84 minutes 1H NMR (400 MHz, methanol-d^): δ 8.13 (s, 1 H), 7.13 (d, 1 H), 6.70 (d. 1 H), 4.61 (s, 1 H), 3.57 - 3.72 (m, 2 H), 3.43 - 3.51 (m, 3 H), 3.36 (s, 3 H),
2.70 - 2.77 (m, 2 H), 2.24 - 2.38 (m, 3 H), 1.41 -1.48 (m, 1 H), 1.32 (t, 1 H). LC/MS (exact mass) calculated for C17H21N7O2S; 387.148, found (M + H*); 388.1.
Racemic 3-azabicyclo[3.1.0]hexane-1-carbonitrile was prepared as follows.
Step 1: Racemic tert-butyl rac-1-formyI-3-azabicyclo[3.1.0]hexane-3-carboxylate
1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (6.5 g, 15.2 mmol) was added to a solution of racemic tert-butyl-1-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (Syn/eff2009, 921) (2.5 g, 11.7 mmol) in anhydrous dichloromethane (60 mL). The reaction mixture stirred for 2 hours at room température. The mixture was diluted with dichloromethane (60 mL), washed with a saturated aqueous solution of sodium sulfite, saturated sodium bicarbonate (30 mL) and brine (50 mL). The organic layer was dried over sodium sulfate and concentrated to give afford the title compound as a colorless oil (1.7 g, 68%). 1H NMR (400 MHz, CDCI3):ô9.01 (d. 1 H), 3.83 (d, 1 H), 3.68 (t. 1H), 3.59 (dd, 1 H), 3.503.36 (m, 1 H), 2.25-2.09 (m, 1 H), 1.63 (t, 1 H) , 1.43 (s, 9 H), 1.19-1.06 (m, 1 H).
Step 2: Racemic tert-butyl-1-[(hydroxyimino)methyl]-3-azabicyclo[3.1.0]hexane-3-carboxy!ate
Potassium carbonate (3.89 g, 28.2 mmol) and hydroxylamine hydrochloride (671 mg, 9.7 mmol) were added to a solution of tert-butyl racemic 1-formyl-3-azabicyclo[3.1,0]hexane-3-carboxylate (1.7 g, 8.05 mmol) in anhydrous dichloromethane (40 mL) at room température and then stirred for 16 hours. The mixture was diluted with ethyl acetate (80 mL), and washed with water (30 mL) and brine (30 mL).
SI
The organic layer was dried over sodium sulfate and concentrated, The residue was chromatographed on silica gel eluting with a gradient of petroleum ether and ethyl acetate (0:100 to 83:17) to afford the title compound as a yellow oil (1.6 g, 88%). 1H NMR (400 MHz, CDCh): δ 7.18 (s, 1 H), 3.74-3.55 (m, 3 H), 3.44-3.40 (m, 1 H), 1.74-1.72 (m, 1 H), 1.44 (s, 9 H), 1.10 (t, 1 H), 0.86-0.83 (m, 1 H).
Step 3: Racemic tert-butyi-1-cyano-3-azabicyc!o[3.1.0]hexane-3-carboxy!ate
To a solution of racemic tert-buty!-1-[(hydroxyimino)methyl]-3-azabicyclo[3.1.0]hexane-3carboxylate (925 mg, 4.09 mmol) in anhydrous tetrahydrofuran (100 mL) was added methyl N(triethylammonium sulfonyl)carbamate (2.92 g, 12.3 mmol). The reaction mixture was heated to reflux for 3 hours. After évaporation of the solvent, the residue was chromatographed on silica gel eluting with a mixture of petroleum ether and ethyl acetate (5:1) to afford the title compound as a colorless oil (570 mg, 67%). iH NMR (400 MHz, CDCIs): δ 3.84 (dd, 1 H), 3.64 (dd, 1 H), 3.50 (d, 1 H), 3.46 (dd, 1 H), 2.21-2.12 (m, 1 H), 1.44 (s, 9 H), 0.96 (t, 1 H).
Step 4: Racemic 3-azabicycio[3.1.0]hexane-1-carbonitrile
A solution of racemic tert-butyl-1-cyano-3-azabicycio[3.1.0]hexane-3-carboxylate în trifluoroacetic acid (1 mL) and dichloromethane (10 mL) was stirred at room température for 1 hour. The solvent was removed to afford the title compound (205 mg, 100%) as a brown oil.
Exampte 24: Racemic 3-cyano-N-{trans-3-[methy/(7H-pyrroio[2,3-d]pyrimidin-4yl)amino]cyciobutyl}pyrrolidine-1-sulfonamide
This compound was synthesized following the procedure of Example 10, substituting 3cyanopyrrofidine-1-sulfonyl chloride for cyclopropylmethanesulfonyl chloride. The crude product was purified using préparative high performance liquid chromatography to afford the title compound as an offwhite solid (5%). 1H NMR (400 MHz, CDsOD): δ 8.13 (s, 1 H), 7.14 (d, 1 H), 6.67 (d, 1 H), 5.45-5.41 (m, 1
H), 4,00-3.64 (m, 1 H), 3.62-3.52 (m, 1 H), 3.51-3.47 (m, 2 H), 3.45-3.39 (m, 2 H), 3.369 (s, 3 H), 2.78-
2.70 (m, 2 H), 2.53-2.47 (m, 2 H); 2.39-2.36 (m, 1 H); 2,27-2.24 (m, 1 H). LC/MS (exact mass) calculated for C16H21N7O2S; 375.148, found (M + H+); 375.9.
Racemic 3-cyanopyrro!îdine- 1-sulfonyl chloride
A solution of racemic pyrrolidine-3-carbonitrile (53 mg, 0,4 mmol) and triethylamine (101 g, 1 mmol) in dry dichloromethane (1.0 mL) was added dropwise to a stirred solution of sulfuryl chloride (64.8 mg, 0.48 mmol) in dichloromethane (3.0 mL) was added at -78“C. The reaction was stirred at -78°C for 30 minutes, and then allowed to warm to room température over 1 hour. The reaction solution was washed with aqueous 1M hydrochloric acid (5 mL) and brine (5 mL), dried over sodium sulfate and con10 centrated to afford the title compound as colorless oil (68 mg, crude).
Example 25: N-(cis-3-{[(4,4-Difluoropiperidin- l-yOsulfonyljmethytycyclobutyli-N-methyl^H-pyrrolofé, 3d]pyrimidin-4-amine
Step 1 : cis/trans-Ethy! 3-[(tert-butoxycarbonyl)amino]cyclobutanecarboxylate
To a solution of a mixture of cis- and trans-ethyl 3-aminocyclobutanecarboxylate hydrochloride (cis/trans =10:1) (W02009/60278) (10 g, 55.7 mmol) and triethylamine (19.4 mL, 139.1 mmol.) in dichloromethane (370 mL) at 0°C was added dropwise di-terf-butyl dicarbonate (15.8 g, 72.3 mmol). After addition was complété, the mixture was stirred at room température overnight. The solvent was evaporated under reduced pressure and the resulting residue was chromatographed on silica gel eluting with a gradient of petroleum ether and ethyl acetate (10:1 to 3:1) to afford the title mixture as a white solid (19 g, 92%). 1H NMR (400 MHz. CDCb): δ 4.77 (s, 1 H), 4.13 (q, 3 H), 2.68-2.82 (m, 1 H), 2.60 (d. 2 H), 1.99 2.17 (m, 2 H), 1.43 (s, 9 H), 1.25 (t, 3 H).
Step 2: cis/trans-[3-(Methylamino)cyclobuty!]methanol
Lithium aiuminum hydride (9.14 g, 240.4 mmol) was suspended in dry tetrahydrofuran (350 mL). The mixture was cooled to 0°C and a solution of cis/trans ethyl 3-[(tertbutoxycarbonyl)amino]cyclobutanecarboxylate (cis/trans = 10:1) (11.7 g, 48.1 mmol) in dry tetrahydrofuran (170 mL) was added drop wise. After addition was complété, the resulting mixture was heated to reflux ovemight. After it was cooled to room température, the reaction was diluted with tetrahydrofuran (1.5 L) and then cooled to 0~5°C. Small portions of NaïSCk.lOHzO were added until gas évolution had ceased. The mixture was filtered to remove the solids, which were washed with more tetrahydrofuran (500mL). The filtrate was concentrated to dryness affording the title mixture (cis/trans = 10:1) as an oil (10 g, >100%), 1H NMR (400 MHz, CDCb): δ 3.58 (d, J = 3.8 Hz, 2 H), 3.06-3.17 (m, 1 H),
2.34-2.43 (m, 3 H), 2.32 (s, 3 H), 1.48-1.57 (m, 2 H).
Step 3: cis/trans-[3-(Methy!{7-[(4-methylphenyl)sulfonyl]-7H-pyrro!o[2,3-d]pyrimîdin-4yl}amino)cyclobutyl}me‘hanol
Potassium iodide (173 mg) and triethylamine (13 mL, 93.8 mmol) were added to a solution of cis/trans-[3-(methylamino)cyclobutyl]methanol (6.0 g, 52.1 mmol) in acetone (250 mL). 4-Chloro-7-[(415 methylphenyl)su1fonyl]-7H-pyrrolo[2,3-d]pyrimidine (14.4 g, 46.9 mmol) was then added and the resulting mixture was heated to reflux ovemight. After évaporation of the solvent under reduced pressure, the residue was diluted with dichloromethane (500 mL). The solution was washed sequentially with water (300 mL), 2% aqueous citric acid (300 mL) and brine (300 mL), and then dried over sodium sulfate. After filtration, the solution was filtered and concentrated to afford the title mixture as a light solid (15.3 g, 85%). A portion (5.0 g) of the cis/trans-[3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)-cyclobutyl]methanol mixture was separated by supercritical fluid chromatography using a Chiralpak-AD column:
cis isomer, 4.6 g: 1H NMR (400 MHz, methanol-di): δ 8,20 (s, 1 H), 7.98 (d, 2 H), 7.53 (d, 1 H), 7,34 (d, 2 H), 6.83 (d, 2 H), 4.99-4.95 (m, 1 H), 3.56 (d, J = 5.6 Hz, 1 H), 3.24 (s, 3 H), 2.36 (s. 3 H), 2.34-2.28 (m, 2
H), 2.24-2.19 (m, 1 H), 2.11-2.03 (m, 2 H). LC/MS (exact mass) calculated for C19H22N4O3S: 386.14, found (M + H+): 387.3 trans isomer, 0.4 g: 1H NMR (400 MHz, methanol-d4): δ 8.20 (s, 1 H), 7.98 (d, 2 H), 7.55 (d, 1 H), 7.35 (d, 2H), 6.84 (d. 2H), 5.26-5.22 (m, 1H), 3.69 (d, 1H), 3.30 (s, 3H), 2.46-2.41 (m. 3H), 2.39 (s, 3H), 2.19-2.14 (m, 2H). LC/MS (exact mass) calculated for CtsH22N4O3S; 386.14, found (M + H*): 387.3
Step 4: ds-[3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin~4yl}amino)cydobutyl]methyl 4-methy/benzenesulfonate
To a solution of cis-[3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobuty1]methanol (20 g, 51.8 mmol) and N,N-dimethyiamjnopyridine (12.6 g, 103.6 mmol) in dichloromethane (500 mL) at 0°C was added p-toluenesulfonyl chloride (14.8 g, 77.7 mmol). The reaction mixture was stirred at room température for 16 hours and then washed with water (500 mL). The combined aqueous washes were extracted with dichloromethane (2 x 800 mL). The combined organic layers were dried, filtered and concentrated under vacuum. The residue was chromatographed on silica gel eluting with a gradient of dichloromethane and methanol (100:0 to 95:5) to afford the title compound (23 g, 82%) as a white solid. LC/MS (exact mass) calculated for C2SH28N4O5S2: 540.150, found (M + H+): 541.3. Step 5: S-{[cis-3-(Methyl{7-[(4-methylpheny/)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]methyl}ethanethioate
To a solution of potassium thioacetate (678 mg, 5.93 mmol) in N,N-dimethylformamide (5 mL) was added a solution of [cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]methyl 4-methylbenzenesulfonate (2.0 g, 3.70 mmol) in N,N-dimethylformamide (6 mL) dropwise over 5 minutes at room température. The mixture was then heated to at 50-55°C ovemight.
The mixture was cooled to room température and quenched by pouring into aqueous saturated sodium bicarbonate solution (60 mL). The mixture was extracted with ethyl acetate (3 x 30 mL) and the combined organic layers were washed with water (3 x 30 mL), brine (30 mL). After drying over NazSCU the solution was concentrated. The residue was chromatographed on silica gel eluting with a gradient of dichloro5 methane and methanol (100:0 to 80:20) to afford the title compound (1.2 g, 73%) as a yellow solid. 1H NMR (400 MHz, CDCh): 8 8.39 (s, 1 H), 8.04 (d, 2 H), 7.45 (d, 1 H), 7.27 (d, 2 H), 6.63 (d, 1 H), 4.98-4.88 (m, 1 H) 3.22 (s, 3 H) 3.02-3.00 (m, 2 H) 2.45-2.44 (m. 2 H), 2.47 (m, 3 H) 2.22 (m, 3 H) 2.21-2.24 (m, 1 H) 1.92-1.87 (m. 2 H). LC/MS (exact mass) calculated for C21H24N4O3S2: 444.129. found (M + H*): 445.1. Step 6: [ds-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-410 yl}amino)cyclobutyl]methanesulfonic add
To a solution of S-f[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl)amino)cyclobutyl]methyl} ethanethioate (580 mg, 1.31 mmol), in formic acid (10 mL) at room température was added 30% aqueous hydrogen peroxide solution (0.7 mL, 6.92 mmol). The resulting mixture was stirred at room température ovemight. The reaction was poured into an aqueous 33% aqueous sodium bisulfate solution (1,12 mL) and then stined for 10 minutes. Aqueous 33% sodium hydroxide solution (1.8 mL) was then added to adjust the pH to 5. The resulting mixture was stirred at room température for 1 hour. The solid was collected solid by filtration, washed with water (10 mL) and vacuum dried at about 60°C to afford the title compound (634 mg, crude) as a white solid. LC/MS (exact mass) calculated for C19H22N4O5S2; 450.103, found (M + H+); 451.3.
Step 7: ds-[3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]methanesulfonyl chloride
Thionyl chloride (0,3 ml, 3.33 mmol) was added dropwise over 5 minutes to a solution of cis-[3(methyl(7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyclobutyl]methanesulfonic
acid (150 mg, 0.33 mmol) in dichloromethane (20 mL) at 0°C. Two drops of N,N-dimethylformamide were added to the solution, which was then heated at 75°C for 2 hours. The mixture was cooled and the solvent was evaporated. The residue was washed with anhydrous dichloromethane (3 x 10 mL) to afford the crude title compound (170 mg) as a yellow solid. LC/MS (exact mass) calculated for C19H21CIN4O4S2;
468.069, found (M + H+); 469.2.
Step 8: N-(cis-3f[(4,4-Difluoropiperidin- 1-yl)sulfonyi]methyl}cyciobutyl)-N-methyl-7-[(4methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
To a mixture of 4,4-difiuoropiperidine (77 mg, 0.64 mmol) and triethylamine (97 mg, 0.96 mmol) in tetrahydrofuran (20 mL) at 0DC was added dropwise a solution of cis-[3-(methyl{7-[(410 methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}arTiino)cyclobutyl]methanesulfonyl chloride (150 mg, 0.320 mmol) in tetrahydrofuran (10 mLJ.The mixture was alfowed to warm to room température overnight. The solvent was evaporated and the residue was taken up in ethyl acetate (80 mL). The solution was washed with brine (30 mL), dried over sodium sulfate and concentrated to afford the crude title compound (134 mg) as a white solid. LC/MS (exact mass) calculated for C24H29F2N5O4S2; 553.651, found (M + H+); 554.3.
Step 9: N-(cis-3-{[(4,4-difluoropiperidin- 1-yl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3dJpyrîmidin-4-amine
N-(cis-3-{[(4,4-Difluoropiperidin-1-yl)sulfonyl]methyl}cyclobutyl)-N-methyl-7-[(4methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (134 mg, 0.24 mmol) and lithium hydroxide monohydrate (51 mg, 1.21 mmol) were combined in a mixture of éthanol (14 mL) and water (7 mL) and then heated at 50°C overnight. The reaction was concentrated under vacuum and diluted with ethyl acetate (100 mL). The resulting solution was washed with brine (30 mL), dried over sodium sulfate and concentrated. The residue was chromatographed using préparative thin layer chromatography eluting with a
mixture of ethyl acetate and methanol (20:1) to afford the title compound (31 mg, 32,3 %) as a white solid.
’H NMR (400 MHz, methanol-do): δ 8.13 (s, 1H). 7.13 (d, J = 3.6, 1H),6.70 (d, J = 3.6, 1 H), 5.12 (m, 1H),
3.49-3.47 (m, 4H), 3.46 (m, 3H), 3.33 (m, 2H), 2.62-2.54 (m, 3H), 2.25-2.20 (m, 1H), 2.11-2.05 (m. 2H).
LC/MS (exact mass) calculated for C17H23F2N5O2S; 399.154, found (M + H*); 400.3.
Examples 26 to 29. The following compounds were made starting from cis-[3-(methyl{7-[(4methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyc!obutyl]methanesulfonyl chloride (Example 25, Step 7), according to the procedures of Exampie 25, Step 8 (sulfonylation) and step 9 (deprotection), substituting the appropriate amine for 4,4-difluoropiperidine in Step 8.
Example 26: 1-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyc!obutyl}-methyl)sulfonyl]Y(trifÎuoromethyl)piperidin-4-ol
The title compound (31 mg) was prepared using 4-(trifluoromethyl)piperidin-4-ol in the sulfonylation step and was deprotected using the method from Example 25, Step 9. The compound was purified using préparative thrn layer chromatography eluting with eluting with a mixture of ethyl acetate and methanol (20:1). ’H NMR (400 MHz, methanol-di): δ 8.13 (s, 1H), 7.13 (d, J = 3.6, 1 H), 6.70 (d, J = 3.6, 1H), 5.10-5.08 (m, 1 H), 3.74-3.71 (m, 2 H). 3.36 (m, 3 H), 3.32-3.27 (m, 2 H), 3.19-3,13 (m, 2 H), 2.62-2.54 (m, 3 H), 2.25-2.21 (m, 2 H), 1.86-1.84 (m, 4 H). LC/MS (exact mass) calculated for CiaH24F3N5O3S; 447.155, found (M + H+); 448.3.
Example 28 and 29: (3R) and (3S)- 1-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4y!)amino]cyclobutyl}methy!)su!fonyl]pyrrolidine-3-carbonitrile
The titfe compounds (330 mg total) were prepared using pyrrolidine-3-carbonitrile enriched as an 80:20 scalemic mixture of (3/i)-pyrrotidine-3-carbonitrile and (3^-pyrrolidine-3-carbonitrile enantiomers in the sulfonylation step and was de-protected using the method from Example 19, Step 2. The compound was purified by chromatography on silica gel eluting with gradient of petroleum ether and ethyl acetate (10:1 to 1:10). LC/MS m/z=375.2 (M+1). The enantiomers were separated by préparative supercritical fluid chromatography:
3/?-enantiomer(28): 178 mg. ’H NMR (400 MHz, CDCh):58.31 (s, 1H), 7.06 (d. 1 H), 6.58 (d, 1 H), 5.195.10 (m, 1 H), 3.77-3.75 (m, 1 H), 3.61-3.54 (m, 3 H), 3.33 (s. 3 H). 3.21-3.19 (m, 3 H), 2.69-2.66 (m, 3 H), 2.36-2.31 (m, 2 H), 2.14-2.11 (m, 2 H). LC/MS (exact mass) calculated for C17H22NSO2S; 374.15, found (M + H+); 375.2. Chiral HPLC rétention time = 2.65 minutes
3S-enantiomer(29): 31 mg. 1H NMR (400 MHz, CDCI3): 5 8.31 (s, 1H),7.06(d, 1 H), 6.58 (d, 1 H). 5.195.10 (m, 1 H), 3.77-3.75 (m, 1 H), 3.61-3.54 (m, 3 H), 3.33 (s, 3 H), 3.21-3.19 (m, 3 H). 2.69-2.66 (m, 3 H), 2.36-2.31 (m, 2 H), 2.14-2.11 (m, 2 H). LC/MS (exact mass) calculated for C17H22N6O2S; 374.15, found (M + H+); 375.2 Chiral HPLC rétention time = 2.53 minutes
Example 30: N-{cis-3-[(Buty/sulfony/)methyl]cydobutyl}-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Step 1 : N-{cis-3-[(Butylthio)methyl]cyclobutyl}-N-methyl-7H-pyrroÎo[2,3-d]pyrimidin-4-amine
A solution of cis-[3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]methyl 4-methyibenzenesuifonate from Example 25, Step 4 (23 g, 42.6 mmol) was stirred in N-methylpyrrolidine (100 mL). Then 1,8-diazabicycloundec-7-ene (12.8 g, 85.2 mmol) and 1butanethiol (7.8 g, 85.2 mmol) was added to the reaction mixture. The reaction was stirred at room température for 16 hours. Water (200 mL) and ethyl acetate (500 mL) were added. The aqueous layer was extracted with ethyl acetate (2 x 500 mL) and the combined organic layers were dried and concentrated.
The residue was chromatographed on silica gel eluting with a gradient of dichloromethane and methanol (100:0 to 90:10) to afford the title compound (11.8 g, 91%). LC/MS (exact mass) calculated for C1GH24N4S; 304.172, found (M + H*); 305.3.
Step 2: N-(cis-3-[(Buty!sulfonyl)methyl]cyclobuty/}-N-methyl-7H-pyrro!o[2,3-d]pyrimidin-4-arnine
N-{cis-3-[(Butylthio)methyl]cyclobutyl}-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-arnirie (12 g, 39.5 mmol) was dissolved in a mixture of tetrahydrofuran (200 mL), éthanol (200 mL) and water (200 mL). Potassium peroxomonosulfate (48.6 g, 79.0 mmol) was added and the reaction was stirred at room température for 1 hour. The mixture was then filtered; the solids were washed with a mixture of tetrahydrofuran (40 mL), éthanol (40 mL) and water (20 mL). The filtrate was treated with aqueous 10% sodium bisulfite solution (200 mL) and stirred at room température for 20 minutes. A saturated solution of aqueous sodium bicarbonate was added to adjust the pH to -7. The mixture was extracted with dichloromethane (3 x 800 mL) and the combined organic layers were dried and concentrated under vacuum. The crude residue was chromatographed on silica gel eluting with a gradient of dichloromethane and methanol (100:0 to 95:5) to obtain the title compound (11.4g, 86%). ’H NMR (400 MHz, methanol-di): 8 8.13 (s,
1 H), 7.13-7.12 (m. 1 H), 6.70-6.69 (m, 1 H), 5.13-5.10 (m, 1 H), 3.42 (s, 3 H). 3.33 (m, 2 H), 3.11-3.07 (m, 2 H), 2.65-2.63 (m, 3 H), 2.29-2.25 (m, 2 H),1.86-1.78 (m, 2 H), 1.55-1.50 (m. 2 H), 1.03-0.99 (m, 3 H). LC/MS (exact mass) calculated for C16H24N4O2S; 336.162, found (M + H+); 337,3
Example 31 : N-Methyl-N-(trans-3-((propylsulfony!)methyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
The title compounds were made as a mixture of cis and trans isomers (50 mg) startîng from cis and trans-[3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyclobutyi]methyl 4-methylbenzene sulfonate (cis/trans = 10:1) (Example 25, Step 4), according to procedures similar to those of Example 30, Steps 1 and 2, using propane-1-thiol instead of butane-1 -thiol in Step 2. The mix-
ture of cis and trans tsomers was purified by reverse phase high performance liquid chromatography éluting with gradient of water and acetonitrile (95:5 to 5:95). LC/MS (exact mass) calculated for C15H22N4O2S; 322.15, found (M + H*); 323.2
The cis and trans isomers were then separated by préparative supercritical fluid chromatography.
trans isomer (31), 12 mg: 1H NMR (400 MHz, methanol-d4): δ 8.12 (s, 1 H), 7.13-7.12 (m, 1 H), 6.69-6.66 (m, 1 H), 5.45-5.41 (m, 1 H), 3.46-3.44 (m, 2 H), 3.36 (s, 3 H), 3.11-3.09 (m, 2 H), 2.88-2.86 (m. 1 H), 2.75-2.67 (m, 2 H), 2.40-2.38 (m, 2 H), 1.91-1.86 (m, 2 H), 1.12-1.10 (m, 3 H). LC/MS (exact mass) calculated for C15H22N4O2S; 322.15, found (M + H+); 323.2 cis isomer, 36 mg: 1H NMR (400 MHz, methanol-d4): δ 8.12 (s, 1 H), 7.13-7.12 (m, 1 H), 6.70-6.69 (m, 1
H), 5.10-5.20 (m. 1 H), 3.36 (s, 3 H), 3.33-3.32 (m. 2 H), 3.08-3.04 (m, 2 H), 2.64-2.61 (m, 3 H), 2.24-2.22 (m, 2 H), 1.90-1.84 (m, 2 H), 1.13-1.09 (m, 3 H). LC/MS (exact mass) calculated for C15H22N4O2S; 322.15, found (M + H+); 323.2
Example 32: N-(cis-3-{[(2-Cyclopropylethyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,315 dJpyrimidin-4-amine
Step 1 : N-(cis-3-{[(2-Cyclopropylethyl)sulfanyl]methyl}cyclobutyl)-N-methyl-7-[(4-methy!pheny!)sulfonyl]7H-pyrroio[2,3-d]pyrimidin-4-amine
Nitrogen was bubbled through a mixture of S-{[cis-3-(methyl{7-[(4-methylphenyl)sulfonyt]-7Hpyrrolo[2,3-d]pyrimidin-4-yl}amino)cyclobutyl]methyl} ethanethioate Example 25, Step 5 (190 mg, 0.43 mmol) and potassium carbonate (129 mg, 0.94 mmol) in methanol (10 mL) at 0'C for 2 minutes. 2Cyclopropylethyl 4-methylbenzenesulfonate (159 mg, 1.53 mmol) was then added and the solution was stirred for 6 hours at room température. Dichloromethane (30 mL) and water (20 mL) were added and the aqueous layer was extracted with dichloromethane (2 x 20 mL). The combined organic layers were
washed with brine, dried over sodium sulfate and concentrated. The crude product was purified by préparative thin layer chromatography using ethyl acetate-petroleum ether (1:2) to give the title compound as a white solid (62 mg, 31%). LC/MS (exact mass) calculated for C24H30N4O2S2; 470.18, found (M + H*); 471.1
Step 2: N-(cis-3-{[(2-Cyclopropylethyi)sulfonyl]mefhyi}cyclobutyl)-N-methyl-7-[(4-methyiphenyl)sulfonyl]7H-pyrro!o[2,3-d]pyrimidin-4-amine
The mixture of N-(cis-3-{[(2-cyclopropylethyl)sulfanyl]-methyl}cyc!obutyl)-N-methyl-7-[(4methyl phenyl)-sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (24 mg, 0.051 mmol) and potassium peroxomonosulfate (49 mg, 0.079 mmol) in tetrahydrofuran (1.2 mL), water (0.6 mL) and éthanol (1.2 mL) was stirred at room température for 20 minutes. Aqueous sodium bisulfite was added, followed by dichloromethane (20 mL). The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic layers were extracted with brine, dried over sodium sulfate and concentrated. The crude material was used directly in next step. LC/MS (exact mass) calculated for C24H30N4O4S2; 502.17, found (M + H*); 503.3
Step 3: N-(cis-3-{[(2-Cyclopropylethyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3-dJpyrimidin-4amine
The mixture of N-(cis-3-{K2-cyclopropylethyl)sulfonyl]methyl}cyclobutyl)-N-methyl-7-[(4methylphenyl)sulfonyl]-7H-pyrrofo[2,3-dlpyrimidin-4-amine (49 mg, 0.097 mmol) and lithium hydroxide (30 mg, 1.3 mmol) in water (5 mL) and éthanol (10 mL) was stirred at 50°C for 2 hours. Then, dichloro20 methane (20 mL) was added and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried over sodium sulfate and concentrated. The crude product was purified by reverse phase high performance liquid chromatography using a gradient of water and acetonitrile gradient (95:5 to 5:95) to give the title compound (14 mg, 40%) as white solid. 1H NMR (400
MHz, methanol-di): δδ.12 (s, 1 H), 7.13 (d, 2 H), 6.70 (d, 2 H), 5.12-5,09 (m, 1 H), 3.34 (s, 3 H), 3.343.33 (m, 2 H), 3.20-3.17 (m, 2 H), 2.64-2.61 (m. 3 H), 2.26-2.22 (m, 2 H), 1.75-1.69 (m, 2 H), 0.89-0.86 (m, 2 H), 0.56-0.52 (m, 2 H), 0.18-0.17 (m, 2 H). LC/MS (exact mass) calculated for C17H24N4O2S; 348.16, found (M + H+); 349.1
Example 33: N-[ds-3f{[(3,3-Difluorocyclobutyl)methyl]sulfonyl}-methyl)cyc!obutyl]-N-methy/-7Hpyrro!o[2,3-d]pyrimidin-4-amine
Step 1 : N-[cis-3-({[(3,3-Difluorocyc!obutyl)methyl]sulfanyl}methyl)cyclobutyl]-N-methyl-7H-pyn-olo[2,3d]pyrimidin-4-amine
Nitrogen was bubbled through a mixture of S-{[cis-3-(methyl(7-[(4-methylphenyl)-sulfonyl]-7Hpymolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl]methyl} ethanethioate, Example 25, Step 5 (250 mg, 0.56 mmol) and potassium carbonate (194 mg, 1.41 mmol) in methanol (100 mL) for two minutes at 0°C followed by addition of (3,3-difluorocyclobutyl)methyl 4-methylbenzenesulfonate (prepared as described in W02004/032834) (310 mg, 1.12 mmol). The mixture stirred for 6 hours at room température, filtered, and concentrated to give the title compound (270 mg, crude) as white solid. LC/MS (exact mass) calculated for C17H22F2N4S; 352.15, found (M + H+); 353.2
Step 2: N-[cis-3-({[(3,3-Difluorocyciobutyl)methyl]sulfony!}methyl)cyclobLityl]-N-rnethyl-7H-pyn-oÎo[2,3d]pyrîmidin-4-amine
The mixture of N-[cis-3-(([(3,3-dif!uorocyclobutyl)methyl]sulfanyl}-methyl)cyclobutyl]-N-methyl-7H20 pyrrolo[2,3-d]pyrimidin-4-amtne (45 mg, 0.13 mmol) and potassium peroxomonosulfate (157 mg, 0.26 mmol) in a mixture of tetrahydrofuran (20 mL), water (10 mL) and éthanol (20 mL) was stirred at room température for 20 minutes. Aqueous sodium bisulfite was then added, followed by dichloromethane (20 mL). The aqueous layer was extracted with dichloromethane (2 x 20 mL) and the combined organic lay-
ers were extracted with brine, dried over sodium sulfate, and concentrated. The crude product was purified by reverse phase high performance liquid chromatography using water-acetonitrrle gradient (95:5 to 5:95) to give the title compound as white solid (34 mg, 39%). 1H NMR (400 MHz, methanol-d4): δ 8.29 (s,
H), 7.42 (d, 1 H), 7.03 (d. 1 H). 4.86 (m, 1 H), 3.51 (s, 3 H), 3.39-3.33 (m, 4 H), 2.84 (m, 1 H), 2.76-2.71 (m, 4 H), 2.53 (m, 2 H), 2.37-2.34 (m, 2 H). LC/MS (exact mass) calculated for C17H22F2N4O2S; 384.14, found (M + H+); 385.1.
Example 34A and 34B: (1R, 3R)and(1S, 3S)-[({cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidîn~4yl)amino]cyclobutyl}methyl)sulfonyl]cyclopentanecarbonitrile
The title compound mixture of (1 R, 3R) and (1 S, 3S)-3-[({cis-3-[methyl(7H-pyrrolo[2,3d]pyrimidin-4-yl)amino]cyclobutyl}-methyl)sulfonyl]cyclopentane-carbonitrile was prepared from S-{[cis-3(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyc1obutyl]methyl} ethanethioate Example 25, Step 5, according to the procedure of Example 30, steps 1 and 2.
The title compound (180 mg) was separated by préparative supercritical fluid chromatography us15 ing a Chiralpak AS column:
(1R, 3Ri enantiomer 34A: 60 mg, 1H NMR (400 MHz, methanol-d4): δ 8.12 (s, 1 H), 7.13-7.12 (d, 1 H), 6.70-6.69 (d, 1 H), 5.17-5.11 (m, 1H), 3.86-3.78 (m, 1H), 3.41-3.36 (m. 5 H), 3.15-3.11 (m, 1 H), 2.63-2.53 (m, 4 H), 2.37-2.13 (m, 6 H), 2.03-1.91 (m, 1 H). LC/MS (exact mass) calculated for C17H22F2N4O2S; 373.16, found (M + H+); 374.1 (1S, 3S) enantiomer 34B: 27 mg, LC/MS (exact mass) calculated for C17H22F2N4O2S; 373.16, found (M +
H+); 374.1
The intermediate 3-cyanocyclopentyl 4-methylbenzenesuifonate used in step-1 was prepared as shown below:
3-Cyanocydopentyi 4-methylbenzenesulfonate
4-Methylbenzene-1-sulfonyl chloride (6.9 g, 36 mmol) and N,N-dimethylpyridin-4-amine (100 mg) were added to a solution of compound 3-hydroxycyclopentane-carbonitrile (J. Org. Chem. 2007, 72, 7423) (2 g, 18 mmol) and triethylamine ( 5.5 g, 54 mmol) in dichloromethane (100 mL). The reaction was stirred at room température for 15 hours and then quenched mixture was quenched by addition of saturated aqueous sodium bicarbonate solution (20 mL). The mixture was extracted with dichloromethane (4 x 50 mL). The combined organic layers were dried over magnésium sulfate and concentrated. The residue was chromatographed on silica gel by eluting with a mixture of petroleum ether and ethyl acetate (1:1) to give the title compound as yellow oil (0.5 g, 11% yield). LC/MS (exact mass) calculated for
I0 C13H15NO3S; 265.08, found (M + 23); 287.9.
Example 35: RacemicN-methyl-N-[ds-3-({[1-(propan-2-yl)pyrrolldin-3-yl]sulfonyl}methyl)cydobutyl]-7Hpyrro!o[2,3-d]pyrimidin-4-amine
Step 1 : tert-Buty! 3-({[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyiTolo[2,3-d]pyrimidin~415 yl}amino)cydobutyl]methyl}sulfanyl)pyrrolidine- 1-carboxylate
The solution of cis-[3-(methyl{7-[(4-rnethylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4yl}amino)cyclobutyl]methyl 4-methylbenzenesulfonate from Example 25, Step 4 (2 g, 3.7 mmol) was stirred în N-methylpyrrolîdine (40 mL). LS-Diazabicycloundec-Z-ene (1.13 g, 7.4 mmol) and 3-mercapto20 pyrrolidine-1-carboxylic acid tert-butyl ester (1.13 g. 5.6 mmol) were then added to the reaction mixture. The reaction was stirred at room température for 16 hours. Water (200 mL) and ethyl acetate (500 mL) were added. The aqueous layer was extracted with ethyl acetate (2 x 500 mL).and the combined organic
layers were dried and concentrated under vacuum to give the title compound as a white solid (2.6 g, 118%). LC/MS (exact mass) calculated for C2BH37N5O4S2; 571.23, found (M + H+): 572.1.
Step 2: N-Methyl-7-[(4-methylphenyl)sulfony!]-N-{cis-3-[(pyrro)idin-3-yisulfanyl)methyl]cyclobutyl}-7Hpyrro!o[2,3-d]pyrimidin-4-amine
To a solution of tert-butyl 3-({[cis-3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3d]pyrimidin-4-yl}amino)cyclobutyl]methyl}sulfanyl)pyrrolidine-1-carboxylate (2.6 g, 4.5 mmol) in methanol (15 mL) was added 3M hydrochloricacid solution in methanol (40 mL). The resulting solution was stirred at room température for 1 hour. The solution was concentrated to give the crude product, which was purified by chromatography on silica gel eluting with a gradient of dichloromethane and methanol (100:0 to 85:15) to give the title compound as colorless oil (1.7 g, 52%). 1H NMR (400 MHz, methanol^): δ 8.21 (s, 1 H), 7.99 (d, 2 H), 7.56 (d, 1 H), 7.37 (d, 2 H), 6,88 (d, 1 H), 4.95-4.87 (m, 1H), 3.29 (s, 1 H), 3.27 (s, 3 H), 3.21-3.17 (m, 1 H), 3.04-3.96 (m, 1 H), 2.92-29 (m, 1 H), 2.72-2.01 (m, 3 H), 2.50-2.43 (m, 2 H), 2.39 (s, 3 H). 2.29-2.15 (m. 2 H), 2.03-2.01 (m, 2 H), 1.98-1.65 (m, 1 H). LC/MS (exact mass) calculated for C23H29N5O2S2; 471.18, found (M + 23): 494.
Step 3: N-Methyl-7-[(4-methylphenyl)sulfonyl]~N-[cis-3-({[ 1-(propan-2-yl)pyrTolidin-3yl]sulfanyl}methyl)cyclobutyl]-7H~pyrrolo[2,3-d]pyrimidin-4-amine
To a solution of N-methyl-7-[(4-methylphenyl)sulfonyl]-N-{cis-3-[(pyrrolidin-3y[sulfanyl)methyl]cyclobutyl}-7H-pyrrolo[2,3-d]pyrimidin-4-amine (472 mg, 1 mmol) in dichloromethane (50 mL) was added acetone (174 mg, 3 mmol), 4Â molecular sieves (40 mg) and sodium cyanoborohydride (189 mg, 3 mmol). The resulting solution was stirred at room température for 1 hour, then diluted with dichloromethane (70 mL) and water (70 mL). The aqueous layer was extracted with dichloromethane (2 x 50 mL) and the combined organic layers were washed with brine (100 mL). The organic layer was dried
over anhydrous sodium sulfate and concentrated to give title compound (500 mg, 97% yield) as cotorless oil. LC/MS (exact mass) calculated for C26H35N5O2S2; 513.22, found (M + H+); 514.1.
Step 4: N-Methyl-7-[(4-methylphenyl)sulfony/]-N-[cis-3-({[ 1-(propan-2-yl)pyrro!idin-3yl]sulfonyl}methyl)cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
The mixture of N-methyl-7-[(4-methylphenyl)su!fonyl]-N-[cis-3-({[1-(propan-2-yl)pyrrolidin-3yl]sulfanyl}methyl)cyclobutyl]-7H-pyrTOlo[2,3-d]pyrimidin-4-amine_(500 mg, 1.0 mmol) and potassium peroxomonosulfate (1.23 g, 2.0 mmol) in tetrahydrofuran (20 mL), water (10 mL), and éthanol (20 mL) was stirred at room température for 30 minutes. The reaction solution was diluted with ethyl acetate (100 mL) and water (50 mL). The aqueous layer was extracted with ethyl acetate (3 x 50 mL) and the combined organic layers were washed with brine (100 mL), dried over sodium sulfate and concentrated to give title compound as colorless oil (420 mg, 90%). LC/MS (exact mass) calculated for C26H35N5O4S2; 545.21, found (M + H*): 546.3.
Step 5: N-Methyl-N-[cis-3-({[1-(propan-2-yl)pyn-olidin-3-yl]sulfonyl}methyl)-cyclobutyl]-7H-pyirolo[2,3d]pyrimidin-4-amine
The mixture of N-methyl-7-[(4-methylphenyl)sulfonyl]-N-[cis-3-({[1-(propan-2-yl)pyrrolidin-3yl]sulfonyl}methyl)cyclobutyl]-7H-pymjlo[2,3-d]pyrimidin-4-amine_(330 mg, 0.6 mmol) and lithium hydroxide (126 mg, 3 mmol) in a mixture of water (5 mL) and éthanol (10 mL) was stirred at 50°C for 2 hours. The mixture was then concentrated and the residue was taken up rn ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated. The crude product was purified by reverse phase high performance liquid chromatography using a gradient of water and acetonitrile (95:5 to 5:95) to give the title compound (89 mg, 38%) as white solid. 1H NMR (400 MHz, CDCh): δ 8.32 (s, 1 H), 7.07 (d, 1 H), 6.57 (d, 1 H), 5.13 (m, 1H), 3.57 (m, 1H), 3.33 (s, 3 H) 3.05-3.22 (m, 3H), 2.92 (m, 1H), 2.78
- 2.87 (m, 1H), 2.58-2.77 (m, 4H), 2.50 (m, 1H). 2.19-2.34 (m, 2H), 2.06-2.19 (m, 2H), 1.12 (d, 6H).
LC/MS (exact mass) calculated for CiaHzgNsOîS; 391.20, found (M + H+); 392.3
Example 36: N-(cis-3-{[(3-Chloro-4-f!uorophenyl)sulfony/]methyl}cyclobutyl)-N-methy!-7H-pyrrolo[2,35 d]pyrimidin-4-amine
Step 1 : N-(cis-3-{[(3-Chloro-4-fluorophenyl)sulfanyl]methyl}cyclobutyl)-N-methyl-7H-pyrrolo[2,3dJpyrimîdin-4-amine
To a solution of 3-chloro-4-fluorothiophenol (93 mg, 0.55 mmol) in tetrahydrofuran (1.5 mL) was added 50% aqueous sodium hydroxide (44 mg, 0.55 mmol) and éthanol (1.5 mL). The mixture was stirred at room température for 1 hour. A solution of cis-[3-(methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyaolo[2,3d]pyrimidin-4-yl}amino)cyclobutyl]methyl 4-methylbenzenesulfonate from Example 25, Step 4 (200 mg, 0.37 mmol) in tetrahydrofuran (1.5 mL) was added to the reaction mixture. The combined mixture was heated at 40°C ovemight. The reaction was concentrated and purified by silica column eluting with a gradient of heptanes and ethyl acetate (90:10 to 0:100) to afford the title compound (69 mg, 49.6%). ’H NMR (400 MHz, CDCh): δ 8.18 (s, 1 H), 7.39 (dd, 1 H), 7.28 (s, 1 H), 7.03-7.08 (m, 1 H), 7.00 (d, 1 H), 6.52 (d,
H), 4.97-5.07 (m, 1 H), 3.35 (m, 2 H), 3.23 (s, 3 H), 2.89 (s, 1 H), 2.43-2.52 (m, 2 H), 2.19-2.30 (m, 2 H). Step 2: N-(cis-3-{[(3-Chloro-4-fluorophenyl)sulfonyl]methyl}cyclobutyÎ)-N-methy/-7H-pyrrolo[2,3d]pyrimidin-4-amine
To a solution of N-(cis-3-{[(3-chloro-4-fluorophenyl)sulfanyl]methyl}cyc1obutyl)-N-methyl-7H20 pyrrolo[2,3-d]pyrimidin-4-amine (75 mg, 0.2 mmol) in dichloromethane (10 mL) was added 3chlorobenzoperoxoic acid (107 mg). The reaction was stirred at room température ovemight and then concentrated. The crude residue was chromatographed on silica gel eluting with a gradient of dichloromethane and 2M ammonia in methanol (80:20) to obtain the title compound (48 mg, 59.2%). ’H NMR
(400 MHz, methanol-d4): 8 8.31 (s, 1H), 8.02 (m, 1H), 7.81-7.83 (m, 1H) 7.37-7.27 (m, 1H), 7.09 (d, 1H),
6.65 (s, 1 H). 5.18-5.10 (m, 1 H), 4.15-4.09 (m, 1 H), 3.32 (m, 5 H), 2.59-2.54 (m, 2 H), 2.44-2.42 (m, 2 H).
LC/MS (exact mass) calculated for C18H18CIFN4O2S; 408.08, found (M + H*); 409
Example 37: 2-[({cis-3-[Methy!(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl) sulfonyljpyridine4-carbonitrile
Step 1:2-({[cis-3-(Methyl{7-[(4-methylphenyl)sulfonyl]-7H-pyrrOlo[2,3-d]pyrimidin-4yl}amino)cyclobuty!]methyl}su!fanyl)pyridine-4-carbonitrile
1,8-Dtazabicycloundec-7-ene (24.6 g, 161 mmol) and 2-mercapto-isonicotinonitrile (16.1 g, 118 mmol) were added to a solution of [cis-3-(methyl{7-[(4-methylphenyi)sulfonyl]-7H-pyrrolo[2,3-d]pyrim!din4-yl}amino)cyclobutyl]-methyl methanesulfonate (50 g, 110 mmol) in N-methylpyrrolidine (250 mL). The reaction was heated at 50°C ovemight. Additional 2-mercaptoisonicotinonitrile (8.1 g, 59 mmol) was added to drive the reaction to completion. The mixture was cooled to about 0°C and then the reaction was quenched by dropwise addition of water. The solids were collected by filtration, washed with water, and dried under vacuum at 50‘C to give the title compound as a bright yellow solid (45.8 g, 82.8%). LC/MS (exact mass) calculated for C25H24N6O2S2; 504.14, found (M + H+); 505.1
Step 2: 2-[({cis-3-[Methyi(7H-pyrro/o[2,3-d]pyrimidin-4-y!)amino]cyclobutyl}methyl)sulfanyl]pyndine-4carbonitri/e
To a solution of 2-({[cis-3-(methyl{7-[(4-methylpheny!)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-420 yl}amino)cycfobutyl]methyl}sulfanyl)pyridine-4-carbonitrile (45.3 g, 89.8 mmol) in tetrahydrofuran (180 mL) was added a solution of 1M tetrabutylammonium fluoride in tetrahydrofuran (269 mL). The reaction mixture was heated to reflux for 6 hours and then cooled to room température. Water was added dropwise over 45 minutes. The solids were collected by filtration and washed with a mixture of 20% tetrahydrofuran (33 mL) and water (97 mL). The wet cake was dried under vacuum at 50’C to give the title compound as a tan solid (25 g, 79%). LC/MS (exact mass) calculated for CisHiaNeSz 350.13, found (M + H+); 351.1 Step 3: 2-[({cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methyl)sulfonyl]pyridine~4carbonitriïe
Potassium peroxomonosulfate (236.8 g, 385.2 mmol) was added slowly to a mixture of 2-[({cis-3[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-methyl)sulfanyl]pyridine-4-carbonitrile (22.5 g, 64.2 mmol) in methanol (337 mL) and water (56 mL) at 0°C. The reaction was stirred at 3DC for 20 hours. The reaction was quenched using 10% aqueous sodium bisulfate solution (40 mL). and the resulting slurry was stirred at room température for 2 hours. Aqueous 10% potassium carbonate solution was added unti! the pH was 4 to 5. The material was filtered and rinsed with water. The wet filter cake was dried under vacuum at 40°C to give an off-white solid. This material was taken up in tetrahydrofuran (50 mL) and heated to reflux for 3 hours. The mixture was cooled to room température and filtered to collect the solid, which was dried under vacuum at 40'C to the title compound as a light tan powder (17.3 g, 70.46%). 1H NMR (400 MHz, CDCh): S 11.97 (s, 1 H), 8.95 (d, 1 H), 8.33-8.28 (m, 2 H), 7.81 (d, 1 H) 7.1 (d. 1 H), 6.54 (d, 1 H). 5.13-5.08 (m, 1 H), 3.63 (m, 2 H), 3.30 (s, 3 H), 2.54-2.48 (m. 3 H), 2.09-2.07 (m, 2 H). LC/MS (exact mass) calculated for CiaHieNeOaSï; 382.12, found (M + H+); 383.1.
Example 38. 2-Methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}-1,3-thiazole5-su/fonamîde
Step 1: 2-Methyl-N-[cis-3-(methyl{7~[(4-rnethylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrÎmidin-4yl}amino)cyclobutylJ-1,3-thiazole-5-sulfonamide
Triethylamine (62.0g, 0.613 mol) is added to a solution of cis-N-methyl-N-7H-pyrrolo[2,3dlpyrimidin-4-ylcyclobutane-1,3-diamÎne hydrochloride (22.2.g, 0.102 mol) in dichloromethane (250 mL).
100
2-Methylthiazole-5-sulfonyl chloride (28,0g, 0,142 mol) in dichloromethane (250 mL) is added over 30 minutes at room température to the reaction mixture. After 1.5 hours the solvent is removed under reduced pressure and the résultant solid dissolved in 4:1 ethyacetate:dichloromethane (400 mL). The solution is fiîtered through a 40g silica plug, rinsing with ethylacetate (800 mL) and dichloromethane (100 mL).
The solvent from the filtrate is removed under reduced pressure to give solid (59g). The solid is purified using silica gel column chromatography eluting from 1:1 dichloromethane:ethylacetate to neat ethylacetate to give the title compound (44.4g, 81 %); m/z (Cl) 533 [M+H]+.
Step 2: 2-Methyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidÎn-4-y/)amino]cyclobutyl}-1,3-thiazole-5sulfonamide
Lithium hydroxide (12.1g, 0.505 mol) in water (290 mL) is added to 2-methyl-N-[cis-3-(methyl{7[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)cyc!obutyl]-1,3-thiazole-5-sulfonamide (43.8g, 82.2 mmol) in isopropyl alcohol (435 mL) and the mixture heated to 60oC overnight. After cooling to room température the reaction mixture is fiîtered rinsing with water (145 mL). The filtrate is pH is adjusted to 6-7 using 6M aqueous hydrochloric acid. The reaction slurry is concentrated under reduced pressure. Water (370 mL) is added and the mixture cooled to 0°C. The solved is colîected by filtration, washed with cold water (150 ml) then vacuum dried at 60°C overnight to give the title compound (25.0g, 80%); ’H NMR (DMSO-d6); δ 11.66-11.71 (1 H), 8.44-8.47 (1 H), 8.11-8.08 (2 H). 7.16-7.17 (1 H),6.636.65 (1 H), 4.86-4.94 (1 H), 3.58-3.68 (1 H), 3.22 (3 H), 2,74 (3 H), 2.40-2.46 (2 H), 2.10-2.18 (2H). m/z (Cl) 379 [M+H]*.
Biological Evaluation
JAK Caliper Enzyme Assay at 1 mM ATP
ΙΟΙ
Test article was solubilized in dimethyl sulfoxide (DMSO) to a stock concentration of 30 mM. An 11-point hatf log dilution sériés was created in DMSO with a top concentration of 600 μΜ. The test compound plate also contained positive control wells containing a known inhibitor to define 100% inhibition and négative control wells containing DMSO to define no inhibition. The compound plates were diluted 1 to 60 resulting in a top final assay compound concentration of 10 μΜ and a 2% DMSO concentration.
Test article and assay controls were added to a 384-well plate. Reaction mixtures contained 20 mM HEPES, pH 7.4,10 mM magnésium chloride, 0.01% bovine sérum albumin (BSA), 0.0005% Tween 20, 1 mM ATP and 1 μΜ peptide substrate. The JAK1 and TYK2 assays contained 1 μΜ of the IRStide peptide (5FAM-KKSRGDYMTMQID) and the JAK2 and JAK3 assays contained 1 μΜ of the JAKtide pep10 tide (FITC-KGGEEEEYFELVKK). The assays were initiated by the addition of 20 nM JAK1,1 nM JAK2, 1 nM JAK3 or 1 nM TYK2 enzyme and were incubated at room température for three hours for JAK1,60 minutes for JAK2, 75 minutes for JAK3 or 135 minutes for TYK2. Enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified sfightly over time to ensure 20%30% phosphorylation. The assays were stopped with a final concentration of 10 mM EDTA, 0.1 % Coat15 ing Reagent and 100 mM HEPES, pH=7.4. The assay plates were placed on a Caliper Life Science Lab
Chip 3000 (LC3000) instrument, and each well was sampled using appropriate séparation conditions to measure the unphosphorylated and phosphorylated peptide.
Table 1. Data for JAK Caliper™ Enzyme assay at 1 mM ATP.
Structure | Example | JAK1 IC50 (nM) | JAK2 IC50 (nM) | JAK3 IC5Q (nM) | Tyk2 ICso (nM) |
102
οΛος 'χ'-' 0 0 F N H | 1 | 22 | 381 | >9220 | 1020 |
O x.·...../......™ xQ | 2 | 29 | 803 | >10000 | 1250 |
O rxii CQ | 3 | 14 | 542 | >10000 | 479 |
.....O......Mo ' Λ ° Y M-γ l | 4B | 6 | 607 | >10000 | 965 |
XJ > A ° VX VQ s | 4A | 18 | 1400 | >10000 | 2710 |
H ,? _ N /V ôo | 5 | 6 | 313 | 8090 | 878 |
103
.. .n'AVOo ÔQ | 6 | 28 | 933 | >10000 | 2380 |
Ο An ° vV I V w “ | 7A | 31 | 2020 | >10000 | 5240 |
>.....Ο......Y Ύυ Ν | 7B | 16 | 750 | >10000 | 2440 |
Η ο °Αη IL JO H ™ H | 8 | 3 | 700 | >10000 | 260 |
i I H O ... ..□ ° w· w | 9 | 231 | 5630 | >10000 | 6670 |
A> | 10 | 1030 | 7180 | >10000 | >10000 |
104
.... Ο/Υ | 11 | 29 | 574 | 5950 | 2040 |
Η Ρ Ία h 03 ’ ' | 12 | 6 | 413 | >9670 | 770 |
Η J-^r ^ο·Ύ Ύ | 13 | 5 | 177 | 8840 | 323 |
ΖΫ | 14 | 42 | 1200 | >10000 | 1870 |
γ-Υ<° ?Υ_ Ϋ, ν Μ Η | 15 | 6 | 597 | >10000 | 4910 |
^,Ο <Γο ti» ™ Η | 16 | 51 | 1100 | >10000 | 1780 |
105
H H Y°ZQ W N H | 17A | 5 | 308 | >10000 | 337 |
Aq CQ x- | 17B | 13 | 434 | >9770 | 1120 |
//V ° o Ύ | 18 | 46 | 1080 | >10000 | 7380 |
y2...... VO | 19 | 34 | 1150 | >10000 | 2030 |
-Y ° n Y ÇQ N H | 20 | 4 | 171 | 5500 | 332 |
h O r-YS? Λ Y | 21 | 1 | 52 | 3120 | 365 |
106
A | 22 | 22 | 412 | >10,000 | 1190 |
AV w | 23 | 8 | 551 | >10000 | 565 |
-A w A | 27 | 17 | 987 | >10000 | 1970 |
N A | 24 | 241 | 3370 | >10000 | 7870 |
F p A γ-α^< ^....O <To A | 25 | 9 | 373 | >10000 | 713 |
_cA □ <?% ^hT' Ά | 26 | 6 | 88 | 1880 | 358 |
107
-/G Μ.......... ά? | 28 | 5 | 179 | 5270 | 444 |
29 | 17 | 372 | >9930 | 1100 | |
nz>c^ ^N' dx N H | 30 | 9 | 220 | >6710 | 553 |
.....o-7 ào | 31 | 67 | 946 | >10000 | 3610 |
Cq | 32 | 14 | 426 | >10000 | 1460 |
□O’C'O/ ^N F ÔX Η H | 33 | 5 | 161 | 6570 | 582 |
108
34 B | 9 | 309 | >10000 | 840 | |
34A | 37 | 801 | >10000 | 3280 | |
ύο N H | 35 | 106 | 3760 | >10000 | >10000 |
^xr: □ M | 36 | 4 | 85 | 3190 | 242 |
/ / O O ôx ™ H | 37 | 6 | 569 | >8880 | 418 |
μ —f 0 0 N Ô3 | 38 | 4.6 | 512 | >10000 | 546 |
109
HWB INF alpha induced STAT3 phosphorylation Assay
Test articles were prepared as 30 mM stocks in 100% DMSO, and then diluted to 5 mM, A 10point 2,5 dilution sériés was created in DMSO with a top concentration of 5 mM, Further dilution was done by adding 4 μ|_ of the above test article solutions into 96 μΙ_ of PBS with a top concentration of 200 μΜ.
To a 96-well polypropylene plate (VWR 82007-292) 90 μΙ of HWB was added per well, followed by addition of 5 μΙ test article solutions prepared above to give a top concentration of 10 μΜ, The plate was mixed and incubated for 45 minutes at 37°C. To each well was added 5 μΙ of human IFN alpha (Universal Type I IFN, R&D Systems #11200-2; final concentration of 5000U/ml) or D-PBS (unstimulated control), mixed and incubated 15 minutes at 37°C. The reaction was quenched by adding Lyse/Fix Buffer [BD Phosflow 5x Lyse/Fix Buffer (BD #558049)] to ali wells at 1000 μΙ/well and incubated for 20 minutes at 37°C; after washing with FACS buffer [D-PBS (Invitrogen cat# 14190) containing 0.1 % BSA and 0.1% sodium azide], 400 pl ice cold 90% methanol/water was added to each well and incubated on ice for 30 minutes. One more wash was done with cold FACS buffer and ail samples were finally resuspended in 250 μΙ/well of the desired Alexa Fluor 647 conjugated anti-phospho-STAT3 (pY705) antibody (BD #557815) at 1:125 dilution in FACS buffer. After overnight incubation at 4 degree ail the samples were transferred into a 96-well polypropylene U-bottom plate (Falcon #353077) and checked by flow cytometry machine. ICso values obtained for examples 1 to 9, 11-23, 25-38 were in the range of 22 to 2610 nM.
Canine în w&üT-cell prolifération assay
I ΙΟ
T-cell activation play s a key rôle in a variety of inflammatory and autoimmune disorders as well as asthma, allergies and pruritus. Since T-cell activation can, in part, can be triggered by cytokines that signal through the JAK-STAT pathway, a JAK inhibitor could be effective against such diseases involving aberrant T-cell activation.
Methods: Canine whole blood was collected in sodium heparin tubes from 29 beagle dogs and 23 mixed breed dogs. Whole blood (20 pL) was plated in 96-well plates (Costar 3598) with 180 pL of medium (RPMI 1640, Gibco #21870-076, with 1% heat inactivated fêtai bovine sérum, Gîbco #10082-39, 292 pg/ml L-glutamine, Gibco #250030-081, 100 u/ml penicillin and 100pg streptomycin per ml, Gibco #15140-122) contaîning vehicle control or test compound (0,001 to 10 μΜ), concanavalrn A (ConA; 1 pg/ml, Sigma C5275), and canine interleukrn-2 (IL-2; 50 ng/ml, R&D Systems 1815-CL/CF). Wells containing whole blood, medium with vehicle control and no ConA or IL-2 were used as background controls. Plates were incubated at 37° C for 48 hours. Tritiated thymidine, 0.4 pCi/well (Perkin Elmer, Net027A005MC), was added for 20 additional hours. Plates were frozen and then thawed, washed and filtered using a Brandel MLR-96 cell harvester and pre-wet filter mats (Wallac 1205-401, Perkin Elmer). Filters were dried at 60° C for one hour (Précision 16EG convection oven) and placed into filter sample bags (Wallac 1205-411, Perkin Elmer) with 10 mL of scintillant (Wallac 1205-440, Perkin Elmer). Sealed filters were counted on a LKB Wallac 1205 Betaplate liquid scintillation counter. Data were collected via Gterm Betaplate program v1.1 and transformed into percent inhibition, calculated using the following formula:
100[(Mean Drug Treatment cpm) — (Mean BCK cpm)] — — 1 χ [(Mean Non Drug Treatment cpm) — (Mean BCK cpm)]
100 = % Inhibition
Data were graphically displayed as percent inhibition using GraphPad Prison 4.0, and ICso curves were fitted using a point to point analysis.
ni
Example 38 had an ICao of 48.5 nM in this assay. This data suggests that the compounds of the présent invention are effective in inhibiting T-ceJI prolifération, a key feature in diseases resulting from
JAK dysrégulation.
112
Claims (2)
- What is claimed is:1. A compound of formula l having the structure:or a pharmaceutically acceptable sait thereof, whereinR1 is hydrogen or C1-C4 alkyl, wherein said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, CFs, and Ca-Ce10 cycloalkyl;R2 and R3 are each independently hydrogen, deuterium, C-i-Ce linear or branched chain alkyl, C3Ce cycloalkyl, Ci-Cs linear or branched chain perfiuoroalkyl, Ci-Ce linear or branched chain alkoxy, Ci-Ce linear or branched chain perfluoroalkoxy, halogen, cyano, hydroxyl, amino, carboxy, aminocarbonyl, aryl, 15 heteroaryl, (aryi)Ci-Ce linear or branched chain alkyl, (heteroaryl)Ci-Ce linear or branched chain alkyl, (heterocyclic)Ci-C<> linear or branched chain alkyl, (Ci-Ce linear or branched chain alkyljaryl, (Ci-Cs linear or branched chain alkyl)heteroaryl, (Ci-Ce linear or branched chain alkyl)heterocyclic, (C1-C6 linear or113 branched chain alkoxyl)carbonyl, (Ci-Ce linear or branched chain alkyl)amino-carbonylamino, or (Ci-Ce linear or branched chain alkyljaminocarbonyl;R4 is selected from hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, Ci-Cb linear or branched chain perfluoroalkyl, aryl, and alkylaryl;X is selected from -NH- and —CRaRb-, where (a) Ra and Rb are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, Ca-Ce cycloalkyl, aryl, (aryl)Ci-C6 linear or branched chain alkyl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, (heteroaryl)Ci-Cs linear or branched chain alkyl, (heterocyclic)Ci-C6 linear or branched chain alkyl, or (b) Ra and Rb together form a chain comprising — (CRcRd)/-, where Rc and Rd are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, aryl, (C1-C6 linear or branched chain alkyl)aryl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, halo, CN, CF3, hydroxyl, CONH2, or SO2CH3;Y rs -A-R5, where A rs a bond, -(CH2)k- or -(CD2)k- and R5 is Ci-Ce linear or branched chain alkyl, Ca-Ce cycloalkyl, aryl, or -NRaRb, or is an unsaturated, saturated or partially saturated monocyclic or brcyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C3-C6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Cb linear or branched chain alkyl, CN, hydroxyl, CF3, -ORe, -NReRf, -S(O)PRe and C3-Ce cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH2, and SO2CH3, where (a) Ra· and Rb- are independently hydrogen, deuterium, Ci-Ce linear ll4 or branched chain alkyl, C3-Cs cycloalkyl, aryl, (Ci-Cs linear or branched chain alkyljaryl, heteroaryl, or (Ci-Ce linear or branched chain alkyljheteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc·, or (b) Ra- and Rb· together form a chain comprising —(CRc-Rtr)/-, where Rc- and R<r are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, aryl, (Ci-Cë linear or5 branched chain alkyljaryl, heteroaryl, (Ci-Ce linear or branched chain alkyljheteroaryl, halo, CN, hydroxyl, CF3, CONH2, --ORb, NReRt, or -S(O)PRe; where Re and Rf are independently hydrogen, deuterium, C1Cs linear or branched chain alkyl, or C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2;/is 2, 3, 4 or 5; /ris 1, 2; 3, or4; p is 0, 1 or 2; and, n is 1 or 2.15 2, The compound of claim 1 which is a compound of formula IA having the structure:or a pharmaceutically acceptable sait thereof, wherein Y is -A-R5, where A is a bond, --(CFLJk- or -(CD2)k- and R5 is Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, or -NRaRb·, or is an un-H5 saturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C3-C6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Cb linear or branched chain alkyl, CN, hydroxyl, CF3, --ORe, -NRBRf, -S(O)PRe and Cs-Ce cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH2, and SO2CH3, where (a) Ra· and Rb- are independently hydrogen, deuterium, Ci-Cb linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, (Ci-Cb linear or branched chain alky!)aryI, heteroaryl, or (Ci-Cb linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc-, or (b) Ra- and Rb· together form a chain comprising —(CRcRd·)/-, where Rc· and R<j· are independently hydrogen, deuterium, C1-C6 linear or branched chain alkyl, aryl, (Ci-Cb linear or branched chain alkyljaryl, heteroaryl, (Ci-Cb linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF3, CONH2, —ORa, -NReRf, or -S(O)PRa; where Ra and Rr are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, or Cs-Ce cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONHîj/ts 2, 3, 4 or 5; Aris 1,2; 3, or 4; and, p is 0, 1 or 2.3. A compound of claim 2 wherein A is a bond and R5 is a C1-C6 linear or branched chain alkyl, C3-C6 cycloalkyl or aryl.1164. A compound of claim 2 wherein A is a bond or --(CHî)^-, and Rs is Ca-Ce cycloalkyl wherein said C3-C6 cycloalkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, Ci-Cs linear or branched chain alkyl, and CN where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo,5 CN, hydroxyl, CONH2, and SO2CH3; where Ais 1, 2, or 3.5. A compound of claim 2 wherein A is a bond or -(CH2)k--, and R5 is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containîng a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen,10 and sulfur, wherein said alkyl, Ca-Cs cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C1-C6 linear or branched chain alkyl, CN, hydroxyl, CF3, --NRa Rb·, -ORe, -S(O)PRe and Ca-Cs cycloalkyl: where Ais 1, 2, or 3,15 6. The compound of daim 1 which is a compound of formula IB having the structure:IB117 or a pharmaceutically acceptable sait thereof, wherein (a) Ra- and Rb· are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, CaCe cycloalkyl, aryl, (Ci-Ce linear or branched chain alkyl)aryl, heteroaryl, or (Ci-Ce linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rcj (b) Ra· and Rb- together form a chain comprising —(CRcRd )/-, where Rc· and Rd· are independently hydrogen, deuterium, Ci-Cs linear or branched chain alkyl, aryl, (Ci-Ce linear or branched chain alkyl)aryl, heteroaryl, (C1-C6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF3, CONH2, --ORe, NRaRf, or --S(O)PRe; where Re and Rt are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, or C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consîsting of halo, CN, hydroxyl, CF3, and CONH2; or, (c) Ra· and Rb· together form an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, hydroxyl, CF3, --NRa Rt>·, --OR0, -S(O)PRe and C3-C6 cycloalkyl; /is 2, 3, 4 or 5; and, p is 0, 1 or 2.7. The compound of cfaim 1 which îs a compound of formula IC having the structure:R.· or a pharmaceutically acceptable sait thereof, wherein (a) Ra- and Rb· are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, C3Ce cycloalkyl, aryl, (Ci-Ce linear or branched chain alkyl)aryl, heteroaryl, or (Ci-Cb linear or branched5 chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc;(b) Ra· and Rb· together form a chain comprising — (CRc Rdj/-, where Rc· and Rd· are independently hydrogen, deuterium, Ci-Cs linear or branched chain alkyl, aryl, (Ci-Ce linear or branched chain alkyl)aryl, heteroaryl, (Ci-Cb linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CFa, CONH2, -ORe, -10 NReRr, or -S(O)PRe; where RB and Rt are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, or C3-C« cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2; or, (c) Ra· and Rb· together form an unsaturated, saturated or partially saturated monocyclic or bicy-15 clic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic1I9 ring structure is further optionally substituted with one or more substituents selected from the group con sisting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, hydroxyl, CFa, --NRa'Rb·, --0Re, S(0)PRe and Ca-Ce cycloalkyl; jis 2, 3, 4 or 5; and, p is 0, 1 or 2,5 8. The compound of claim 1 which is a compound of formula ID having the structure:or a pharmaceutically acceptable sait thereof, whereinY is -AR5, where A is a bond or --(CHîJn-, and R5 is Ci-Ce linear or branched chain alkyl, Ca-Ce10 cycloalkyl, aryl, or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, Ca-Ce cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, Ci-Ce linear or branched chain alkyl, CN, hydroxyl, CF3, -NRaRt»·,15 -ORe, —S(O)pRe and C3-C6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH2, and SO2CH3, where (a) Ra· and Rb· are independently hydrogen, deuterium, Ci-Ce linear or branched chain alkyl, C3-C6 cycloalkyl, aryl, (arylJCi-Ce linear or branched chain alkyl, heteroaryl, (Ci-Ce linear or branched chain al-120 kyl)heteroaryl, (heteroarylJCi-Ce lînear or branched chain alkyl, (heterocyclic)Ci-Cs lînear or branched chain alkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more Rc, or (b) Ra· and Rb· together form a chain comprising —(CRcRdj/-, where Rc· and Rd are independently hydrogen, deuterium, Ci-Ce lînear or branched chain alkyl, aryl, (Ci-Ce lînear or branched chain alkyljaryl, heteroaryl, (Ci-Ce linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF3, CONHz, -ORe, NReRf, or -S(O)PRe; where Re and Rt where are independently hydrogen, deuterium, Ci-Cs linear or branched chain alkyl, or C3-Ce cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF3, and CONH2; y is 2, 3, 4 or 5; kis 1, 2, or 3; and, p is 0, 1 or 2,9, The compound of claim 1 selected from the group consisting of: 4-cyano-N-{cis-3-[methyl(7H-pyrroio[2,3-d]pyrimidin-4-yl)aminoJcyclobutyl)pyridine-2-sulfonamide; 2,2,2-trifl uoro- N-{cis-3-[methyl(7 H-pyrrolo[2,3 - d ] py ri m idîn-4-yl)amino]cyclobuty I}ethanesulfonamide;
- 2-methyl·N-{cis-3-[methyl(7l·l-pyrΓOlo[2t3-d]pyrimidin-4-yl)amino]cyclobutyl}-pΓopaπe-1sulfonamide;N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)aminoîcyclobutyl}propane-1-sulfonamide,·1-cyclopropyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}methanesulfonamide;N-{ciS'3-[(butylsu1fonyl)methyl]cyclobutyl}-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 1-cyclopropyl-N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin~4-yl)amino]cyclobutyl}-azetidine-3sulfonamide;
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/767,947 | 2013-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17460A true OA17460A (en) | 2016-12-22 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9549929B2 (en) | Pyrrolo[2,3-D]pyrimidine derivatives | |
EP3180344B1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase | |
ES2859510T3 (en) | Pyridazinone fused tricyclic compounds useful for treating orthomyxovirus infections | |
ES2655971T9 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
WO2019046318A1 (en) | Spirocycle compounds and methods of making and using same | |
EP3946606A1 (en) | Bicyclic jak inhibitors and uses thereof | |
WO2022217118A1 (en) | Pyrimidine based ras modulators and uses thereof | |
OA17460A (en) | Pyrrolo [2, 3 - D]pyrimidine derivatives as inhibitors of Janus-Related Kinases (JAK). |